Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.1.4 - phospholipase A2

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model.
The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue.
Abscess
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis].
Acalculous Cholecystitis
Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A2.
Acidosis
Extracellular presence of IL-8 in the astrocyte-rich cultured cerebellar granule cells under acidosis.
Fatty acid oxidation and myocardial phospholipase A2 activity.
Renal peroxiredoxin 6 interacts with anion exchanger 1 and plays a novel role in pH homeostasis.
Acidosis, Lactic
Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach.
Acne Vulgaris
Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state.
Tetracycline Actions Relevant to Rosacea Treatment.
Acquired Immunodeficiency Syndrome
Exploration of associations between phospholipase A2 gene family polymorphisms and AIDS progression using the SNPlex method.
The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad.
The diversity of bioactive proteins in Australian snake venoms.
Acute Chest Syndrome
A two-event in vitro model of acute chest syndrome: The role of secretory phospholipase A(2) and neutrophils.
Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.
Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome.
Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.
The role of secretory phospholipase A2 in acute chest syndrome.
Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2.
Acute Coronary Syndrome
Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
C-reactive protein, interleukin-6, secretory phospholipase A(2) group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
CRP, interleukin-6, secretory phospholipase A(2) group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.
Inhibition of Secretory Phospholipase A(2) in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial.
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation.
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion.
Varespladib methyl in cardiovascular disease.
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Varespladib.
Acute Kidney Injury
A Biochemical and Pharmacological Characterization of Phospholipase A2 and Metalloproteinase Fractions from Eastern Russell's Viper (Daboia siamensis) Venom: Two Major Components Associated with Acute Kidney Injury.
Alterations in rabbit renal microvascular prostanoid synthesis in acute renal failure.
Marine toxins and nephrotoxicity:Mechanism of injury.
Peroxiredoxin 6 overexpression attenuates lipopolysaccharide-induced acute kidney injury.
Phospholipase A2 inhibits cisplatin-induced acute kidney injury by modulating regulatory T cells by the CD206 mannose receptor.
Role of fatty acid beta-oxidation and calcium-independent phospholipase A2 in ischemic acute renal failure.
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Acute Lung Injury
Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.
Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.
Acute lung injury induced by phospholipase A2. Structural and functional changes.
Changes of pulmonary glucocorticoid receptor and phospholipase A2 in sheep with acute lung injury after high dose endotoxin infusion.
Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.
Correlation between sPLA2-IIA and phosgene-induced rat acute lung injury.
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Deletion of peroxiredoxin 6 is protective in lipopolysaccharide-induced acute lung injury in mice*
Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis.
Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.
Genetic inactivation of the phospholipase A2 activity of peroxiredoxin 6 in mice protects against LPS-induced acute lung injury.
Group V Phospholipase A2 Mediates Endothelial Dysfunction and Acute Lung Injury Caused by Methicillin-Resistant Staphylococcus Aureus.
Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury.
Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium.
Inhibition of pulmonary surfactant function by phospholipases.
Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model.
Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia.
Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin.
Mechanical induction of Group V phospholipase A2 causes lung inflammation and acute lung injury.
Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma.
Peroxiredoxin 6 knockout aggravates cecal ligation and puncture-induced acute lung injury.
Phospholipase A2 and acute lung injury: it's just not that simple.
Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis.
Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury.
Reductions of phospholipase A(2) inhibition of pulmonary surfactant with hyaluronan.
Role of peroxiredoxin 6 in acute lung injury: potential target?
Secretory Group V Phospholipase A2 Regulates Acute Lung Injury and Neutrophilic Inflammation Caused by LPS in Mice.
Secretory Phospholipase A2 Enzymes in Acute Lung Injury.
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea.
Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture.
The serpentine path to a novel mechanism-based inhibitor of acute inflammatory lung injury.
Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection.
[Antioxidative role of peroxiredoxin 6 in acute lung injury]
Adenocarcinoma
Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
Cytokeratin 8 and 19 as antigens recognized by adenocarcinoma-reactive human monoclonal antibody AE6F4.
Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells.
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
Expression of cytosolic and group X secretory phospholipase A(2) genes in human colorectal adenocarcinomas.
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Expression of secreted phospholipase A2-Group IIA correlates with prognosis of gastric adenocarcinoma.
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis.
Secretory Phospholipase A(2) Inhibition Attenuates Intercellular Adhesion Molecule-1 Expression in Human Esophageal Adenocarcinoma Cells.
Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway.
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Adenocarcinoma of Lung
Adrenergic receptors: possible mechanism of inverse regulation of alpha- and beta-receptors.
Anti-tumor activity of CrTX in human lung adenocarcinoma cell line A549.
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA?1 cells.
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.
Keratinocyte Growth Factor and Glucocorticoid Induction of Human Peroxiredoxin 6 Gene Expression Occur by Independent Mechanisms That Are Synergistic.
Phospholipase A2-induced stimulation of A549 lung adenocarcinoma cell line proliferation.
Prognostic roles of mRNA expression of peroxiredoxins in lung cancer.
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Adenoma
Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis.
Early gene expression differences in inbred mouse strains with susceptibility to pulmonary adenomas.
Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice.
Expression of group II phospholipase A2 in Paneth cells of an adenoma of the rectum. A case report.
Expression of group XIIA phospholipase A2 in human digestive organs.
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Adenomatous Polyposis Coli
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Impact of Phospholipase A2 group IIa gene polymorphism on phenotypic features of patients with familial adenomatous polyposis.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis.
Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli.
Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours.
Adenomatous Polyps
Group II phospholipase A2 is not a major modifier of colonic adenomatous polyps in humans.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Adenoviridae Infections
Adenovirus-mediated transfer of the 1-cys peroxiredoxin gene to mouse lung protects against hyperoxic injury.
Human group III phospholipase A2 suppresses adenovirus infection into host cells. Evidence that group III, V and X phospholipase A2s act on distinct cellular phospholipid molecular species.
Adrenoleukodystrophy
Arachidonic acid metabolism in fibroblasts from patients with peroxisomal diseases: response to interleukin 1.
Agranulocytosis
Peroxiredoxin 6 is a natural radioprotector.
Airway Obstruction
Intranasal curcumin ameliorates airway inflammation and obstruction by regulating MAPKinase activation (p38, Erk and JNK) and prostaglandin D2 release in murine model of asthma.
Alopecia
Publisher Correction: Secretory phospholipase A2-IIA overexpressing mice exhibit cyclic alopecia mediated through aberrant hair shaft differentiation and impaired wound healing response.
Secretory phospholipase A2-IIA overexpressing mice exhibit cyclic alopecia mediated through aberrant hair shaft differentiation and impaired wound healing response.
alpha-Thalassemia
Sickle cell trait as a limiting factor for high-level performance in a semi-marathon.
Alveolar Bone Loss
The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.
Alzheimer Disease
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex.
Acceleration of the Development of Alzheimer's Disease in Amyloid Beta-Infused Peroxiredoxin 6 Overexpression Transgenic Mice.
Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.
Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer's disease brain.
Association study of interferon-?, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease.
Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in A? vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model.
Bee Venom Phospholipase A2 Induces Regulatory T Cell Populations by Suppressing Apoptotic Signaling Pathway.
Bee Venom Soluble Phospholipase A2 Exerts Neuroprotective Effects in a Lipopolysaccharide-Induced Mouse Model of Alzheimer's Disease via Inhibition of Nuclear Factor-Kappa B.
Cerebrospinal Fluid Secretory Ca2+-Dependent Phospholipase A2 Activity Is Increased in Alzheimer Disease.
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.
Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue.
Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain.
Cytosolic Phospholipase A2 Facilitates Oligomeric Amyloid-? Peptide Association with Microglia via Regulation of Membrane-Cytoskeleton Connectivity.
Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease.
Effects of Acetylcholine on ?-Amyloid-Induced cPLA2 Activation in the TB Neuroectodermal Cell Line: Implications for the Pathogenesis of Alzheimer's Disease.
Essential fatty acids and the brain.
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.
Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1.
Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.
Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease.
Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.
Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease.
Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology.
Phospholipase A2 and arachidonic acid in Alzheimer's disease.
Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lypoxygenase activity in SH-SY5Y cells.
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.
Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity.
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma.
Plasmalogen-selective phospholipase A2 and its involvement in Alzheimer's disease.
Platelet phospholipase A(2) activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.
Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death.
Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease.
Role of constitutive calcium-independent phospholipase A2 beta in hippocampo-prefrontal cortical long term potentiation and spatial working memory.
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Role of sphingomyelinases in neurological disorders.
Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease.
Study of association between genetic polymorphisms of phospholipase A2 enzymes and Alzheimer's disease.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
The cholesterol ester cycle regulates signalling complexes and synapse damage caused by amyloid-?.
The neurotoxic secreted phospholipase A2 from the Vipera a. ammodytes venom targets cytochrome c oxidase in neuronal mitochondria.
The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer's disease.
The role of platelet activating factor in prion and amyloid-beta neurotoxicity.
The role of secretory phospholipase A2 in the central nervous system and neurological diseases.
Ubiquitin profile and amyloid enhancing factor activity in Alzheimer and 'normal' human brain extracts.
[Relevance of metabolism of membrane phospholipids for Alzheimer dementia]
Amnesia
Inhibitors of phospholipase A2 produce amnesia for a passive avoidance task in the chick.
Amyloidosis
A high resolution ultrastructural study of experimental murine AA amyloid.
Aggregation of Mouse Serum Amyloid A Protein Was Promoted by Amyloid-Enhancing Factors with the More Genetically Homologous Serum Amyloid A.
Amyloid enhancing factor and dietary transmission in accelerated amyloid A amyloidosis.
Attempts at suppression of amyloidogenesis in a mouse model by a variety of anti-inflammatory agents.
Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.
Down-regulation of the major circulating precursors of proteins deposited in secondary amyloidosis by a recombinant mouse interleukin-1 receptor antagonist.
Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition.
Fibril amyloid enhancing factor (FAEF)-accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis.
Long term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice.
Presence and role of glycosaminoglycans in amyloidosis.
Rapid induction of experimental AA amyloidosis in mink by intravenous injection of amyloid enhancing factor.
Serum amyloid A gene expression and AA amyloid formation in A/J and SJL/J mice.
Ubiquitin: its potential significance in murine AA amyloidogenesis.
Amyotrophic Lateral Sclerosis
Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis.
Anaphylaxis
Aspirin is an Enhancing Factor for Food-dependent Exercise-induced Anaphylaxis in Children.
Comparative study of etidronate and SR 41319, a new diphosphonate, on passive cutaneous anaphylaxis and phospholipase A2 activity.
Crotoxin: a novel allergen to occupational anaphylaxis.
Glutamine Prevents Late-Phase Anaphylaxis via MAPK Phosphatase 1-Dependent Cytosolic Phospholipase A2 Deactivation.
Group IID, IIE, IIF and III secreted phospholipase A2s.
Influence of mepacrine on the reaction of adoptive cutaneous anaphylaxis.
Papyriflavonol A from Broussonetia papyrifera inhibits the passive cutaneous anaphylaxis reaction and has a secretory phospholipase A2-inhibitory activity.
Phospholipase A2 Triggers Anaphylaxis to Snake Venom by Repeated Skin Sensitization-A Case Report.
Secreted phospholipase A2 and mast cells.
Toxoplasma gondii-derived heat shock protein 70 induces lethal anaphylactic reaction through activation of cytosolic phospholipase A2 and platelet-activating factor via Toll-like receptor 4/myeloid differentiation factor 88.
[Emerging roles of phospholipase A2s in mast cell biology].
Anemia, Hemolytic
Erythroid accelerating activity of rat serum in early stage of drug induced hemolysis.
Anemia, Sickle Cell
A two-event in vitro model of acute chest syndrome: The role of secretory phospholipase A(2) and neutrophils.
Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease.
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.
Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome.
Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department.
Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.
The role of secretory phospholipase A2 in acute chest syndrome.
Aneurysm
sPLA2: linking atherosclerosis to aneurysm progression.
Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE-/- Mice.
Aneurysm, Dissecting
Group V secreted phospholipase A2 plays a protective role against aortic dissection.
Angina Pectoris
Circulating secretory type IIA phospholipase A2, lipoprotein (a) and soluble cellular adhesion molecule levels in patients with angina pectoris.
Angina, Stable
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Angina, Unstable
Circulating secretory type IIA phospholipase A2, lipoprotein (a) and soluble cellular adhesion molecule levels in patients with angina pectoris.
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Serum phospholipase A2 and lysolecithin changes following myocardial infarction.
Angioedema
Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients.
The pathophysiology of hereditary angioedema.
Angioedemas, Hereditary
Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency.
Aniridia
Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia.
Anthrax
Edema toxin impairs anthracidal phospholipase A2 expression by alveolar macrophages.
In vivo protective role of human group IIa phospholipase A2 against experimental anthrax.
Involvement of phospholipase A2 activation in anthrax lethal toxin-induced cytotoxicity.
Antiphospholipid Syndrome
Antiphospholipid antibodies inhibit prostaglandin release by decidual cells of early pregnancy: possible involvement of extracellular secretory phospholipase A2.
Aortic Aneurysm, Abdominal
Group V Secretory Phospholipase A(2) Enhances the Progression of Angiotensin II-Induced Abdominal Aortic Aneurysms but Confers Protection against Angiotensin II-Induced Cardiac Fibrosis in ApoE-Deficient Mice.
Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice.
Serum secreted phospholipase A2 is associated with abdominal aortic aneurysm presence but not progression.
Trans-Serosal Leakage of Proinflammatory Mediators during Abdominal Aortic Aneurysm Repair: Role of Phospholipase A2 in Activating Leukocytes.
Appendicitis
Phospholipase A2, C-reactive protein, and white blood cell count in the diagnosis of acute appendicitis.
Arteriovenous Malformations
Methylation of Phospholipase A2 Group VII Gene Is Associated with Brain Arteriovenous Malformations in Han Chinese Populations.
Arteritis
Effect of Treatment for 12 weeks with Rilapladib, a Lipoprotein-associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed with 18F-Fluorodeoxyglucose-PET Imaging.
Arthritis
A novel anti-inflammatory role for secretory phospholipase A(2) in immune complex-mediated arthritis.
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Bee venom phospholipase A2 alleviates collagen-induced polyarthritis by inducing Foxp3+ regulatory T cell polarization in mice.
Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.
Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism.
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption.
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Effects of Ginkgetin from Ginkgo biloba Leaves on cyclooxygenases and in vivo skin inflammation.
Eicosanoid production and phospholipase A2 secretion by peritoneal macrophages from rats with adjuvant-induced arthritis.
Enzymatic activity and distribution of phospholipase A2 in human cartilage.
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer.
Exacerbation of collagen antibody-induced arthritis in transgenic mice overexpressing peroxiredoxin 6.
Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A2.
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.
Functional site of endogenous phospholipase A2 inhibitor from python serum.
Group II phospholipase A2 in synovial fluid and serum in acute arthritis.
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA.
Modulation of phospholipase A2 activity in human synovial fluid by cations.
Phospholipase A2 activity associated with synovial fluid cells.
Phospholipase A2 and arthritis.
Phospholipase A2 from human synovial fluid: purification and structural homology to the placental enzyme.
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Phospholipase A2 inhibitors in development.
Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA.
Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis.
Posttranscriptional effect of insulin-like growth factor-I on interleukin-1beta-induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes.
Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.
Protein kinase A-dependent stimulation of rat type II secreted phospholipase A(2) gene transcription involves C/EBP-beta and -delta in vascular smooth muscle cells.
Respective contribution of cytosolic phospholipase A2? and secreted phospholipase A2 IIA to inflammation and eicosanoid production in arthritis.
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
Secreted phospholipase A(2) induces vascular endothelial cell migration.
Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis.
Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.
Structure-based grafting, mutation, and optimization of peptide inhibitors to fit in the active pocket of human secreted phospholipase A2: find new use of old Peptide agents with anti-inflammatory activity.
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Synergy between 15-lipoxygenase and secreted PLA2 promotes inflammation by formation of TLR4 agonists from extracellular vesicles.
Synthesis and release of phospholipase A2 by unstimulated human articular chondrocytes.
The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia - A Prospective Cohort Study.
Arthritis, Experimental
Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen-induced arthritis.
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A2.
Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis.
Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2.
Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis.
[Antiphlogistic effectiveness of combinations of inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases of the arachidonic acid cascade]
[Simultaneous and sequential inhibition of the arachidonic acid cascade by inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases in carrageenan edema and adjuvant arthritis in the rat]
Arthritis, Juvenile
Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity.
Arthritis, Psoriatic
Interleukin 15 Primes Natural Killer Cells to Kill via NKG2D and cPLA2 and This Pathway Is Active in Psoriatic Arthritis.
Arthritis, Rheumatoid
A catalytically independent physiological function for human acute phase protein group IIA phospholipase A2: cellular uptake facilitates cell debris removal.
A novel anti-inflammatory role for secretory phospholipase A(2) in immune complex-mediated arthritis.
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
Activation of phospholipase A2 in rheumatoid arthritis.
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis.
Assay and purification of phospholipase A2 from human synovial fluid in rheumatoid arthritis.
Biochemical characterization of soluble phospholipase A2 from rheumatoid synovial fluid.
Cellular activation products in osteoarthritis synovial fluid.
Characterisation of soluble and cell associated phospholipase A2 from rheumatoid synovial fluid.
Characteristics and pathophysiological roles of extracellular phospholipase A2 in inflamed sites.
Characterization of phospholipase A2 from human nasal lavage.
Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro.
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.
Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.
Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032.
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile.
Enhanced phospholipase A2 and C activities of peripheral blood polymorphonuclear leukocytes from patients with rheumatoid arthritis.
Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients.
Exacerbation of collagen antibody-induced arthritis in transgenic mice overexpressing peroxiredoxin 6.
Group II phospholipase A2 in synovial fluid and serum in acute arthritis.
Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo.
Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin ?v?3.
Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium.
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline.
Interleukin-1 activates phospholipase A2 in human synovial cells.
Melittin binds to secretory phospholipase A2 and inhibits its enzymatic activity.
Membrane-associated phospholipase A2 detected by a radioimmunoassay is a sensitive marker of inflammation in rheumatoid arthritis.
Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids.
Methyltransferase and phospholipase A2 activity in the cell membrane of neutrophils and lymphocytes from patients with Behçet's disease, systemic lupus erythematosus, and rheumatoid arthritis.
Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein.
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells.
Phospholipase A2 activity in peripheral blood cells of rheumatoid arthritis patients treated with methotrexate: a preliminary study.
Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme.
Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity.
Phospholipase A2 in rat gingival tissue.
Phospholipase A2 modulates respiratory burst developed by neutrophils in patients with rheumatoid arthritis.
Phospholipase A2 sensitivity of the dorsal root and dorsal root ganglion.
Phospholipid metabolism in polymorphonuclear leukocytes from rheumatoid arthritis patients: effects of non-steroidal anti-inflammatory agents and clotrimazole.
Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis.
Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase.
Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis.
Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis.
Raised epidermal phospholipase A2 activity in rheumatoid arthritis.
Regulation of synovial cell growth: basic fibroblast growth factor synergizes with interleukin 1 beta stimulating phospholipase A2 enzyme activity, phospholipase A2 activating protein production and release of prostaglandin E2 by rheumatoid arthritis synovial cells in culture.
Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis.
Respective contribution of cytosolic phospholipase A2? and secreted phospholipase A2 IIA to inflammation and eicosanoid production in arthritis.
Reversible inhibition by protamine of human synovial and rabbit platelet secretory phospholipase A2.
Rheumatoid arthritis synovial fluid phospholipase A2 activating protein (PLAP) stimulates human neutrophil degranulation and superoxide ion production.
Roles of secreted phospholipases A? in the mammalian immune system.
Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients.
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes.
Serum phospholipase A2 activity and immunoreactive group II phospholipase A2 in rheumatoid arthritis.
Serum phospholipase A2 activity in patients with rheumatoid arthritis before and after treatment with methotrexate, auranofin, or combination of the two.
Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis.
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis.
sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.
Stopping the traffic: a route to arthritis therapy.
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Synovial type (group II) phospholipase A2 in cartilage.
Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes.
Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells.
[Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]
[Immune function of rheumatoid arthritis treated by medicated-bath therapy in Tibetan medicine]
[Role of type II secreted phospholipase A2 in inflammatory processes]
Arthus Reaction
Characterization of phospholipase A2 activity in rat RPAR-induced pleurisy.
Phospholipase A2 acyl-hydrolytic activity in rat RPAR-induced pleurisy.
Time-course of phospholipase A2, eicosanoid release and cellular accumulation in rat immunological air pouch inflammation.
Asbestosis
Biochemical components of bronchoalveolar lavage in early experimental asbestosis of the sheep: phospholipase A2 activity, prostaglandin E2 and proteins.
Asthenozoospermia
Asthenozoospermia and membrane remodeling enzymes: a new role for phospholipase A2.
Asthma
85-kDa cytosolic phospholipase A2 group IValpha gene promoter polymorphisms in patients with severe asthma: a gene expression and case-control study.
Additional insights into epithelial secreted phospholipase A2 group X in asthma.
Allergen-induced proteolytic cleavage of annexin-1 and activation of cytosolic phospholipase A2 in the lungs of a mouse model of asthma.
Bee Venom Phospholipase A2 Ameliorates House Dust Mite Extract Induced Atopic Dermatitis Like Skin Lesions in Mice.
Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin-induced asthma model through the induction of regulatory T cells.
Bioactive lysophosphatidylcholine 16:0 and 18:0 are elevated in lungs of asthmatic subjects.
Blockade of Human Group X Secreted Phospholipase A2 (GX-sPLA2)-induced Airway Inflammation and Hyperresponsiveness in a Mouse Asthma Model by a Selective GX-sPLA2 Inhibitor.
Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis.
Contribution of opioid and neurotensin receptors in the anti-inflammatory activity of PK20 hybrid compound in murine airways.
Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism.
Emerging roles of secreted phospholipase A(2) enzymes: Lessons from transgenic and knockout mice.
Eosinophil cysteinyl leukotriene synthesis mediated by exogenous secreted phospholipase A2 group X.
Function of secreted phospholipase A2 group-X in asthma and allergic disease.
Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma.
Hyperoxidized peroxiredoxins in peripheral blood mononuclear cells of asthma patients is associated with asthma severity.
Identification of Epithelial Phospholipase A2 Receptor 1 (PLA2R1) as a Potential Target in Asthma.
Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma.
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model.
Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine.
Induction of group IVC phospholipase A2 in allergic asthma: transcriptional regulation by TNF? in bronchoepithelial cells.
Mechanism of glutamine inhibition of cytosolic phospholipase A2 (cPLA2 ): Evidence of physical interaction between glutamine-induced MAPK phosphatase-1 and cPLA2.
Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats.
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics.
Phospholipase A2 in experimental allergic bronchitis: a lesson from mouse and rat models.
Plasma phospholipase A2 activity in patients with asthma: association with body mass index and cholesterol concentration.
Protective Effects of Intratracheally-Administered Bee Venom Phospholipase A2 on Ovalbumin-Induced Allergic Asthma in Mice.
Regulation and function of epithelial secreted phospholipase A2 group X in asthma.
Regulation of Arachidonate Remodeling Enzymes Impacts Eosinophil Survival During Allergic Asthma.
Regulation of leukotriene and platelet-activating factor synthesis in human alveolar macrophages.
Relationship between levels of secreted phospholipase A(2) groups IIA and X in the airways and asthma severity.
Reply to: The Intricate Web of Phospholipase A2s and Specific Features of Airway Hyperresponsiveness in Asthma.
Role of lipopolysaccharide (LPS) in asthma and other pulmonary conditions.
Roles of secreted phospholipases A? in the mammalian immune system.
Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness.
Secretory phospholipase A? and airway inflammation and hyperresponsiveness.
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes.
Surface properties after a simulated PLA2 hydrolysis of pulmonary surfactant's main component, DPPC.
The Intricate Web of Phospholipase A2s and Specific Features of Airway Hyperresponsiveness in Asthma.
The role of mast cell-derived secreted phospholipases A(2) in respiratory allergy.
The step further to understand the role of cytosolic phospholipase A2 alpha and group X secretory phospholipase A2 in allergic inflammation: pilot study.
Toxicological effects of ambient fine (PM2.5-0.18) and ultrafine (PM0.18) particles in healthy and diseased 3D organo-typic mucocilary-phenotype models.
Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
[Association of cytoplasmic phospholipase A2 gene polymorphism with bronchial asthma and response to montelukast in children].
[Blood platelets as one hemostatic indicator in patients with bronchial asthma]
[Changes in activity of phospholipase A2 and its metabolic production of prostaglandins in lung tissue of asthmatic guinea pigs]
[Changes in glucocorticoid receptor and phospholipase A2 in guinea pig asthma models]
[Mode of action of corticoids in asthma]
Asthma, Aspirin-Induced
[Serum phospholipase A2 activity in patients with aspirin-induced asthma]
Astrocytoma
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells.
Calcium-sensitive cytosolic phospholipase A2 (cPLA2) is expressed in human brain astrocytes.
Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells.
Cytosolic phospholipase A2 is coupled to muscarinic receptors in the human astrocytoma cell line 1321N1: characterization of the transducing mechanism.
Mepacrine treatment prevents immobilization-induced desensitization of beta-adrenergic receptors in rat hypothalamus and brain stem.
Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link.
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.
Secretory phospholipase A2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity.
Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2.
The presence of a secretory phospholipase A2 in the nuclei of neuronal and glial cells of rat brain cortex.
Thrombin produces phosphorylation of cytosolic phospholipase A2 by a mitogen-activated protein kinase kinase-independent mechanism in the human astrocytoma cell line 1321N1.
[Expressions of peroxiredoxin 1, peroxiredoxin 6 and GFAP in human brain astrocytoma and their clinical significance].
Ataxia
Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes.
Identification of a novel mutation in PLA2G6 gene and phenotypic heterogeneity analysis of PLA2G6-related neurodegeneration.
New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations.
Atherosclerosis
A Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA2)-V Isoenzyme in Coronary Heart Disease: A Modified Mendelian Randomization Analysis Using PLA2G5 Expression Levels.
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
AMPK Signaling Involvement for the Repression of the IL-1?-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.
Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis.
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.
Atherosclerosis assessment and rheumatoid arthritis.
Autocrine and paracrine transcriptional regulation of type IIA secretory phospholipase A2 gene in vascular smooth muscle cells.
Bee Venom Phospholipase A2 Ameliorates Atherosclerosis by Modulating Regulatory T Cells.
Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis.
Chronicles in drug discovery.
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent.
Comprehensive identification of novel post-translational modifications in cellular peroxiredoxin 6.
Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2).
Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis.
Corrigendum to "Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population." [Atherosclerosis 246 (March 2016) 141-147].
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice.
Degeneration and atherosclerosis inducing increased deposition of type IIA secretory phospholipase A2, C-reactive protein and complement in aortic valves cause neutrophilic granulocyte influx.
Design of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid.
Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A2 Type X (sPLA2-X) Inhibitors.
Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis.
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
Effects of crotoxin, a neurotoxin from Crotalus durissus terrificus snake venom, on human endothelial cells.
Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells.
Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease.
Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Emerging roles of secreted phospholipase A(2) enzymes: Lessons from transgenic and knockout mice.
Expression of secretory phospholipase A2s in human atherosclerosis development.
Extracellular phospholipases in atherosclerosis.
Functional Analysis of Two PLA2G2A Variants Associated with Secretory Phospholipase A2-IIA Levels.
Ginsenosides regulation of lysophosphatidylcholine profiles underlies the mechanism of Shengmai Yin in attenuating atherosclerosis.
Gold/Phospholipid nanoconstructs as label-free optical probes for evaluating phospholipase A2 activity.
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Group IIA Secretory Phospholipase A2 Predicts Graft Failure and Mortality in Renal Transplant Recipients by Mediating Decreased Kidney Function.
Group IID, IIE, IIF and III secreted phospholipase A2s.
Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions.
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice.
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Immune modulation of glycosaminoglycan derived from P. lewisi in TNF-? stimulated cells.
Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins.
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant.
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6.
Inhibition of Secretory Phospholipase A(2) in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial.
Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis.
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.
Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL.
Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity.
Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice.
Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.
Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity.
Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.
Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.
New phospholipase A(2) isozymes with a potential role in atherosclerosis.
Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.
Overexpression of Prdx6 reduces H2O2 but does not prevent diet-induced atherosclerosis in the aortic root.
Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells.
Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.
Periodontal microbiota and phospholipases: The Oral Infections and Vascular Disease Epidemiology Study (INVEST).
Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis.
Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism.
Phospholipase A2 and small, dense low-density lipoprotein.
Phospholipase A2 enzymes and the risk of atherosclerosis.
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Phospholipase A2 inhibitors in atherosclerosis: the race is on.
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Phospholipase A2 inhibitors.
Phospholipase A2 modification of lipoproteins: potential effects on atherogenesis.
Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling.
Physiological Roles of Group X-secreted Phospholipase A2 in Reproduction, Gastrointestinal Phospholipid Digestion, and Neuronal Function.
PLA2-V: a real player in atherogenesis.
Platelet arachidonic acid metabolism in severe cerebrovascular disease.
Potential involvement of type II phospholipase A2 in atherosclerosis.
Prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease.
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Protein kinase A-dependent stimulation of rat type II secreted phospholipase A(2) gene transcription involves C/EBP-beta and -delta in vascular smooth muscle cells.
Proteolysis of Apolipoprotein A-I by Secretory Phospholipase A2: A NEW LINK BETWEEN INFLAMMATION AND ATHEROSCLEROSIS.
PX-18 protects human saphenous vein endothelial cells under arterial blood pressure.
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
Role of secretory phospholipases in atherogenesis.
Roles of secreted phospholipases A? in the mammalian immune system.
SB-480848. GlaxoSmithKline.
Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis.
Secretory phospholipase A(2) elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis.
Secretory phospholipase A(2) of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?
Secretory phospholipase a(2): a multifaceted family of proatherogenic enzymes.
Secretory phospholipase A2 enzymes in atherogenesis.
Secretory phospholipase A2 group IIA enhances the metabolic rate and increases glucose utilization in response to thyroid hormone.
Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.
Secretory phospholipase A2, group IIA is a novel serum amyloid a target gene; Activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.
Secretory Phospholipase A2s in Insulin Resistance and Metabolism.
Secretory PLA(2) inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells.
Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development.
Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium.
sPLA2-IIA Augments Oxidized LDL-Induced MCP-1 Expression in Vitro Through Activation of Akt.
sPLA2: linking atherosclerosis to aneurysm progression.
Statin therapy and secretory phospholipase A? in children with heterozygous familial hypercholesterolemia.
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.
The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease.
Thyroid hormone status regulates the expression of secretory phospholipases.
Transplant vascular disease: Role of lipids and proteoglycans.
Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
Usefulness of C-reactive protein as a marker for prediction of future coronary events in the asian Indian population: Indian atherosclerosis research study.
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE-/- Mice.
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Varespladib methyl in cardiovascular disease.
[Lipoprotein-associated phospholipase A2: importance and perspectives]
[Molecular mechanisms of effects of rosuvastatin on systemic oxidative stress and endogenous inflammation in patients with atherosclerosis.]
[Pathogenesis of myocarditis in patients with bronchial asthma and pecilomycosis].
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
[The secretory phospholipase A2 and transport of lipids by lipoproteins in patients with the risk of cardio-vascular pathology (the system "score") of lower and average degree. The diagnostic significance of the test].
Autoimmune Diseases
A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
A Proposal for a Serology-Based Approach to Membranous Nephropathy.
Activation of human inflammatory cells by secreted phospholipases A2.
Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy.
Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Epigallocatechin-3-gallate modulates antioxidant and DNA repair-related proteins in exocrine glands of a primary Sjogren's syndrome mouse model prior to disease onset.
Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2.
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes.
Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.
The Genetic and Environmental Factors of Primary Membranous Nephropathy: An Overview from China.
The genetic contribution to recurrent autoimmune nephritis.
The pathogenesis of human membranous nephropathy: we are (almost) there.
[Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
[In Process Citation].
Bacteremia
Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia.
Cytosolic phospholipase A2? promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.
Bacterial Infections
Bactericidal group IIA phospholipase A2 in serum of patients with bacterial infections.
CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.
Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice.
Cytosolic phospholipase A2 activation in Helicobacter pylori lipopolysaccharide-induced interference with gastric mucin synthesis.
Distinguishing septic from normal donors by detection of sPLA2-IIA from human plasma using a microsieve-based immunoassay.
Eicosanoids in insect immunity: bacterial infection stimulates hemocytic phospholipase A2 activity in tobacco hornworms.
Expression of human group II phospholipase A2 in transgenic mice.
Genes encoding phospholipases A2 mediate insect nodulation reactions to bacterial challenge.
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Leptin modulates the detrimental effect of Porphyromonas gingivalis lipopolysaccharide-induced cytosolic phospholipase A2 activation on salivary mucin synthesis via ERK-signal transduction.
Measurement of a Novel Biomarker, Secretory Phospholipase A2 Group IIA as a Marker of Sepsis: A Pilot Study.
Methyltransferase and phospholipase A2 activity in membranes of neutrophils and lymphocytes from patients with bacterial and viral infections.
Neutrophil response of transgenic mice expressing human group IIA phospholipase A2 in bacterial infections.
Porphyromonas gingivalis lipopolysaccharide-induced cytosolic phospholipase A2 activation interferes with salivary mucin synthesis via platelet activating factor generation.
Rat liver mitochondrial phospholipase A2 is an endotoxin-stimulated membrane-associated enzyme of Kupffer cells which is released during liver perfusion.
Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED.
Secretory phospholipase A2 in dromedary tears: a host defense against staphylococci and other gram-positive bacteria.
Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy.
The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.
The step further to understand the role of cytosolic phospholipase A2 alpha and group X secretory phospholipase A2 in allergic inflammation: pilot study.
Thromboxane synthesis is increased by upregulation of cytosolic phospholipase A2 and cyclooxygenase-2 in peripheral polymorphonuclear leukocytes during bacterial infection in childhood.
Type IIA Secreted Phospholipase A2 in Host Defense against Bacterial Infections.
Barrett Esophagus
Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells.
The Secretory Phospholipase A2 Gene is Required for Gastroesophageal Reflux-Related Changes in Murine Esophagus.
Barth Syndrome
Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome.
Basal Ganglia Diseases
Neurodegeneration with brain iron accumulation.
Biliary Tract Neoplasms
Nutritional factors (nutritional aspects) in biliary disorders: bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction.
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Blepharospasm
Quantification of muscle loss in the doxorubicin-treated orbicularis oculi of the monkey. Effect of local injection of doxorubicin into the eyelid.
Blister
Prevention of Ca(2+)-induced hepatocyte plasma membrane bleb formation by inhibitors of eicosanoid synthesis.
Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity.
Bone Diseases
Peroxiredoxin 6 Inhibits Osteogenic Differentiation and Bone Formation Through Human Dental Pulp Stem Cells and Induces Delayed Bone Development.
Bone Resorption
An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation.
Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption.
Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats.
Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
Secreted phospholipase A2 type II is present in Paget's disease of bone and modulates osteoclastogenesis, apoptosis and bone resorption of human osteoclasts independently of its catalytic activity in vitro.
The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.
Brain Diseases
The Roles of Peroxiredoxin 6 in Brain Diseases.
Brain Edema
Activation of bradykinin B2 receptor induced the inflammatory responses of cytosolic phospholipase A2 after the early traumatic brain injury.
CDP-choline: pharmacological and clinical review.
Lipocortin-1 fails to ameliorate cold-injury brain edema in the rat.
Neuroinflammatory pathways in binge alcohol-induced neuronal degeneration: oxidative stress cascade involving aquaporin, brain edema, and phospholipase A2 activation.
Release of polyunsaturated fatty acids from phospholipids and alteration of brain membrane integrity by oxygen-derived free radicals.
Role of Gd-DOTA in the evaluation and imaging of experimental blood-brain barrier disruption in brain edemas and their improvement after anti-inflammatory drugs treatment.
Brain Injuries
BK-induced cytosolic phospholipase A2 expression via sequential PKC-delta, p42/p44 MAPK, and NF-kappaB activation in rat brain astrocytes.
Chronic intracerebroventricular delivery of the secretory phospholipase A2 inhibitor, 12-epi-scalaradial, does not improve outcome after focal cerebral ischemia-reperfusion in rats.
Cross-talk between oxysterols and glucocorticoids: differential regulation of secreted phopholipase A2 and impact on oligodendrocyte death.
Effects of CDP-choline on phospholipase A2 and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit.
Hippocampal Gene Network Analysis in an Experimental Model of Posttraumatic Epilepsy.
Multiple mechanisms underlying neuroprotection by secretory phospholipase A2 preconditioning in a surgically induced brain injury rat model.
Neuro-Behavioral Status and the Hippocampal Expression of Metabolic Associated Genes in Wild-Type Rat Following a Ketogenic Diet.
Neuroinflammatory signaling upregulation in Alzheimer's disease.
Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
The neuromessenger platelet-activating factor in plasticity and neurodegeneration.
Brain Injuries, Traumatic
Activation of bradykinin B2 receptor induced the inflammatory responses of cytosolic phospholipase A2 after the early traumatic brain injury.
Autoimmune Profiling Reveals Peroxiredoxin 6 as a Candidate Traumatic Brain Injury Biomarker.
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma.
Brain Ischemia
A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.
Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice.
Effects of an endothelin B receptor agonist on secretory phospholipase A2-IIA-induced apoptosis in cortical neurons.
Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain.
Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia.
Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury.
Neuroinflammatory signaling upregulation in Alzheimer's disease.
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
NMDA receptor-mediated arachidonic acid release in neurons: role in signal transduction and pathological aspects.
Peroxiredoxin 6 secreted by Schwann-like cells protects neuron against ischemic stroke in rats via PTEN/PI3K/AKT pathway.
Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke.
Retraction notice to “Secretory phospholipase A2 IIA is up-regulated by TNF-? and IL-1?/? after transient focal cerebral ischemia in rat” [Brain res. 1134 (2007) 199-205].
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Role of phospholipase A2 and membrane-derived lipid second messengers in membrane function and transcriptional activation of genes: implications in cerebral ischemia and neuronal excitability.
Role of phospholipase A2 in the release of free fatty acids during ischemia-reperfusion in the rat cerebral cortex.
Role of sphingomyelinases in neurological disorders.
Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion.
Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat.
Secretory phospholipase A2 inhibitor PX-18 preserves microvascular reactivity after cerebral ischemia in piglets.
Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Brain Neoplasms
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells.
Breast Neoplasms
A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer.
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Antitumor and antimetastatic effects of PLA2-BthTX-II from Bothrops jararacussu venom on human breast cancer cells.
Autophagy is involved in cytotoxic effects of crotoxin in human breast cancer cell line MCF-7 cells.
Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells.
Bee venom in cancer therapy.
Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases.
BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation.
Cancer cells isolated from malignant pleural and peritoneal effusions inhibit phospholipase A2 activity in human polymorphonuclear leukocytes.
Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells.
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Clinical Significance of Expression Changes and Promoter Methylation of PLA2R1 in Tissues of Breast Cancer Patients.
Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.
Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
Dextrin-Phospholipase A(2): Synthesis and Evaluation as a Bioresponsive Anticancer Conjugate.
Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells.
Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.
Ethanol and breast cancer: an association that may be both confounded and causal.
Evaluation of a panel of tumor-associated antigens in breast cancer.
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Genotoxic effects of BnSP-6, a Lys-49 phospholipase A2 (PLA2) homologue from Bothrops pauloensis snake venom, on MDA-MB-231 breast cancer cells.
Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival.
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells.
Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells.
Lipidomic data on lipid droplet triglyceride remodelling associated with protection of breast cancer cells from lipotoxic stress.
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency.
Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.
Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients - Potential differential effects by radiotherapy?
Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Secreted phospholipases A? are differentially expressed and epigenetically silenced in human breast cancer cells.
Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging.
Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation.
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action.
The Prognosis Of Peroxiredoxin Family In Breast Cancer.
Bronchial Spasm
Interaction between chloroquine and indomethacin in airways smooth muscle in vivo.
[Some pathogenetic mechanisms of bacterial bronchial asthma in paecilomycosis]
Bronchitis
Drastic changes in the tissue-specific expression of secreted phospholipases A2 in chicken pulmonary disease.
Phospholipase A2 in experimental allergic bronchitis: a lesson from mouse and rat models.
Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
[The metabolic effects of glucocorticosteroids in patients with chronic obstructive bronchitis]
Bronchopulmonary Dysplasia
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia.
Promotion of Bronchopulmonary Dysplasia Progression Using Circular RNA circabcc4 via Facilitating PLA2G6 Expression by Sequestering miR-663a.
Brucellosis
Construction and Activity Analyses of Single Functional Mouse Peroxiredoxin 6 (Prdx6).
Full-length cDNA cloning, molecular characterization and differential expression analysis of peroxiredoxin 6 from Ovis aries.
Host Prdx6 contributing to the intracellular survival of Brucella suis S2 strain.
Candidemia
A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans.
Candidiasis
Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans.
Carcinogenesis
A calcium-dependent phospholipase A2 (cPLA2) expression is regulated by MIG-6 during endometrial tumorigenesis.
Absence of secretory phospholipase A2 gene alterations in human colorectal cancer.
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Anticarcinogenic activity of quinacrine in the rat mammary gland.
Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells.
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis.
Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Cytosolic phospholipase A2? regulates G1 progression through modulating FOXO1 activity.
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Deletion of cytosolic phospholipase A2 promotes striated muscle growth.
Deletion of phospholipase A2 group IVc induces apoptosis in rat mammary tumour cells by the nuclear factor-?B/lipocalin 2 pathway.
Differential gene expression profiles of hepatocellular carcinomas associated or not with viral infection.
Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis.
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Dual Roles of Group IID Phospholipase A2 in Inflammation and Cancer.
Dysfunction of PLA2G6 and CYP2C44-associated network signals imminent carcinogenesis from chronic inflammation to hepatocellular carcinoma.
Effects of dietary saturated and unsaturated fatty acids on fecal bile acids and colon carcinogenesis induced by azoxymethane in rats.
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis.
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer.
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice.
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth.
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.
HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue.
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing ?-catenin signaling.
Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A(2) and phospholipids investigated by MALDI TOF mass spectrometry.
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis.
Lung Krüppel-like factor (LKLF) is a transcriptional activator of the cytosolic phospholipase A2 alpha promoter.
Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats.
Multifactorial hamster respiratory carcinogenesis with interdependent effects of cannula-induced mucosal wounding, saline, ferric oxide, benzo[a]pyrene and N-methyl-N-nitrosourea.
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Peroxiredoxin 6 in skin carcinogenesis.
Phospholipase A2 Drives Tumorigenesis and Cancer Aggressiveness through Its Interaction with Annexin A1.
Phospholipase A2 superfamily in cancer.
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia.
Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways.
Plasma Levels of Phospholipase A2-IIA in Patients with Different Types of Malignancies: Prognosis and Association with Inflammatory and Coagulation Biomarkers.
Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.
Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer.
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Secreted Phospholipases A2 Are Intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer.
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis.
Silibinin Down-regulates Expression of Secreted Phospholipase A2 Enzymes in Cancer Cells.
Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer.
The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue.
The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma.
Toward understanding interfacial activation of secretory phospholipase A2 (PLA2): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA2 activation.
Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.
Transfection of C3H10T1/2 cells with the Harvey-ras oncogene reduces cytosolic phospholipase A2 function.
Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
[Genetic steps in colorectal cancer]
Carcinoma
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Antitumor potential of Pllans-II, an acidic Asp49-PLA2 from Porthidium lansbergii lansbergii snake venom on human cervical carcinoma HeLa cells.
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells.
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma.
Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Crotoxin induces apoptosis and autophagy in human lung carcinoma cells in vitro via activation of the p38MAPK signaling pathway.
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-?B in oral squamous cell carcinoma.
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Expression of group XIIA phospholipase A2 in human digestive organs.
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth.
Extracellular Acidity-mediated Expression of cPLA2? Confers Resistance in Gastric Cancer Cells.
Glucocorticoids inhibit TNF alpha-induced cytosolic phospholipase A2 activity.
Group IID heparin-binding secretory phospholipase A(2) is expressed in human colon carcinoma cells and human mast cells and up-regulated in mouse inflammatory tissues.
HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue.
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing ?-catenin signaling.
Integrative analysis the characterization of peroxiredoxins in pan-cancer.
Localization and characterization of phospholipase A2 in mouse mammary gland-derived cells.
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Overexpression and biological function of PRDX6 in human cervical cancer.
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Overexpression of phospholipase A2 Group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression.
Phospholipid patterns and phospholipase A2 activities in gastric mucosa of rats developing carcinomas after surgically induced enterogastric reflux.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer (†).
Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.
Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model.
Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo.
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
[Increased phospholipase A2 and diacylglycerol lipase activities in colorectal carcinoma: possibility for carcinoma prevention or therapy?]
Carcinoma, Ductal
Deletion of phospholipase A2 group IVc induces apoptosis in rat mammary tumour cells by the nuclear factor-?B/lipocalin 2 pathway.
Carcinoma, Ehrlich Tumor
Cell swelling activates phospholipase A2 in Ehrlich ascites tumor cells.
Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom.
Hypotonic cell swelling induces translocation of the alpha isoform of cytosolic phospholipase A2 but not the gamma isoform in Ehrlich ascites tumor cells.
The high calcium ion uptake capacity of Ehrlich ascites tumour cell mitochondria is due to inhibition of the permeability transition and phospholipase A2 activity by magnesium.
Carcinoma, Hepatocellular
85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells.
A novel phospholipase A2 associated with nuclear matrix: stimulation of the activity and modulation of the Ca2+ dependency by polyphosphoinositides.
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Aryl hydrocarbon receptor-mediated induction of the cytosolic phospholipase A(2)alpha gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse hepatoma Hepa-1c1c7 cells.
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Dysfunction of PLA2G6 and CYP2C44-associated network signals imminent carcinogenesis from chronic inflammation to hepatocellular carcinoma.
Elevated Expression of Cytosolic Phospholipase A2 Delta Is Associated with Lipid Metabolism Dysregulation during Hepatocellular Carcinoma Progression.
Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma.
Glucocorticoids inhibit oncostatin M-induced phospholipase A2 gene expression in human hepatoma cells.
Glycogen synthase kinase-3beta negatively regulates group IIA phospholipase A2 expression in human aortic smooth muscle and HepG2 hepatoma cells.
Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry.
In situ reverse transcriptase-nested polymerase chain reaction to identify intracellular nucleic acids without the necessity of DNAse pretreatment and hybridisation.
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
Inhibitory effects of inhibitors of arachidonic acid metabolism on the evolution of rat liver preneoplastic foci into nodules and hepatocellular carcinomas with or without phenobarbital exposure.
Membrane phospholipid composition, fluidity and phospholipase A2 activity of human hepatoma cell line HepG2.
Phospholipase A in the plasma membranes in ascites hepatomas and of normal livers in rat.
Purification and characterization of nuclear alkaline phospholipase A2 in rat ascites hepatoma cells.
Purification and properties of a membrane-bound phospholipase A2 from rat ascites hepatoma 108A cells.
Significant Association Between Adiponutrin and Hepatocellular Carcinoma Risk.
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A2 antagonists.
The ménage à trois of autophagy, lipid droplets and liver disease.
The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma.
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Carcinoma, Non-Small-Cell Lung
A blood biomarker for monitoring response to anti-EGFR therapy.
Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.
Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells.
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun.
Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.
Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells.
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Carcinoma, Ovarian Epithelial
Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer.
Carcinoma, Pancreatic Ductal
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
Carcinoma, Squamous Cell
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cells.
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells.
Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas.
Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue.
Secretory phospholipase A(2) inhibits epidermal growth factor-induced receptor activation.
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Cardiomyopathies
HILIC-MS-based metabolomics reveal that Astragalus polysaccharide alleviates doxorubicin-induced cardiomyopathy by regulating sphingolipid and glycerophospholipid homeostasis.
Therapeutic potential of cPLA2 inhibitor to counteract dilated-cardiomyopathy in cholesterol-treated H9C2 cardiomyocyte and MUNO rat.
Cardiomyopathy, Dilated
Secreted Phospholipase A2-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammation-Fibrosis Link.
Cardiotoxicity
Cardiotoxicity of Naja nigricollis phospholipase A2 is not due to alterations in prostaglandin synthesis.
Cobra cardiotoxin and phospholipase A2 as GAG-binding toxins: on the path from structure to cardiotoxicity and inflammation.
Complete amino acid sequence of an acidic, cardiotoxic phospholipase A2 from the venom of Ophiophagus hannah (King Cobra): a novel cobra venom enzyme with "pancreatic loop".
Crotoxin: novel activities for a classic beta-neurotoxin.
Crystallization and preliminary X-ray analysis of cardiotoxic phospholipase A2 from Ophiophagus hannah (king cobra).
Dissecting Cellular Mechanisms of Long-Chain Acylcarnitines-Driven Cardiotoxicity: Disturbance of Calcium Homeostasis, Activation of Ca2+-Dependent Phospholipases, and Mitochondrial Energetics Collapse.
Effect of alkylation of tryptophan residues on the enzymatic and pharmacological properties of snake venom phospholipase A2.
Exploring the potent inhibitors and binding modes of phospholipase A2 through in silico investigation.
Exploring the structural and functional aspects of the phospholipase A2 from Naja spp.
Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Is direct cardiotoxicity the primary cause of death following i.v. injection of the basic phospholipase A2 from Naja nigricollis venom?
Orthogonal optimization of prokaryotic expression of a natural snake venom phospholipase A2 inhibitor from Sinonatrix annularis.
Oxidant-induced inhibition of myocardial calcium-independent phospholipase A2.
Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2 : insight from molecular docking studies.
Snake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural molecules.
Cardiovascular Diseases
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study.
Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease.
Group IIA Secretory Phospholipase A2 Predicts Graft Failure and Mortality in Renal Transplant Recipients by Mediating Decreased Kidney Function.
Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease.
Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation.
Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease.
Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence.
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) and Future Risk of Type 2 Diabetes: Results from the Cardiovascular Health Study.
On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management.
Phospholipase A2 enzymes in metabolic and cardiovascular diseases.
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms.
Polymorphism of Secretary PLA2G2A gene is Associated with its Serum level in Type2 Diabetes Mellitus Patients in Northern Iran.
Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia.
Reply: Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease.
Role of secretory phospholipase A? in women with metabolic syndrome.
Secretory Phospholipase A2-IIA and Cardiovascular Disease: a Mendelian randomization study.
The Molecular Basis for the Pharmacological Activity of Anthocyans.
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
The therapeutic potential of phospholipase A2 inhibitors in cardiovascular disease.
Tracking of secretory phospholipase A2 enzyme activity levels from childhood to adulthood: a 21-year cohort.
Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
[Lp-PLA2 and sPLA2: cardiovascular biomarkers].
Carotid Artery Diseases
Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers.
Cell adhesion molecules and secretory type II phospholipase A2 in relation to carotid atherosclerosis in patients with hypercholesterolaemia.
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.
Cataract
Age-related cataracts and Prdx 6: Correlation between severity of lens opacity, age, and the level of Prdx 6 expression.
Engineered Sumoylation-Deficient Prdx6 Mutant Protein-Loaded Nanoparticles Provide Increased Cellular Defense and Prevent Lens Opacity.
Fatty acids modulate the efficacy of lutein in cataract prevention: Assessment of oxidative and inflammatory parameters in rats.
Functional role of peroxiredoxin 6 in the eye.
Group II phospholipase A2 content of tears in patients with senile cataract and primary open-angle glaucoma.
Increase of lysosomal phospholipase A2 in aqueous humor by uveitis.
Phospholipase A2 content of aqueous humour in cataract patients.
Reduced expression of 1-cys peroxiredoxin in oxidative stress-induced cataracts.
TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity.
Celiac Disease
Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15.
Cellulitis
Circulating Secretory Phospholipase A2 Activity following Snakebites and Its Relationship with Envenomation Status and Progression of Local Swelling.
Central Nervous System Infections
Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain.
Cerebral Infarction
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
Changes and significance of serum CXCL-16, GDF-15, PLA-2 levels in patients with cerebral infarction.
Diagnostic value of combined serological markers in the detection of acute cerebral infarction.
Long non-coding RNA SNHG14 promotes microglia activation by regulating miR-145-5p/PLA2G4A in cerebral infarction.
Cerebrovascular Disorders
The role of secretory phospholipase A2 in the central nervous system and neurological diseases.
Chagas Disease
A phospholipase A2 gene is linked to Jack bean urease toxicity in the Chagas' disease vector Rhodnius prolixus.
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease.
Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine.
Chlamydophila Infections
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Cholangiocarcinoma
Peroxiredoxin 6 expression is inversely correlated with nuclear factor-?B activation during Clonorchis sinensis infestation.
Cholangitis
Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis.
Cholecystitis
Biochemical and morphological correlations in human gallbladder with reference to membrane permeability.
Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A2.
Cholelithiasis
Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones.
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Cholera
Activation of a keratinocyte phospholipase A2 by bradykinin and 4 beta-phorbol 12-myristate 13-acetate. Evidence for a receptor-GTP-binding protein versus a protein-kinase-C mediated mechanism.
Cholera toxin and pertussis toxin stimulate prostaglandin E2 synthesis in a murine macrophage cell line.
Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells.
Differential effects of T-lymphocyte-derived soluble factor on virgin and primed B lymphocytes in vitro.
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
Molecular characterization of cDNA for phospholipase A2-activating protein.
NMDA receptor-mediated arachidonic acid release in neurons: role in signal transduction and pathological aspects.
PDGF-stimulated cyclic AMP formation in airway smooth muscle: assessment of the roles of MAP kinase, cytosolic phospholipase A2, and arachidonate metabolites.
Permissive stimulation of Ca(2+)-induced phospholipase A2 by an adenosine receptor agonist in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells: a new 'cross-talk' mechanism in Ca2+ signalling.
Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes.
Release of phospholipase A2 activity from rat vascular smooth muscle cells mediated by cAMP.
Renal action of cholera toxin: I. Effects on urinary excretion of electrolytes and cyclic AMP.
Role of mast cells and pro-inflammatory mediators on the intestinal secretion induced by cholera toxin.
Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production.
Studies of the ligand binding to cholera toxin, I. The lipophilic moiety of sialoglycolipids.
Cholestasis
Inhibited serum phospholipase A2 activity in hyperbilirubinemia.
Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice.
Choline Deficiency
Resolution of severe hepatosteatosis in a cystic fibrosis patient with multifactorial choline deficiency: A case report.
Chondrocalcinosis
Cellular activation products in osteoarthritis synovial fluid.
Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis.
Chronic Periodontitis
Activity of platelet activating factor acetylhydrolase following phase I periodontal therapy.
IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
Cleft Palate
[Observing the distribution of Annexin I and cPLA2 in the palatal process of mice by immunohistochemical staining]
Clonorchiasis
Peroxiredoxin 6 expression is inversely correlated with nuclear factor-?B activation during Clonorchis sinensis infestation.
Coinfection
A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver.
Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles.
Colic
D-dimer improves the prognostic value of combined clinical and laboratory data in equine gastrointestinal colic.
Colitis
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis.
Back Cover Picture: Eur. J. Immunol. 2'16.
Berberine Suppresses Colonic Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis Through Inhibition of Cytosolic Phospholipase A2 Activity.
Cytosolic phospholipase A2 ? has a crucial role in the pathogenesis of DSS-induced colitis in mice.
Deficiency of Group VIA Phospholipase A2 (iPLA2?) Renders Susceptibility for Chemical-Induced Colitis.
Effect of putative phospholipase A2 inhibitors on acetic acid-induced acute colitis in the rat.
Group X Secreted Phospholipase A2 Releases ?3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility.
Increase in permeability and phospholipase A2 activity of colonic mucosa in Crohn's colitis.
Increased phospholipase A2 activity in peritoneal leukocytes in rat experimental colitis.
Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.
Prdx6 deficiency ameliorates DSS colitis: relevance of compensatory antioxidant mechanisms.
Role of group IIA phospholipase A2 in rat colitis induced by dextran sulfate sodium.
The role of PGE2 in intestinal inflammation and tumorigenesis.
Colitis, Ulcerative
Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis.
Expression of group XIIA phospholipase A2 in human digestive organs.
Gene expression of group II phospholipase A2 in intestine in ulcerative colitis.
Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease.
Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.
Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis.
Phospholipase A2 in serum and colonic mucosa in ulcerative colitis.
Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors.
Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
Roles of secreted phospholipases A? in the mammalian immune system.
Serum phospholipases A2 in patients undergoing panproctocolectomy because of severe ulcerative colitis.
Colonic Diseases
Group IID, IIE, IIF and III secreted phospholipase A2s.
Colonic Neoplasms
Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
Emerging roles for human glycolipid transfer protein superfamily members in the regulation of autophagy, inflammation, and cell death.
Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.
High molecular weight phospholipase A2: its occurrence and quantification in human colon cancer and normal mucosa.
Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: role of cytosolic phospholipase A2-alpha and kinase signaling pathways.
Identification of Metabolic-Associated Genes for the Prediction of Colon and Rectal Adenocarcinoma.
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Oxidative alterations induced in vitro by the photodynamic reaction in doxorubicin-sensitive (LoVo) and -resistant (LoVoDX) colon adenocarcinoma cells.
Peroxiredoxins and Immune Infiltrations in Colon Adenocarcinoma: Their Negative Correlations and Clinical Significances, an In Silico Analysis.
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Colorectal Neoplasms
Absence of secretory phospholipase A2 gene alterations in human colorectal cancer.
Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer.
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Flavonoids Identified from Korean Scutellaria baicalensis Induce Apoptosis by ROS Generation and Caspase Activation on Human Fibrosarcoma Cells.
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Increased lipid peroxidation in malignant tissues of patients with colorectal cancer.
Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer.
PLA2G4A mutants modified protective effect of tea consumption against colorectal cancer.
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+?? Treg polarization.
Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer.
Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.
Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population.
Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa.
Targeting cytosolic phospholipase A2 ? in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation.
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer.
Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours.
[Genetic steps in colorectal cancer]
[Increased phospholipase A2 and diacylglycerol lipase activities in colorectal carcinoma: possibility for carcinoma prevention or therapy?]
Coma
Development of encephalopathic features similar to Reye syndrome in rabbits.
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Communicable Diseases
Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction.
Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases.
[Role of type II secreted phospholipase A2 in inflammatory processes]
Conjunctivitis
Suppressive effect of antiflammin-2 on compound 48/80-induced conjunctivitis. Role of phospholipase A2s and inducible nitric oxide synthase.
Conjunctivitis, Allergic
Quantification of tear proteins and sPLA2-IIa alteration in patients with allergic conjunctivitis.
Contracture
A phospholipase A2 inhibitor (Ro 31-4493) prevents protein loss associated with the calcium paradox in isolated guinea pig hearts without effect on contracture, calcium overload, or the currents through L-type calcium channels.
Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum.
Characterization of a myotoxin from the Duvernoy's gland secretion of the xenodontine colubrid Philodryas olfersii (green snake): effects on striated muscle and the neuromuscular junction.
Contracture induction by snake venom cardiotoxin in skeletal muscle from humans and rats.
Effects of an acidic phospholipase A2 purified from Ophiophagus hannah (king cobra) venom on rat heart.
Functional characterization of a basic D49 phospholipase A2 (LmTX-I) from the venom of the snake Lachesis muta muta (bushmaster).
Identification of phospholipase A2 and neurotoxic activities in the venom of the New Guinean small-eyed snake (Micropechis ikaheka).
In vitro muscle contractures induced by halothane and suxamethonium. I: The rat diaphragm.
In vitro muscle contractures induced by halothane and suxamethonium. II: Human skeletal muscle from normal and malignant hyperthermia susceptible patients.
Mode of neuromuscular blocking action of toxic phospholipases A2 from Vipera ammodytes venom.
Neuromuscular effects of nigexine, a basic phospholipase A2 from Naja nigricollis venom.
Neurotoxic and myotoxic actions of crotoxin-like and Crotalus durissus cascavella whole venom in the chick biventer cervicis preparation.
Neurotoxic and myotoxic effects of crotalus phospholipase A and its complex with crotapotin.
Pharmacological and structural characterization of a novel phospholipase A2 from Micrurus dumerilii carinicauda venom.
Possible mechanisms of action of cobra snake venom cardiotoxins and bee venom melittin.
Rat atrial responses to Bothrops jararacussu (jararacuçu) snake venom.
The role of enzyme activity and charge properties on the presynaptic neurotoxicity and the contracture-inducing activity of snake venom phospholipases A2.
Corneal Diseases
Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
Coronary Artery Disease
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Association between serum secretory phospholipase A2 and risk of ischaemic stroke.
Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent.
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease.
Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease.
Exploring calcium ion-dependent effect on the intermolecular interaction between human secreted phospholipase A2 and its peptide inhibitors in coronary artery disease.
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease.
Novel insights of secretory phospholipase a(2) action in cardiology.
Phospholipase A2 and small, dense low-density lipoprotein.
Prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease.
Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention.
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Secretory phospholipase A2 activity in blood serum: The challenge to sense.
Secretory phospholipase A2 in patients with coronary artery disease.
Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease.
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study.
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
[Clinical role of lipoprotein-associated phospholipase A2].
Coronary Disease
A Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA2)-V Isoenzyme in Coronary Heart Disease: A Modified Mendelian Randomization Analysis Using PLA2G5 Expression Levels.
Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.
Coronary heart disease and genetic variants with low phospholipase A2 activity.
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
New quinoxalinone inhibitors targeting secreted phospholipase A2 and ?-glucosidase.
Phospholipase A2 enzymes and the risk of atherosclerosis.
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
PLA2G10 Gene Variants, sPLA2 Activity and Coronary Heart Disease Risk.
Potential role of lysophosphatidic acid in hypertension and atherosclerosis.
Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.
Type II Secretory Phospholipase A(2) and Prognosis in Patients with Stable Coronary Heart Disease: Mendelian Randomization Study.
Varespladib methyl in cardiovascular disease.
[Elevated serum secretory type II phospholipase A2 in patients with coronary heart disease]
[Lipoprotein-associated phospholipase A2: importance and perspectives]
Coronary Occlusion
Inhibitory effect of quinacrine on myocardial reactive hyperemia in the dog.
Coronary Stenosis
Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.
Coronavirus Infections
Coronavirus-specific antibody production in middle-aged mice requires phospholipase A2G2D.
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
Cough
Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.
COVID-19
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality.
Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.
Role of arachidonic cascade in COVID-19 infection: A review.
Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Cowpox
Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis.
Crohn Disease
Decreased lysophospholipase and increased phospholipase A2 activity in ileal mucosa from patients with Crohn's disease.
Elevated group II phospholipase A2 mass concentration in serum and colonic mucosa in Crohn's disease.
Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis.
Expression of group XIIA phospholipase A2 in human digestive organs.
Gene expression of group II phospholipase A2 in intestine in Crohn's disease.
Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.
Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease.
In favour of prophylactic treatment for post-operative recurrence in Crohn's disease.
Increase in permeability and phospholipase A2 activity of colonic mucosa in Crohn's colitis.
Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.
Initiation of anastomotic recurrence of Crohn's disease after ileocolic resection. Onset proximal to the junction and preceded by increased phospholipase A2 activity.
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissues.
Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.
Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis.
Possible Involvement of Intracellular Calcium-Independent Phospholipase A2 in the Release of Secretory Phospholipases from Mast Cells-Increased Expression in Ileal Mast Cells of Crohn's Disease.
Presence of group IIa secretory phospholipase A2 in mast cells and macrophages in normal human ileal submucosa and in Crohn's disease.
Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease.
Roles of secreted phospholipases A? in the mammalian immune system.
Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease.
Cryptorchidism
Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism.
Cystic Fibrosis
Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia.
Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosa.
Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines.
Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency.
Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells.
Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line.
Pancreatic lipase and phospholipase A2 concentration in amniotic fluid and the prenatal diagnosis of cystic fibrosis.
Rattlesnake Phospholipase A2 Increases CFTR-Chloride Channel Current and Corrects ?F508CFTR Dysfunction: Impact in Cystic Fibrosis.
Cystitis, Interstitial
Prostacyclin production in tryptase and thrombin stimulated human bladder endothelial cells: effect of pretreatment with phospholipase A2 and cyclooxygenase inhibitors.
Cysts
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
LPAR2 and LPAR4 are the Main Receptors Responsible for LPA Actions in Ovarian Endometriotic Cysts.
Darier Disease
Association study of bipolar disorder at the phospholipase A2 gene (PLA2A) in the Darier's disease (DAR) region of chromosome 12q23-q24.1.
Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study.
Dehydration
Catalytic Ca2+-binding site of pancreatic phospholipase A2: laser-induced Eu3+ luminescence study.
Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice.
Dehydration of the lipid-protein microinterface on binding of phospholipase A2 to lipid bilayers.
Dementia
Analysis of PLA2G6 in patients with frontotemporal type of dementia.
Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.
Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer's disease in Japan.
Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Dementia, Vascular
Platelet phospholipase A(2) activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.
Demyelinating Diseases
Effects of phospholipase A2 on lumbar nerve root structure and function.
Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death.
Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination.
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Dengue
Crotoxin and phospholipases A(2) from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses.
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Insights into the antiviral activity of phospholipases A2 (PLA2s) from snake venoms.
MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles.
Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope.
Rapid phospholipase A2 stimulation and diacylglycerol cholinephosphotransferase inhibition in baby hamster kidney cells during initiation of dengue virus infection.
Secretory phospholipase A2 in the pathogenesis of acute dengue infection.
Serum phospholipase A2 in dengue.
Dermatitis
Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.
Dermatitis, Atopic
Arachidonate release and eicosanoid generation by group IIE phospholipase A(2).
Bee Venom Phospholipase A2 Ameliorates House Dust Mite Extract Induced Atopic Dermatitis Like Skin Lesions in Mice.
CD1a presentation of endogenous antigens by group 2 innate lymphoid cells.
Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A2.
Evaluation of patatin as a major cross-reactive allergen in latex-induced potato allergy.
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Positive skin and oral challenge responses to potato and occurrence of immunoglobulin E antibodies to patatin (Sol t 1) in infants with atopic dermatitis.
The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases.
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch.
[Pathobiochemical importance of phospholipases for the release of mast cell mediators]
Dermatitis, Contact
A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study.
Effect of Crotalus venom on the humoral and cellular immune response.
Expression and Function of Group IIE Phospholipase A2 in Mouse Skin.
Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators.
Diabetes Mellitus
A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese population.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians.
Comparison of the Effects of Combination Atorvastatin (40 mg) + Ezetimibe (10 mg) Versus Atorvastatin (40 mg) Alone on Secretory Phospholipase A2 Activity in Patients With Stable Coronary Artery Disease or Coronary Artery Disease Equivalent.
Decreased phospholipase A2 activity in plasma and liver in uncontrolled diabetes mellitus. A defect in the early steps of prostaglandin synthesis?
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Eicosanoid production and phospholipase A2 activity in uterine tissue from castrated rats with non-insulin dependent diabetes mellitus.
Genetic variants of PLA2G6 are associated with Type 2 diabetes mellitus and triglyceride levels in a Chinese population.
Glucocorticoids use in kidney transplant setting.
Group VIA Phospholipase A2 Mediates Enhanced Macrophage Migration in Diabetes Mellitus by Increasing Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4.
Increased glomerular cytosolic phospholipase A2 activity of OLETF rats with early diabetes.
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Peroxiredoxin6, a Multitask Antioxidant Enzyme Involved in the Pathophysiology of Chronic Noncommunicable Diseases.
Polymorphism of Secretary PLA2G2A gene is Associated with its Serum level in Type2 Diabetes Mellitus Patients in Northern Iran.
Protective Effect of Peroxiredoxin 6 Against Toxic Effects of Glucose and Cytokines in Pancreatic RIN-m5F ?-Cells.
Secretory phospholipase A2 in patients with coronary artery disease.
Spontaneous development of endoplasmic reticulum stress that can lead to diabetes mellitus is associated with higher calcium-independent phospholipase A2 expression: a role for regulation by SREBP-1.
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
[Erythrocyte lipid composition at different stages of type 1 diabetes in children].
[Influence of short-term intensive insulin therapy on plasma concentration of lipoprotein-associated phospholipase A(2) and secretory phospholipase A(2) in newly diagnosed type 2 diabetic patients].
Diabetes Mellitus, Type 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Identification of the transcription factor ARNTL2 as a candidate gene for the type 1 diabetes locus Idd6.
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Protective role for cytosolic phospholipase A2alpha in autoimmune diabetes of mice.
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Diabetes Mellitus, Type 2
A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese population.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians.
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.
Genetic variants of PLA2G6 are associated with Type 2 diabetes mellitus and triglyceride levels in a Chinese population.
Increased glomerular cytosolic phospholipase A2 activity of OLETF rats with early diabetes.
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
Isolation and characterization of cytotoxic and insulin-releasing components from the venom of the black-necked spitting cobra Naja nigricollis (Elapidae).
Peroxiredoxin 6, a novel player in the pathogenesis of diabetes.
Polymorphism of Secretary PLA2G2A gene is Associated with its Serum level in Type2 Diabetes Mellitus Patients in Northern Iran.
[Influence of short-term intensive insulin therapy on plasma concentration of lipoprotein-associated phospholipase A(2) and secretory phospholipase A(2) in newly diagnosed type 2 diabetic patients].
Diabetic Cardiomyopathies
Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.
Diabetic Nephropathies
Enhanced expression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulated rat mesangial cells and in kidneys of diabetic rats.
Increased glomerular cytosolic phospholipase A2 activity of OLETF rats with early diabetes.
Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions.
Sp1-mediated upregulation of Prdx6 expression prevents podocyte injury in diabetic nephropathy via mitigation of oxidative stress and ferroptosis.
[Effect of tangshen formula on phospholipids metabolism in diabetic nephropathy patients].
Diffuse Cerebral Sclerosis of Schilder
Insights into Lewy body disease from rare neurometabolic disorders.
Diphtheria
Inhibition of the myotoxic activity of Bothrops asper myotoxin II in mice by immunization with its synthetic 13-mer peptide 115-129.
The Purification and Concentration of Diphtheria Toxin: I. Evaluation of Previous Methods; Description of a New Procedure.
Disseminated Intravascular Coagulation
Sodium oleate, arachidonate, and linoleate enhance fibrinogenolysis by Russell's viper venom proteinases and inhibit FXIIIa; a role for phospholipase A2 in venom induced consumption coagulopathy.
Down Syndrome
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.
Dry Eye Syndromes
sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model.
sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.
sPLA2-IIa participates in ocular surface inflammation in humans with dry eye disease.
Duodenal Ulcer
Bromophenacyl bromide, a phospholipase A(2) inhibitor attenuates chemically induced gastroduodenal ulcers in rats.
Phospholipase A2 activity in gastric juice from patients with active and H. pylori-eradicated healed duodenal ulcer.
Dysarthria
Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration.
Dyslexia
Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia.
Dyslipidemias
Global Inactivation of the Pla2g6 Gene in Mice Does Not Cause Dyslipidemia under Chow or High-fat Diet Conditions.
Lipid-Modulating Treatments for Mixed Dyslipidemia Increase HDL-Associated Phospholipase A2 Activity with Differential Effects on HDL Subfractions.
Dyspnea
Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.
Dystonia
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex.
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Rare causes of dystonia parkinsonism.
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.
Echinococcosis
Alveolar hydatid cyst induced amyloid enhancing factor (AEF): physicochemical properties and abolition of AEF activity by serine protease inhibitors.
Biochemical nature and cellular origin of amyloid enhancing factor (AEF) as determined by anti-AEF antibody.
Induction of amyloid enhancing factor and its biological properties in murine alveolar hydatidosis.
Eczema
Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema.
Embolism, Fat
Catalytic activity of phospholipase A2 in serum in experimental fat embolism in pigs.
Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
Encephalitis
BK Induces cPLA2 Expression via an Autocrine Loop Involving COX-2-Derived PGE2 in Rat Brain Astrocytes.
Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice.
Role of redox signaling in neuroinflammation and neurodegenerative diseases.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Encephalomyelitis
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation.
Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS.
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation.
Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS.
Phospholipid metabolism in experimental allergic encephalomyelitis: activity of mitochondrial phospholipase A2 of rat brain towards specifically labelled 1,2-diacyl-, 1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-sn-glycero-3-phosphorylcholine.
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.
Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
Endometrial Neoplasms
The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology.
Endometriosis
Elevation of the phospholipase A2 activity in peritoneal fluid cells from women with endometriosis.
Lysophosphatidyl choline, a chemotactic factor for monocytes/T-lymphocytes is elevated in endometriosis.
Macrophage activation factors and cytokines in peritoneal fluid from patients with endometriosis.
Phospholipase A2 group IIA is elevated in endometriomas but not in peritoneal fluid and serum of ovarian endometriosis patients.
The 763C>G Polymorphism of The Secretory PLA2IIa Gene Is Associated with Endometriosis in Iranian Women.
Endotoxemia
Are events after endotoxemia related to circulating phospholipase A2?
Effect of glucocorticoid receptor (GR) blockade on endotoxemia in rats.
HDL in infectious diseases and sepsis.
Involvement of a pertussis toxin-sensitive G-protein-coupled phospholipase A2 in lipopolysaccharide-stimulated prostaglandin E2 synthesis in cultured rat mesangial cells.
Enteritis
Cryptogenia multifocal ulcerous stenosing enteritis: An entity on its own as a cause of abdominal pain, iron deficiency anemia and protein-losing enteropathy.
Epilepsy
cPLA2 in Epilepsy: Shutting Down the Leaker at Its Source.
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy.
Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy.
Neuroinflammatory signaling upregulation in Alzheimer's disease.
Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
Epstein-Barr Virus Infections
Co-existing of HSV1/2 or EBV Infection with the Presence of High-Risk HPV DNA in Cervical Lesions in the Southwest of Iran.
Erythema
Increased synthesis of high-molecular-weight cPLA2 mediates early UV-induced PGE2 in human skin.
Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes.
Escherichia coli Infections
Group V Phospholipase A2 in bone marrow derived myeloid cells and bronchial epithelial cells promote bacterial clearance after E. coli pneumonia.
mRNA differential display of acute-phase proteins in experimental Escherichia coli infection.
Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection.
Esophageal Neoplasms
Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery.
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Secretory Phospholipase A(2) Inhibition Attenuates Intercellular Adhesion Molecule-1 Expression in Human Esophageal Adenocarcinoma Cells.
Spatially resolved metabolomics combined with multicellular tumor spheroids to discover cancer tissue relevant metabolic signatures.
Esophageal Squamous Cell Carcinoma
Association of Single Nucleotide Polymorphisms in the Prostaglandin-endoperoxide Synthase 2 (PTGS2) and Phospholipase A2 Group IIA (PLA2G2A) Genes with Susceptibility to Esophageal Squamous Cell Carcinoma.
Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma.
Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Overexpression of phospholipase A2 Group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression.
Esophagitis
Ketoconazole attenuates radiation-induction of tumor necrosis factor.
Leukotrienes in acetylcholine-induced contraction of esophageal circular smooth muscle in experimental esophagitis.
Essential Hypertension
Platelet calmodulin concentration and phospholipase A2 activity in essential hypertension.
Exfoliation Syndrome
Phospholipase A2 content of aqueous humour in cataract patients.
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Exophthalmos
Transdermal Delivery of Adipocyte Phospholipase A2 siRNA using Microneedles to Treat Thyroid Associated Ophthalmopathy-Related Proptosis.
Eye Diseases
Alpha-lecithin:cholesterol acyltransferase deficiency. Lack of both phospholipase A2 and acyltransferase activities characteristic of high density lipoprotein lecithin:cholesterol acyltransferase in fish eye disease.
Human secretory phospholipase A(2), group IB in normal eyes and in eye diseases.
Fatty Liver
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice.
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.
Adiponutrin: A multimeric plasma protein.
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
iPla2? deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.
Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease.
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.
Requirement of Cytosolic Phospholipase A2 gamma in Lipid Droplet Formation.
Tetra-primer ARMS-PCR identified four pivotal genetic variations in bovine PNPLA3 gene and its expression patterns.
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population.
The ménage à trois of autophagy, lipid droplets and liver disease.
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
[Alcoholic and non-alcoholic steatohepatitis: Who is affected and what can we do for them?]
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Fetal Resorption
Prophylactic Effects of Bee Venom Phospholipase A2 in Lipopolysaccharide-Induced Pregnancy Loss.
Fibrosarcoma
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2.
Role of ceramide in stimulation of the transcription of cytosolic phospholipase A2 and cyclooxygenase 2.
Foot-and-Mouth Disease
Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.
Frontotemporal Dementia
Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population.
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
Gallstones
Cholesterol gallstones and bile host diverse bacterial communities with potential to promote the formation of gallstones.
Relative contribution of bile and pancreatic juice duodenogastric reflux in gastric ulcer disease and cholelithiasis.
Role of phospholipase A2 in cholesterol gallstone formation is associated with biliary phospholipid species selection at the site of hepatic excretion: indirect evidence.
Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion.
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Gastritis
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Gastroesophageal Reflux
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model.
Gastrointestinal Neoplasms
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer.
Gaucher Disease
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
gelatinase a deficiency
Modulation of Systemic Metabolism by MMP-2: From MMP-2 Deficiency in Mice to MMP-2 Deficiency in Patients.
Glaucoma
Augmentation of Lysosomal Phospholipase A2 Activity in the Anterior Chamber in Glaucoma.
Betalain exerts a protective effect against glaucoma is majorly through the association of inflammatory cytokines.
Functional role of peroxiredoxin 6 in the eye.
Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage.
Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca(2+) homeostasis.
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
PRDX6 attenuates oxidative stress- and TGFbeta-induced abnormalities of human trabecular meshwork cells.
Prdx6 retards senescence and restores trabecular meshwork cell health by regulating reactive oxygen species.
Glaucoma, Open-Angle
Group II phospholipase A2 content of tears in patients with senile cataract and primary open-angle glaucoma.
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Glioblastoma
Expression of Cytosolic Phospholipase A2 Alpha in Glioblastoma Is Associated With Resistance to Chemotherapy.
Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma.
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
Temozolomide has anti-tumor effects through the phosphorylation of cPLA2 on glioblastoma cells.
Glioma
Benzodiazepines enhance the muscimol-dependent activation of phospholipase A2 in glioma C6 cells.
Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines.
Dying endothelial cells stimulate proliferation of malignant glioma cells via a caspase 3-mediated pathway.
Endothelial PKC?-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
Interleukin-1 beta induces cytosolic phospholipase A2 gene in rats C6 glioma cell line.
Interleukin-1 beta stimulates phospholipase A2 activity in rat C6 glioma cells.
Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier.
Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas.
Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.
Phospholipase A2-mediated inflammation induces regression of malignant gliomas.
Receptor-stimulated phospholipase A2 activation is coupled to influx of external calcium and not to mobilization of intracellular calcium in C62B glioma cells.
The Roles of Peroxiredoxin 6 in Brain Diseases.
The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction.
Glomerulonephritis
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.
Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Group II phospholipase A2 activates mitogen-activated protein kinase in cultured rat mesangial cells.
Immunology of membranous nephropathy: from animal models to humans.
Shedding new light on vasculitis: how the LAMP story unfolded.
[Idiopathic membranous nephropathy: Evolution in understanding the problem].
Glomerulonephritis, Membranous
A cohort study of membranous nephropathy, primary or secondary.
A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor.
A New Chemiluminescence Immunoassay for Phospholipase A2 Receptor 1 Autoantibodies Allows Early Identification of Autoantibody Recurrence in Patients With Membranous Nephropathy.
A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.
A novel time-resolved fluoroimmunoassay based on magnetic microspheres method for detecting antibodies against the phospholipase A2 receptor.
A novel Time-resolved Fluoroimmunoassay for the quantitative detection of Antibodies against the Phospholipase A2 Receptor.
A PLA2R-IgG4 Antibody-Based Predictive Model for Assessing Risk Stratification of Idiopathic Membranous Nephropathy.
A Point-of-Care Immunosensor Based on a Quartz Crystal Microbalance with Graphene Biointerface for Antibody Assay.
A Proposal for a Serology-Based Approach to Membranous Nephropathy.
A Rare Adult Case with Diffuse Segmental Membranous Glomerulonephritis.
ADVANCES IN MEMBRANOUS NEPHROPATHY : SUCCESS STORIES OF A LONG JOURNEY.
An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.
An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.
Analysis of Glomerular IgG Subclasses Switch in Idiopathic Membranous Nephropathy Classified by Glomerular Phospholipase A2 Receptor Antigen and Serum Antibody.
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.
Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.
Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy.
Anti-phospholipase A2 receptor antibody in membranous nephropathy.
Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
Anti-PLA2R-associated membranous nephropathy: a review with emphasis on diagnostic testing methods.
Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation.
Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation.
Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis.
Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy.
Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.
Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.
Antiphospholipase A? receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.
Association between PLA2R1 rs4664308 and susceptibility to idiopathic membranous nephropathy: Protocol for a systematic review and meta-analysis of case-control studies.
Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan.
Association of SNPs in PLA2R1 with idiopathic and secondary membranous nephropathy in two Chinese cohorts.
Autoantibodies against phospholipase A2 receptor in Brazilian patients with glomerular diseases.
Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.
Autoantibodies in renal diseases - clinical significance and recent developments in serological detection.
Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy.
Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy.
Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.
Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.
Circulating antibodies to ?-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy.
Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China.
Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy.
Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy.
Clinical significance of M-type phospholipase A2 receptor and thrombospondin Type 1 domain-containing 7A in primary membranous nephropathy.
Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods.
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.
Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review.
Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis?.
Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy.
Compared staining of the phospholipase A2 receptor in the glomeruli of Chinese adults and children with idiopathic membranous nephropathy.
Comparison of biomarkers between PLA2RAb+ and PLA2RAb- in patients with idiopathic membranous nephropathy.
Complement-induced phospholipase A2 activation in experimental membranous nephropathy.
Correlation and discrepancy of phospholipase A2 receptor staining in membranous nephropathy in paraffin-embedded kidney biopsies.
Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.
Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy.
Detection and Clinical Significance of Glomerular M-type Phospholipase A2 Receptor in Patients with Idiopathic Membranous Nephropathy.
Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy.
Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy.
Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies.
Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy.
Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.
Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.
Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis.
Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans.
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis.
Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.
Differential analysis of urinary albumin for membranous nephropathy patients by online capillary isoelectric focusing - Mass spectrometry.
Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1.
Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy.
Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
Enigma (partially) resolved: phospholipase A2 receptor is the cause of "idiopathic" membranous glomerulonephritis.
Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.
Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study.
Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.
Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy.
Expression of phospholipase A2 receptor in primary cultured podocytes derived from dog kidneys.
Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy.
Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.
Glomerular Diseases Associated with Malignancies: Histopathological Pattern and Association with Circulating Autoantibodies.
Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy.
Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy.
HLA Alleles and Prognosis of PLA2R-Related Membranous Nephropathy.
HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.
HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy.
Identical twins with idiopathic membranous nephropathy.
Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy.
Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.
IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression.
IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study.
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.
Immunohistochemical Glomerular Expression of Phospholipase A2 Receptor in Primary and Secondary Membranous Nephropathy: A Retrospective Study in an Indian Cohort with Clinicopathological Correlations.
Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role.
Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.
Interaction between PLA2R1 and HLA-DQA1 Variants contributes to the increased genetic susceptibility to membranous nephropathy in Western China.
Kimura's disease associated with membranous nephropathy with IgG4 and phospholipase A2 receptor-positive staining of the glomerular basement membrane.
Lipid biology of the podocyte--new perspectives offer new opportunities.
M-type phospholipase A2 receptor (PLA2R) glomerular staining in pediatric idiopathic membranous nephropathy.
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma.
Membranous glomerulopathy: the evolving story.
Membranous Nephropathy and Nonsteroidal Anti-inflammatory Agents.
Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d.
Membranous Nephropathy with Rapid Progression.
Membranous nephropathy-one morphologic pattern with different diseases.
Mercury Intoxication as a Rare Cause of Membranous Nephropathy in a Child.
MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy.
Moore's law for membranous nephropathy.
Nephrotic syndrome: a watershed in the understanding of membranous nephropathy.
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.
Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study.
Pathogenesis of membranous nephropathy: recent advances and future challenges.
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.
Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
Perspectives in membranous nephropathy.
Phospholipase A2 Receptor (PLA2R) Staining Is Useful in the Determination of De Novo Versus Recurrent Membranous Glomerulopathy.
Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy.
Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.
Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy.
Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: Unresolved Issues.
Phospholipase A2 Receptor Antibody IgG4 Subclass Improves Sensitivity and Specificity in the Diagnosis of Idiopathic Membranous Nephropathy.
Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy.
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins.
Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy.
Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis.
Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease: A case report.
Phospholipase A2 Receptor-Positive Idiopathic Membranous Glomerulonephritis with Onset at 95 Years: Case Report.
Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency.
PLA2R and membranous nephropathy: A 3?year prospective Australian study.
PLA2R and THSD7A: Disparate Paths to the Same Disease?
PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians.
PLA2R Immunohistochemistry Staining in Membranous Glomerulopathy: A Challenging Stain to Interpret But a Potentially Useful Diagnostic Tool.
PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes.
Podocytic Infolding Glomerulopathy in a Patient with Phospholipase A2 Receptor-Positive Membranous Nephropathy and Review of the Literature.
Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.
Preparation of an epitope-based recombinant diagnostic antigen specific to anti-phospholipase A2 receptor 1 antibodies.
Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience.
Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management.
Primary Membranous Nephropathy With Enhanced Staining of Exostosin 1/Exostosin 2 in the Glomeruli: A Report of 2 Cases.
Profile of Indian Patients With Membranous Nephropathy.
Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis.
Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.
Progress on the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Rapid, quantitative, and high-sensitivity detection of anti-phospholipase A2 receptor antibodies using a novel CdSe/ZnS-based fluorescence immunosorbent assay.
Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype.
Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir).
Recurrent membranous nephropathy in an allograft caused by IgG3? targeting the PLA2 receptor.
Recurrent membranous nephropathy with a possible alteration in the etiology: a case report.
Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis.
Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy.
Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings.
Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.
Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.
Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study.
Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy.
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.
Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy.
Seropositive PLA2R-associated membranous nephropathy but biopsy-negative PLA2R staining.
Serum Albumin Still of Interest to Predict Outcomes in Membranous Nephropathy in the Era of Phospholipase A2 Receptor.
Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis.
Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study.
Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients.
Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy.
Serum Antibody and Glomerular Antigen of Antiphospholipase A2 Receptor in Chinese Patients with Idiopathic Membranous Nephropathy.
Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: Clinical value assessment.
Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy.
Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen.
Shedding new light on vasculitis: how the LAMP story unfolded.
Single-nucleotide polymorphism rs4664308 in PLA2R1 gene is associated with the risk of idiopathic membranous nephropathy: a meta-analysis.
sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1ser757 signaling pathway.
sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.
Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.
Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes.
Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy.
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.
The association between variants in PLA2R and HLA-DQA1 and renal outcomes in patients with primary membranous nephropathy in Western China.
The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis.
The Evolving Role of Novel Biomarkers in Glomerular Disease: A Review.
The pathogenesis of human membranous nephropathy: we are (almost) there.
The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: A meta-analysis.
The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiation Primary Membranous Nephropathy From Secondary Membranous Nephropathy in Renal Biopsy.
The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation.
THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity.
THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1.
Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
Unmet challenges in membranous nephropathy.
Utility of Determining Autoantibodies to M-type Phospholipase A2 Receptor in Diagnosing Primary Membranous Nephropathy: An Ideal Setting.
Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis.
Validation of phospholipase A2 receptor direct immunofluorescence staining in the diagnosis of primary membranous glomerulonephritis.
[Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
[Association of single nucleotide polymorphism in M-type phospholipase A2 receptor gene with membranous nephropathy].
[Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy].
[Expression of renal PLA2R in patients with idiopathic membranous nephropathy and its relationship with the curative effect of immunotherapy].
[Idiopathic and secondary membranous nephropathies].
[Membranous nephropathy - the most commonly diagnosed glomerulopathy in patients who underwent renal biopsy in the Department of Internal Medicine, Nephrology and Endocrinology St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszow].
[Membranous nephropathy: Pathophysiology and natural history].
[Phospholipase A2 receptor antigen antibodies in serum and renal biopsies of patients with membranous nephropathy].
[Role of M-type phospholipase A2 receptor and its antibody in hepatitis B virus-associated membranous nephropathy].
Glucose Intolerance
Glucocorticoids use in kidney transplant setting.
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Glycogen Storage Disease Type I
[Epidemiology and risk factors of hepatocellular carcinoma].
Graft vs Host Disease
Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d.
Granuloma
Biochemical modes of action of Cassia occidentalis and Cardiospermum halicacabum in inflammation.
Identification and characterization of a phospholipase A1 activity type three secreted protein, PP_ExoU from Pseudomonas plecoglossicida NB2011, the causative agent of visceral granulomas disease in large yellow croaker (Larimichthys crocea).
Stimulation of phospholipase A2 and vascular permeability by an extract of granuloma induced in the rat by carrageenin.
Tetracycline Actions Relevant to Rosacea Treatment.
[Phospholipase A2 activator in carrageenin-induced granuloma of rats]
[Serum and ascitic phospholipase A2 activities and their heat stabilities in taurocholate induced rat acute pancreatitis]
Granulomatous Disease, Chronic
Cytosolic phospholipase A2alpha is targeted to the p47phox-PX domain of the assembled NADPH oxidase via a novel binding site in its C2 domain.
iPLA2 Activation Mediates Granular Exocytosis and Corrects Microbicidal Defects in ROS-Deficient and CGD Human Neutrophils.
The role of reactive oxygen species in thromboxane b2 generation by polymorphonuclear leukocytes.
Graves Disease
Immunoglobulins from Graves' disease patients stimulate phospholipase A2 and C systems in FRTL-5 and human thyroid cells.
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
Graves Ophthalmopathy
Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy.
Guillain-Barre Syndrome
The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats.
Head Injuries, Closed
Brain phospholipase A2 is activated after experimental closed head injury in the rat.
Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue.
Superoxide dismutase activity is not affected by closed head injury in rats.
Heart Arrest
In silico identification of viper phospholipaseA2 inhibitors: validation by in vitro, in vivo studies.
Heart Diseases
The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population.
Heart Failure
Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure.
Exploring the structural and functional aspects of the phospholipase A2 from Naja spp.
The role of calcium-independent phospholipase A2 in cardiolipin remodeling in the spontaneously hypertensive heart failure rat heart.
Heart Neoplasms
[Phospholipase A2, group IIa, as an earlier unknown immunohistological marker of cardiac myxoma]
Heart Rupture
Lack of phospholipase A2 receptor increases susceptibility to cardiac rupture after myocardial infarction.
Helicobacter Infections
Experimental Helicobacter felis infection in transgenic mice expressing human group IIA phospholipase A2.
Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach.
Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection.
Hemangioendothelioma
Origin of circulating group II phospholipase A2 in hepatocytes in a patient with epitheloid hemangioendothelioma of the liver.
Hematologic Diseases
[Expression of Peroxiredoxin-6 Gene in Patients with Acute Myeloid Leukemia and Its Clinical Significance].
Hemochromatosis
A possible link between genetic hemochromatosis and autoimmune thyroiditis.
[Epidemiology and risk factors of hepatocellular carcinoma].
Hemorrhagic Septicemia, Viral
Shape-Shifted Red Blood Cells: A Novel Red Blood Cell Stage?
Hepatic Insufficiency
[The significance of lipid peroxidation (free radical) on hepatocellular dysfunction following hepatectomy]
Hepatitis
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues.
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
[Effect of phytoecdysteroids and steranobols on the activity and stability of membrane-bound enzymes of liver mitochondria in experimental hepatitis]
Hepatitis A
Hepatocyte nuclear factor 4? and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus.
MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles.
Hepatitis B
Expression and characterization of hepatitis B surface antigen in transgenic potato plants.
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.
Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.
[Role of M-type phospholipase A2 receptor and its antibody in hepatitis B virus-associated membranous nephropathy].
Hepatitis B, Chronic
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Hepatitis C
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.
Hepatocyte nuclear factor 4? and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus.
MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles.
Regioselective ?-extension of indoles with rhodium enalcarbenoids--synthesis of substituted carbazoles.
Hepatitis, Chronic
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Hepatoblastoma
Peroxiredoxin 6 Down-Regulation Induces Metabolic Remodeling and Cell Cycle Arrest in HepG2 Cells.
Hepatolenticular Degeneration
Rare causes of dystonia parkinsonism.
Herpes Simplex
Phospholipase A2 activity is copurified together with herpes simplex virus-specified Fc receptor proteins.
Herpes Zoster
GABA, progesterone and zona pellucida activation of PLA2 and regulation by MEK-ERK1/2 during acrosomal exocytosis in guinea pig spermatozoa.
Lysophosphatidylcholine induces changes in physicochemical, morphological, and functional properties of mouse zona pellucida: a possible role of phospholipase A2 in sperm-zona pellucida interaction.
Progesterone primes zona pellucida-induced activation of phospholipase A2 during acrosomal exocytosis in guinea pig spermatozoa.
Zona pellucida induces activation of phospholipase A2 during acrosomal exocytosis in guinea pig spermatozoa.
Histiocytosis, Langerhans-Cell
Group II phospholipase A2 and pulmonary histiocytosis X.
Homozygous Familial Hypercholesterolemia
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Integrated analysis of microRNA and mRNA expression profiles in homozygous familial hypercholesterolemia patients and validation of atherosclerosis associated critical regulatory network.
Hyaline Membrane Disease
Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Hydronephrosis
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Hyperalgesia
Abdominal hyperalgesia in secretory phospholipase A(2)-induced rat pancreatitis: Distinct roles of NK(1) receptors.
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury.
Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products.
Acute thermal hyperalgesia in the rat is produced by activation of N-methyl-D-aspartate receptors and protein kinase C and production of nitric oxide.
Analgesic Effects of Bee Venom Derived Phospholipase A(2) in a Mouse Model of Oxaliplatin-Induced Neuropathic Pain.
Bromoenol Lactone, an Inhibitor of Calcium-Independent Phospholipase A2, Suppresses Carrageenan-Induced Prostaglandin Production and Hyperalgesia in Rat Hind Paw.
Characterization of distinct phospholipases mediating bradykinin and noradrenaline hyperalgesia.
Immediate inhibition of spinal secretory phospholipase A2 prevents the pain and elevated spinal neuronal hyperexcitability and neuroimmune regulatory genes that develop with nerve root compression.
Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice.
Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice.
Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice.
mRNA expression of interleukins, phospholipase A2, and nitric oxide synthase in the nerve root and dorsal root ganglion induced by autologous nucleus pulposus in the rat.
Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats.
Pathomechanism of pain-related behavior produced by allografts of intervertebral disc in the rat.
Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone.
Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide.
Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2.
Spinal phospholipase A2 in inflammatory hyperalgesia: role of the small, secretory phospholipase A2.
Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A2.
Suppressive Effects of Bee Venom-Derived Phospholipase A2 on Mechanical Allodynia in a Rat Model of Neuropathic Pain.
Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin e2 release.
The role of phospholipase A2 and nitric oxide in pain-related behavior produced by an allograft of intervertebral disc material to the sciatic nerve of the rat.
Hypercalcemia
Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors.
Hypercholesterolemia
An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
Hyperemia
Endometrial phospholipases A2, polycystic ovaries and pelvic pain.
Inhibition of phospholipase A2 attenuates functional hyperemia in the hamster cremaster muscle.
Phospholipase A2 induced diffuse alveolar damage--effect of indomethacin and dexamethasone upon morphology and plasma-histamine level.
[Acute purulent parotitis as a sequela of alkylphosphate (E 605) poisoning]
Hypereosinophilic Syndrome
Cytosolic phospholipase A2, increased and activated in the eosinophils of patients with hypereosinophilic syndrome in vivo, is involved in the augmented release of leukotriene C4.
Hypergammaglobulinemia
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.
Hyperglycemia
Activation of the VEGF-A/ERK/PLA2 Axis Mediates Early Retinal Endothelial Cell Damage Induced by High Glucose: New Insight from an In Vitro Model of Diabetic Retinopathy.
Adiponutrin gene is regulated by insulin and glucose in human adipose tissue.
Functional role of peroxiredoxin 6 in the eye.
Gene expression of type I phospholipase A2 in pancreatic beta cells. Regulation of mRNA levels by starvation or glucose excess.
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2.
KLF9 regulates PRDX6 expression in hyperglycemia-aggravated bupivacaine neurotoxicity.
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Peroxiredoxin 6, a novel player in the pathogenesis of diabetes.
Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.
The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance.
Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Hyperinsulinism
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Hyperkalemia
Myoblast transplantation in whole muscle of nonhuman primates.
Hyperlipidemias
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Group 1B phospholipase A? deficiency protects against diet-induced hyperlipidemia in mice.
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.
Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.
sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Thyroid hormone status regulates the expression of secretory phospholipases.
Hyperlipoproteinemia Type II
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Statin therapy and secretory phospholipase A? in children with heterozygous familial hypercholesterolemia.
Hypersensitivity
A murine model of wheat versus potato allergy: Patatin and 53kDa protein are the potential allergen from potato.
Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis.
Anti-inflammatory and antioxidant properties of Helichrysum italicum.
Biologically active molecules regulating the IgE antibody system: biochemical and biological comparisons of suppressive factor of allergy (SFA) and enhancing factor of allergy (EFA).
Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity.
Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines.
Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.
Enzymatic activity of soluble phospholipase A2 does not affect the specific IgE, IgG4 and cytokine responses in bee sting allergy.
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.
Evaluation of patatin as a major cross-reactive allergen in latex-induced potato allergy.
Evaluation of Phototoxic and Skin Sensitization Potentials of PLA 2 -Free Bee Venom.
FcR epsilon+ lymphocytes and regulation of the IgE antibody system. III. Suppressive factor of allergy (SFA) is produced during the in vitro FcR epsilon expression cascade and displays corollary physiologic activity in vivo.
FcR epsilon+ lymphocytes and regulation of the IgE antibody system. V. Preliminary physicochemical characterization of the T cell-selective IgE-induced regulant EIRT.
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages.
Hypersensitivity of an Arabidopsis sugar signaling mutant toward exogenous proline application.
Identification of a B-cell epitope of hyaluronidase, a major bee venom allergen, from its crystal structure in complex with a specific Fab.
In Vitro and In Vivo Anti-Allergic and Anti-Inflammatory Effects of eBV, a Newly Developed Derivative of Bee Venom, through Modulation of IRF3 Signaling Pathway in a Carrageenan-Induced Edema Model.
Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2.
Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.
Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy.
Phospholipase A2 augments contraction and intracellular calcium mobilization through thromboxane A2 in bovine tracheal smooth muscle.
Positive skin and oral challenge responses to potato and occurrence of immunoglobulin E antibodies to patatin (Sol t 1) in infants with atopic dermatitis.
Possible mechanism of painful radiculopathy in lumbar disc herniation.
Prophylactic immunization of mice with phospholipase A2-loaded gas-filled microbubbles is protective against Th2-mediated honeybee venom allergy.
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase.
Recent insights into the structure, function and biology of cPLA2.
Regulation of IgE antibody production by serum molecules. IV. Complete Freund's adjuvant induces both enhancing and suppressive activities detectable in the serum of low and high responder mice.
Sensitivity to bee venom antigen phospholipase A2: association with specific HLA class I and class II alleles and haplotypes in beekeepers and allergic patients.
The IgE antibody system is coordinately regulated by FcR epsilon-positive lymphoid cells and IgE-selective soluble factors.
The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity.
Therapeutic applications of antiflammin peptides in experimental ocular inflammation.
Toward understanding interfacial activation of secretory phospholipase A2 (PLA2): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA2 activation.
Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).
[Investigations on the histology of allergic reactions of the liver to sepatotoxin and myotoxin in experimental animals.]
[Some pathogenetic mechanisms of bacterial bronchial asthma in paecilomycosis]
Hypertension
Alterations to the vascular vasodepressor prostaglandin system in DOCA-salt hypertensive rats and their enzymatic analysis.
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
Correlative studies on the effects of obesity, diabetes and hypertension on gene expression in omental adipose tissue of obese women.
Dexamethasone attenuates reversal of hypertension in one-kidney, one-clip rats.
Lipid alterations in renal membrane of stoke-prone spontaneously hypertensive rats.
Phospholipase A2 in experimental hypertension.
Renal prostaglandins and phospholipase A2 in spontaneously hypertensive rats.
Role of Secretory Phospholipase A2 in Rhythmic Contraction of Pulmonary Arteries of Rats With Monocrotaline-Induced Pulmonary Arterial Hypertension.
Secretory phospholipase A2 in patients with coronary artery disease.
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
The study of the relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure.
TRPV4 activates cytosolic phospholipase A2 via Ca2+ -dependent PKC/ERK1/2 signalling in controlling hypertensive contraction.
[Lipid alterations in renal membrane of stroke-prone spontaneously hypertensive rats (SHRSP)]
[The relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure]
Hypertension, Pulmonary
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Hyperthyroidism
Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
[Determination of phospholipase A2 activity in liver mitochondria using fluorescent dye 1,8-anilinonaphthalene sulfonate]
[Effects of experimental hyperthyroidism on the phospholipase A2, lipase, cholesterolesterase and trypsin activity of the pancreatic juice and of the pancreas in rats]
Hypertriglyceridemia
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Reversal of obesity-induced hypertriglyceridemia by (R)-?-lipoic acid in ZDF (fa/fa) rats.
Hypertrophy, Left Ventricular
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
Hyperventilation
The effect of centrally injected CDP-choline on respiratory system; involvement of phospholipase to thromboxane signaling pathway.
Hypokinesia
Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration.
Hypoparathyroidism
[Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism]
Hypotension
Bothrops leucurus venom induces acute hypotension in rats by means of its phospholipase A2 (blD-PLA2).
Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.
Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.
Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.
Hypothyroidism
Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
Response of mitochondrial function to hypothyroidism in normal and regenerated rat skeletal muscle.
Serum Phospholipase A2-IIA, hs-CRP, and Lipids in Women With Subclinical Hypothyroidism.
Hypoxia, Brain
Potentiation of NMDA receptor currents by arachidonic acid.
Ichthyosis
Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function.
Idiopathic Pulmonary Fibrosis
CREB-dependent LPA-induced signaling initiates a pro-fibrotic feedback loop between small airway basal cells and fibroblasts.
Ileitis
Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis.
Immunoglobulin G4-Related Disease
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.
Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease: A case report.
Infarction, Middle Cerebral Artery
Activation of CRHR1 contributes to cerebral endothelial barrier impairment via cPLA2 phosphorylation in experimental ischemic stroke.
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke.
The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion.
Infections
A bacterially produced virus enhancing factor from an entomopoxvirus enhances nucleopolyhedrovirus infection in armyworm larvae.
A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Activation of apoptosis, but not necrosis, during Mycobacterium tuberculosis infection correlated with decreased bacterial growth: role of TNF-alpha, IL-10, caspases and phospholipase A2.
Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.
Adenovirus type 5 exerts multiple effects on the expression and activity of cytosolic phospholipase A2, cyclooxygenase-2, and prostaglandin synthesis.
An Amperometric Biosensor for the Determination of Bacterial Sepsis Biomarker, Secretory Phospholipase Group 2-IIA Using a Tri-Enzyme System.
An antisense oligonucleotide to 1-cys peroxiredoxin causes lipid peroxidation and apoptosis in lung epithelial cells.
Antibacterial actions of secreted phospholipases A2. Review.
Antibacterial effects of human group IIA and group XIIA phospholipase A2 against Helicobacter pylori in vitro.
Application of pancreatic phospholipase A2 for treatment of bovine mastitis.
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Burkholderia pseudomallei interferes with host lipid metabolism via NR1D2-mediated PNPLA2/ATGL suppression to block autophagy-dependent inhibition of infection.
Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction.
Catalytic and non-catalytic functions of human IIA phospholipase A2.
Characterization by electrospray mass spectrometry of human Ca(2+)-sensitive cytosolic phospholipase A2 produced in baculovirus-infected insect cells.
Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.
Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication.
Club cell 10-kDa protein (CC10) inhibits cPLA2/COX2 pathway to alleviate RSV-induced airway inflammation and AHR.
Conditional knock-out of lipoic acid protein ligase 1 reveals redundancy pathway for lipoic acid metabolism in Plasmodium berghei malaria parasite.
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection.
Crotoxin stimulates an M1 activation profile in murine macrophages during Leishmania amazonensis infection.
Current concepts in the management of preterm labour.
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Cytosolic phospholipase A2 contributes to innate immune defense against Candida albicans lung infection.
Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.
Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity.
Cytosolic phospholipase a2? and eicosanoids regulate expression of genes in macrophages involved in host defense and inflammation.
Cytosolic phospholipase A2? promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.
Cytotoxicity of Vibrio vulnificus cytolysin on rat peritoneal mast cells.
Defining Postpartum Uterine Disease and the Mechanisms of Infection and Immunity in the Female Reproductive Tract in Cattle.
Early identification of bacteremia by biochemical markers of systemic inflammation.
Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis.
Effects of bacteriophage M13 infection upon phospholipid and fatty acid compositions of Escherichia coli.
Effects of human parvovirus B19 VP1 unique region protein on macrophage responses.
Eicosanoid mediation of immune responses at early bacterial infection stage and its inhibition by Photorhabdus temperata subsp. temperata, an entomopathogenic bacterium.
Eicosanoids mediate insect nodulation responses to bacterial infections.
Experimental Helicobacter felis infection in transgenic mice expressing human group IIA phospholipase A2.
Functional coupling and differential regulation of the phospholipase A2-cyclooxygenase pathways in inflammation.
Genes encoding phospholipases A2 mediate insect nodulation reactions to bacterial challenge.
Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections.
Group II phospholipase A2 in serum in critically ill surgical patients.
Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery.
Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells.
Group V Phospholipase A2 in bone marrow derived myeloid cells and bronchial epithelial cells promote bacterial clearance after E. coli pneumonia.
Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach.
Helicobacter pylori associated phospholipase A2 activity: a factor in peptic ulcer production?
High-level production of biologically active human cytosolic phospholipase A2 in baculovirus-infected insect cells.
Host Prdx6 contributing to the intracellular survival of Brucella suis S2 strain.
Human group II phospholipase A2 expressed in Trichoplusia ni larvae--isolation and kinetic properties of the enzyme.
In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.
Inactivation of Peroxiredoxin 6 by the Pla Protease of Yersinia pestis.
Increased flexibility in the use of exogenous lipoic acid by Staphylococcus aureus.
Initiation of labour.
Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles.
Klebsiella pneumoniae induces an inflammatory response in an in vitro model of blood-retinal barrier.
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
Leishmania donovani-Induced Prostaglandin E2 Generation Is Critically Dependent on Host Toll-Like Receptor 2-Cytosolic Phospholipase A2 Signaling.
Lipid mediators and vector infection: Trypanosoma rangeli inhibits Rhodnius prolixus hemocyte phagocytosis by modulation of phospholipase A2 and PAF-acetylhydrolase activities.
Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2.
Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2.
Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis.
Mercury Intoxication as a Rare Cause of Membranous Nephropathy in a Child.
Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection.
Modification of phospholipase C and phospholipase A2 activities during poliovirus infection.
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Modulation of the activity of secretory phospholipase A2 by antimicrobial peptides.
Molecular characterization of infectious clones of the minute virus of canines reveals unique features of bocaviruses.
mRNA differential display of acute-phase proteins in experimental Escherichia coli infection.
Multiple roles of phospholipase A2 during lung infection and inflammation.
Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity.
Peroxiredoxin 6 expression is inversely correlated with nuclear factor-?B activation during Clonorchis sinensis infestation.
Peroxiredoxin 6 phospholipid hydroperoxidase activity in the repair of peroxidized cell membranes.
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Peroxiredoxin-6 Negatively Regulates Bactericidal Activity and NF-?B Activity by Interrupting TRAF6-ECSIT Complex.
Pertussis toxin-sensitive G proteins as mediators of the signal transduction pathways activated by cytomegalovirus infection of smooth muscle cells.
Phospholipase A2 functions in Pseudomonas aeruginosa-induced apoptosis.
Phospholipases A2 in gastric juice of Helicobacter pylori--positive and negative individuals.
Porcine Fc?RI Mediates Porcine Reproductive and Respiratory Syndrome Virus Multiplication and Regulates the Inflammatory Reaction.
Premature labor. II. Bacterial sources of phospholipase.
Preterm labor and bacterial intra-amniotic infection: arachidonic acid liberation by the action of phospholipase A2.
Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of Fusobacterium nucleatum.
Proteomic identification of peroxiredoxin 6 for host defence against Opisthorchis viverrini infection.
Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.
Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity.
Purification of an isoform of patatin with antimicrobial activity against Phytophthora infestans.
Regulation of cytosolic phospholipase A2 expression by cytokines in human amnion cells.
Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Renal deposits of lipoprotein-immunoglobulin complexes in Plasmodium chabaudi-infected mice.
Reprogramming of fatty acid and oxylipin synthesis in rhizobacteria-induced systemic resistance in tomato.
Requirement of Cytosolic Phospholipase A2 gamma in Lipid Droplet Formation.
Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection.
Rickettsia typhi possesses phospholipase A2 enzymes that are involved in infection of host cells.
RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection.
Role of human group IIA secreted phospholipase A2 in malaria pathophysiology: Insights from a transgenic mouse model.
Role of mitogen-activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells.
Roles of secreted phospholipase A2 group IIA in inflammation and host defense.
RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication.
Secreted Group IIA Phospholipase A2 Protects Humans Against the Group B Streptococcus: Experimental and Clinical Evidence.
Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.
Secretory phospholipase A(2) in newborn infants with sepsis.
Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED.
Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).
Secretory phospholipase A2 in the pathogenesis of acute dengue infection.
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Selective Mycobacterium avium-induced production of nitric oxide by human monocyte-derived macrophages.
Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.
Serum mannan-binding lectin (MBL) in patients with infection: clinical and laboratory correlates.
Serum phospholipase A2 in dengue.
Serum phospholipase A2 in patients after splenectomy.
Snake Venom Phospholipases A2: A Novel Tool Against Bacterial Diseases.
Source of group II phospholipase A2 in gastric juice.
Staphylococcus aureus pneumonia in hamsters with elastase-induced emphysema--the virulence enhancing activity of mucin.
Structure of Penaeus stylirostris densovirus, a shrimp pathogen.
Study of the chemical nature of Frp/3 cell recognition units for hepatitis A virus.
The effect of phospholipase A2 from Crotalus durissus collilineatus on Leishmania (Leishmania) amazonensis infection.
The Prostaglandin E2-EP3 Receptor Axis Regulates Anaplasma phagocytophilum-Mediated NLRC4 Inflammasome Activation.
The role of Cryptosporidium parvum-derived phospholipase in intestinal epithelial cell invasion.
The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.
The role of phospholipase in host cell penetration by Toxoplasma gondii.
The role of the innate immune response in hospital- versus community-acquired infection in febrile medical patients.
Toll/IMD signal pathways mediate cellular immune responses via induction of intracellular PLA 2 expression.
Transcriptomic profiling of phospholipase A2 and the role of arachidonic acid during Brucella abortus 544 infection in both in vitro and in vivo systems.
Type 1 interferon-dependent repression of NLRC4 and iPLA2 licenses down-regulation of Salmonella flagellin inside macrophages.
Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection.
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
[Effect of fish oil on intestinal Paneth cells in mouse with abdominal infection].
[Pathogenesis of myocarditis in patients with bronchial asthma and pecilomycosis].
[Platelet phospholipase A2 mRNA content changes and cDNA cloning in rat blood with bacteria infection]
[Profiles of intracellular expression, distribution, and activation of phospholipase A2 in host macrophages infected with Mycobacterium avium complex]
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis].
Infertility
Cytosolic phospholipase A2 and F2 isoprostanes are involved in semen quality and human infertility-A study on leucocytospermia, varicocele and idiopathic infertility.
Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis.
Peroxiredoxin 6 is the primary antioxidant enzyme for the maintenance of viability and DNA integrity in human spermatozoa.
Infertility, Male
Cytosolic phospholipase A2 and F2 isoprostanes are involved in semen quality and human infertility-A study on leucocytospermia, varicocele and idiopathic infertility.
Mechanistic insights into the urea-induced denaturation of a non-seleno thiol specific antioxidant human peroxiredoxin 6.
Oxidative stress and sperm function: A systematic review on evaluation and management.
Peroxiredoxin 6 regulates the phosphoinositide 3-kinase/AKT pathway to maintain human sperm viability.
[Detection and clinical significance of phospholipase A2 in semen of male infertile patients]
Inflammatory Bowel Diseases
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis.
Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor.
Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407).
Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease.
Elevated group II phospholipase A2 mass concentration in serum and colonic mucosa in Crohn's disease.
Gene expression of group II phospholipase A2 in intestine in Crohn's disease.
Gene expression of group II phospholipase A2 in intestine in ulcerative colitis.
Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease.
Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.
Interleukin-6 changes tight junction permeability and intracellular phospholipid content in a human enterocyte cell culture model.
Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.
Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis.
Phospholipase A2 in inflammatory bowel disease.
Phospholipid-Based Prodrugs for Drug Targeting in Inflammatory Bowel Disease: Computational Optimization and In-Vitro Correlation.
Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease.
Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes.
Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
The effect of phospholipids and fatty acids on tight-junction permeability and bacterial translocation.
Influenza, Human
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
Major Shifts in the Spatio-Temporal Distribution of Lung Antioxidant Enzymes during Influenza Pneumonia.
Production of a viral growth enhancing factor (enhancer) in eggs infected with influenza virus (PR 8).
Insulin Resistance
Adiponutrin gene is regulated by insulin and glucose in human adipose tissue.
Adiponutrin: A new gene regulated by energy balance in human adipose tissue.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Genomic Variants Associated with Resistance to High Fat Diet Induced Obesity in a Primate Model.
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Inflammatory Biomarkers of Cardiometabolic Risk in Obese Egyptian Type 2 Diabetics.
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function.
Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients.
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
Prostaglandin in the ventromedial hypothalamus regulates peripheral glucose metabolism.
Secreted Phospholipase PLA2G2D Contributes to Metabolic Health by Mobilizing ?3 Polyunsaturated Fatty Acids in WAT.
Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.
Secretory Phospholipase A2s in Insulin Resistance and Metabolism.
Skeletal muscle expression of adipose-specific phospholipase in peripheral artery disease.
Specifically PNPLA3-Mediated Accumulation of Liver Fat in Obese Patients with Type 2 Diabetes.
The Molecular Basis for the Pharmacological Activity of Anthocyans.
[Alcoholic and non-alcoholic steatohepatitis: Who is affected and what can we do for them?]
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Insulinoma
Arginine vasopressin-stimulated insulin secretion and elevation of intracellular Ca++ concentration in rat insulinoma cells: influences of a phospholipase C inhibitor 1-[6-[[17 beta-methoxyestra-1,3,5(10)-trien- 17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U-73122) and a phospholipase A2 inhibitor N-(p-amylcinnamoyl)anthranilic acid.
Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells.
Evidence for association of an ATP-stimulatable Ca(2+)-independent phospholipase A2 from pancreatic islets and HIT insulinoma cells with a phosphofructokinase-like protein.
Glucose-responsitivity and expression of an ATP-stimulatable, Ca(2+)-independent phospholipase A2 enzyme in clonal insulinoma cell lines.
Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1.
Pancreatic islets and insulinoma cells express a novel isoform of group VIA phospholipase A2 (iPLA2 beta) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA2 beta transcript.
Peroxiredoxin 6 Attenuates Alloxan-Induced Type 1 Diabetes Mellitus in Mice and Cytokine-Induced Cytotoxicity in RIN-m5F Beta Cells.
Protective Effect of Peroxiredoxin 6 Against Toxic Effects of Glucose and Cytokines in Pancreatic RIN-m5F ?-Cells.
Rat and human pancreatic islet cells contain a calcium ion independent phospholipase A2 activity selective for hydrolysis of arachidonate which is stimulated by adenosine triphosphate and is specifically localized to islet beta-cells.
Studies of insulin secretory responses and of arachidonic acid incorporation into phospholipids of stably transfected insulinoma cells that overexpress group VIA phospholipase A2 (iPLA2beta ) indicate a signaling rather than a housekeeping role for iPLA2beta.
Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress group VIA phospholipase A2.
Studies of the role of group VI phospholipase A2 in fatty acid incorporation, phospholipid remodeling, lysophosphatidylcholine generation, and secretagogue-induced arachidonic acid release in pancreatic islets and insulinoma cells.
The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase.
Intellectual Disability
Both rare and common genetic variants contribute to autism in the Faroe Islands.
Intervertebral Disc Degeneration
Effect of percutaneous nucleoplasty with coblation on phospholipase A2 activity in the intervertebral disks of an animal model of intervertebral disk degeneration: a randomized controlled trial.
Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam.
Intervertebral Disc Displacement
A controlled biochemical and immunohistochemical study of human synovial-type (group II) phospholipase A2 and inflammatory cells in macroscopically normal, degenerated, and herniated human lumbar disc tissues.
Comparative immunohistochemical study of group II (synovial-type) and group IV (cytosolic) phospholipases A2 in disc prolapse tissue.
High levels of inflammatory phospholipase A2 activity in lumbar disc herniations.
Human group II phospholipase A2 in normal and diseased intervertebral discs.
Immunocytochemical localization of immunoglobulins in disc herniations.
Inhibition of phospholipase A2 purified from human herniated disc.
Pathomechanism of pain-related behavior produced by allografts of intervertebral disc in the rat.
Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam.
Phospholipase A2 sensitivity of the dorsal root and dorsal root ganglion.
Possible mechanism of painful radiculopathy in lumbar disc herniation.
The role of phospholipase A2 and nitric oxide in pain-related behavior produced by an allograft of intervertebral disc material to the sciatic nerve of the rat.
Intestinal Diseases
Genetic analysis is helpful for the diagnosis of small bowel ulceration.
Intestinal Polyposis
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Intracranial Aneurysm
Methylation of Phospholipase A2 Group VII Gene Is Associated with Brain Arteriovenous Malformations in Han Chinese Populations.
Iron Overload
A possible link between genetic hemochromatosis and autoimmune thyroiditis.
Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen.
Specific roles for Group V secretory PLA? in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.
Ischemic Attack, Transient
A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.
Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia.
Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia.
Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A2 activity, reduces functional deficits after global ischemia in rats.
Ischemic Stroke
Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes.
Activation of CRHR1 contributes to cerebral endothelial barrier impairment via cPLA2 phosphorylation in experimental ischemic stroke.
Association between serum secretory phospholipase A2 and risk of ischaemic stroke.
Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis.
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Peroxiredoxin 6 secreted by Schwann-like cells protects neuron against ischemic stroke in rats via PTEN/PI3K/AKT pathway.
Phospholipase A2 and Ischemic Stroke Etiology.
Phospholipase A2 and Ischemic Stroke Etiology: Erratum.
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Platelet phospholipase A(2) activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Joint Diseases
Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo.
Inactivation of human synovial fluid phospholipase A2 by the marine natural product, manoalide.
Keratoconjunctivitis Sicca
Group IIA phospholipase A2 content of tears in patients with keratoconjunctivitis sicca.
Keratoconus
Corneal Oxidative Damage in Keratoconus Cells due to Decreased Oxidant Elimination from Modified Expression Levels of SOD Enzymes, PRDX6, SCARA3, CPSF3, and FOXM1.
Kidney Diseases
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.
Excessive arachidonic acid induced actin bunching remodeling and podocyte injury via a PKA-c-Abl dependent pathway.
Glucocorticoids use in kidney transplant setting.
ROS and kidney disease in the evolution from acute phase to chronic end stage disease: A commentary on "Oxidative signaling in renal epithelium: Critical role of cPLA2 and p38SAPK".
Kidney Failure, Chronic
Group I and group II phospholipases A2 in serum in uraemia.
Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor.
Kidney Neoplasms
Bee venom secretory phospholipase A2 and phosphatidylinositol-homologues cooperatively disrupt membrane integrity, abrogate signal transduction and inhibit proliferation of renal cancer cells.
Kimura Disease
Kimura's disease associated with membranous nephropathy with IgG4 and phospholipase A2 receptor-positive staining of the glomerular basement membrane.
Lacrimal Duct Obstruction
TFF peptides and mucins are major components of dacryoliths.
Lecithin Cholesterol Acyltransferase Deficiency
Alpha-lecithin:cholesterol acyltransferase deficiency. Lack of both phospholipase A2 and acyltransferase activities characteristic of high density lipoprotein lecithin:cholesterol acyltransferase in fish eye disease.
Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase.
Leiomyoma
DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids.
The measurement of phospholipase A2 activity in human myometrium: physiological and pathological implications.
Transethnic and race-stratified genome-wide association study of fibroid characteristics in African American and European American women.
Leishmaniasis
Pentalinonsterol, a Phytosterol from Pentalinon andrieuxii, is Immunomodulatory through Phospholipase A2 in Macrophages toward its Antileishmanial Action.
Leishmaniasis, Cutaneous
The effect of phospholipase A2 from Crotalus durissus collilineatus on Leishmania (Leishmania) amazonensis infection.
Leprosy
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Leukemia
A guanine nucleotide-binding protein participates in IgE receptor-mediated activation of endogenous and reconstituted phospholipase A2 in a permeabilized cell system.
Activation mechanism for CRAC current and store-operated Ca2+ entry: calcium influx factor and Ca2+-independent phospholipase A2beta-mediated pathway.
Arachidonic acid release by basophilic leukemia cells and macrophages stimulated by Ca2+ ionophores, antigen and diacylglycerol: essential role for protein kinase C and prevention by glucocorticosteroids.
Bee venom in cancer therapy.
Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins.
Ca2+/calmodulin-dependent protein kinase II and cytosolic phospholipase A2 contribute to mitogenic signaling in myeloblastic leukemia U-937 cells.
Changes of phospholipase A2 inhibitory activity in the K+-sensitive actin gelation factor during the differentiation of myeloid leukemia cells.
Cobra venom cytotoxin free of phospholipase A2 and its effect on model membranes and T leukemia cells.
Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine.
Differentiation of HL60 promyelocytic cells is promoted by a 'differentiation enhancing factor' produced by erythroleukemia cells.
Epigenetic regulation of the PGE2 pathway modulates macrophage phenotype in normal and pathologic wound repair.
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Inhibition of leukotriene synthesis by azelastine.
Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells.
iTRAQ-based proteomics reveals novel biomarkers of osteoarthritis.
Lactadherin inhibits secretory phospholipase A2 activity on pre-apoptotic leukemia cells.
Leukemia inhibitory factor induces the 85-kDa cytosolic phospholipase A2 gene expression in cultured human bronchial epithelial cells.
Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties.
Phospholipase A2 stimulation during cell secretion in rat basophilic leukemia cells.
Potentiation of leukemogenicity and infectivity of Rauscher leukemia virus by an enhancing factor present in egg fluids.
Regulation of interleukin-1 and tumor necrosis factor-alpha induced granulocyte-macrophage colony-stimulating factor gene expression: potential involvement of arachidonic acid metabolism.
Regulation of phospholipase A2 in human leukemia cell lines: its implication for intracellular signaling.
Taiwan cobra phospholipase A2 suppresses ERK-mediated ADAM17 maturation, thus reducing secreted TNF-? production in human leukemia U937 cells.
Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen.
[Granulocyte-macrophage colony enhancing factor activity in supernatant from murine myelo-monocytic leukemia cell line (WEHI-3B)--studies of target cell using hydroxyurea suicide technic]
Leukemia, Erythroblastic, Acute
A vincristine-resistant murine erythroleukemia cell line secretes a differentiation enhancing factor.
Characterization of the biological role of murine erythroleukemia cells "differentiation enhancing factor" using antisense oligodeoxynucleotides.
Cytotoxicity of crotoxin on murine erythroleukemia cells in vitro.
Differentiation of HL60 promyelocytic cells is promoted by a 'differentiation enhancing factor' produced by erythroleukemia cells.
Differentiation of murine erythroleukemia cells by hexamethylenebisacetamide involves secretion and binding to membranes of a differentiation enhancing factor.
Extracellular release of the 'differentiation enhancing factor', a HMG1 protein type, is an early step in murine erythroleukemia cell differentiation.
Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
JNK1/c-Jun and p38 alpha MAPK/ATF-2 pathways are responsible for upregulation of Fas/FasL in human chronic myeloid leukemia K562 cells upon exposure to Taiwan cobra phospholipase A2.
Leukemia, Myeloid
Changes of phospholipase A2 inhibitory activity in the K+-sensitive actin gelation factor during the differentiation of myeloid leukemia cells.
PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia.
Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells.
Regulation of leukotriene-biosynthetic enzymes during differentiation of myelocytic HL-60 cells to eosinophilic or neutrophilic cells.
Leukemia, Myeloid, Acute
PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia.
The expression of cytosolic phospholipase A2 and biosynthesis of leukotriene B4 in acute myeloid leukemia cells.
Leukemia, T-Cell
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Leukodystrophy, Globoid Cell
Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death.
Role of endogenous psychosine accumulation in oligodendrocytes differentiation and survival: Implication for Krabbe disease.
Liposarcoma
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities.
Liver Abscess
Vitamin supplementation increases the virulence of Entamoeba histolytica grown axenically.
Liver Cirrhosis
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients.
Interactions of allelic variance of PNPLA3 with non genetic factors in predicting NASH and non-hepatic complications of severe obesity.
Liver cirrhosis induces renal and liver phospholipase A2 activity in rats.
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
Secreted phospholipase A2 of Clonorchis sinensis activates hepatic stellate cells through a pathway involving JNK signalling.
The NF-?B signalling pathway and TM7SF3 contribute to liver fibrosis caused by secreted phospholipase A2 of Clonorchis sinensis.
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease.
[Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis]
Liver Cirrhosis, Alcoholic
PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.
Liver Diseases
A common variant in the adiponutrin gene influences liver enzyme levels.
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.
Adiponutrin: A multimeric plasma protein.
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population.
Identification and Optimization of a Minor Allele-Specific Small Interfering RNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression of the acute phase response.
iPla2? deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.
Liver diseases and cancer associated with lack of lymphocytic cortisol metabolism enhancing factor.
Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases.
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function.
Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism.
Peroxiredoxin 6 mediates acetaminophen-induced hepatocyte death through JNK activation.
Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease.
Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice.
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Requirement of Cytosolic Phospholipase A2 gamma in Lipid Droplet Formation.
Tetra-primer ARMS-PCR identified four pivotal genetic variations in bovine PNPLA3 gene and its expression patterns.
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
The ménage à trois of autophagy, lipid droplets and liver disease.
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease.
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Liver Diseases, Alcoholic
Adiponutrin (PNPLA3) in liver fibrogenesis: Is unaltered HepG2 cell line a better model system compared to murine models?
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Role of cytochrome P450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity.
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease.
Liver Failure
Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.
Liver Failure, Acute
Mucosal expression of defensin-5, soluble phospholipase A2 and lysozyme in the intestine in a rat model of acute liver failure and its relationship to intestinal bacterial translocation.
[Expression of intestinal defensin-5, soluble phospholipase A2 and lysozyme and the relation to bacterial translocation in rat models of acute liver failure].
Liver Neoplasms
PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.
The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients.
Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition.
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Lung Diseases
Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia.
AdipoR-increased intracellular ROS promotes cPLA2 and COX-2 expressions via activation of PKC and p300 in adiponectin-stimulated human alveolar type II cells.
Drastic changes in the tissue-specific expression of secreted phospholipases A2 in chicken pulmonary disease.
Pathophysiologic changes induced by phospholipase A2 in the isolated, perfused guinea pig lung.
Phospholipase A2-induced pathophysiologic changes in the guinea pig lung.
Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
Lung Diseases, Obstructive
Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease.
Lung Injury
A Peptide Inhibitor of NADPH Oxidase (NOX2) Activation Markedly Decreases Mouse Lung Injury and Mortality Following Administration of Lipopolysaccharide (LPS).
A Peptide Inhibitor of Peroxiredoxin 6 Phospholipase A2 Activity Significantly Protects against Lung Injury in a Mouse Model of Ventilator Induced Lung Injury (VILI).
A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice.
Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2.
Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice.
Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration.
Bile acids increase alveolar epithelial permeability via MAP kinase, cytosolic phospholipase A2 , cyclooxygenase-2, PGE2 and junctional proteins.
Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome.
Cell-specific expression of group X and group V secretory phospholipases A(2) in human lung airway epithelial cells.
Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice.
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model.
Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells.
Feasibility of extracellular competitive inhibition of phospholipase A2 in neonatal and pediatric lung injury.
Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion.
Gut phospholipase A2 mediates neutrophil priming and lung injury after mesenteric ischemia-reperfusion.
Human meconium has high phospholipase A2 activity and induces cellular injury and apoptosis in piglet lungs.
In vivo function of surfactants containing phosphatidylcholine analogs.
Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury.
Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia.
Inhibitory effects of surfactant protein A on surfactant phospholipid hydrolysis by secreted phospholipases A2.
Lung injury and mortality with hyperoxia are increased in peroxiredoxin 6 gene-targeted mice.
Natural disruption of group 2 phospholipase A2 gene protects against choline-deficient ethionine-supplemented diet-induced acute pancreatitis and lung injury.
Neutrophils and neutrophil products do not mediate pulmonary hemodynamic effects of endotoxin on oleic acid-induced lung injury.
Pancreatic phospholipase A2 contributes to lung injury in experimental meconium aspiration.
Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress.
Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.
Phospholipase A2 in meconium-induced lung injury.
Phospholipase A2 inhibition decouples lung injury from gut ischemia-reperfusion.
Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis.
Phospholipase A2-induced lung edema and its mechanism in isolated perfused guinea pig lung.
Phospholipase A2-induced pathophysiologic changes in the guinea pig lung.
Polydatin up-regulates Clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro.
Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Telomere shortening activates TGF-?/Smads signaling in lungs and enhances both lipopolysaccharide and bleomycin-induced pulmonary fibrosis.
The protective effect of mepacrine on acute lung edema induced by phorbol myristate acetate in rats.
Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection.
Transgenic mice overexpressing peroxiredoxin 6 show increased resistance to lung injury in hyperoxia.
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
[Antioxidative role of peroxiredoxin 6 in acute lung injury]
[Relationship between cytoplasmic phospholipase A2 and nuclear factor ?B in one lung ventilation-induced lung injury in rabbits].
Lung Neoplasms
A blood biomarker for monitoring response to anti-EGFR therapy.
Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression.
Anti-Cancer Effect of Thiacremonone through Down Regulation of Peroxiredoxin 6.
Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.
Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.
Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells.
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun.
Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.
Inhibition of PLA2G4A Reduces the Expression of Lung Cancer-Related Cytokines.
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Long non?coding RNA SLNCR1 regulates non?small cell lung cancer migration, invasion and stemness through interactions with secretory phospholipase A2.
Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development.
Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A? inhibition.
Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2.
Lung tumor growth-promoting function of peroxiredoxin 6.
Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells.
Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells.
Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt.
Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells.
Phospholipase A2 inhibitory activity in lung cancer cell lines.
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities.
PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model.
Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.
Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data.
Prognostic roles of mRNA expression of peroxiredoxins in lung cancer.
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.
Surfactant Protein B Suppresses Lung Cancer Progression by Inhibiting Secretory Phospholipase A2 Activity and Arachidonic Acid Production.
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.
Lupus Erythematosus, Cutaneous
Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Lupus Erythematosus, Systemic
Adenosine inhibits the release of arachidonic acid in activated human peripheral mononuclear cells. A proposed model for physiologic and pathologic regulation in systemic lupus erythematosus.
Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity.
Methyltransferase and phospholipase A2 activity in the cell membrane of neutrophils and lymphocytes from patients with Behçet's disease, systemic lupus erythematosus, and rheumatoid arthritis.
Lupus Nephritis
Antibodies to M-Type Phospholipase A2 Receptor (PLA2R) and Membranous Lupus Nephritis.
Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis.
Lyme Disease
Peroxidative metabolism of arachidonic acid in the course of Lyme arthritis.
Lymphangioleiomyomatosis
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Lymphatic Metastasis
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Lymphoma
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Identification of novel bioactive molecules from garlic bulbs: A special effort to determine the anticancer potential against lung cancer with targeted drugs.
Identification of the transgenic integration site in 2C T cell receptor transgenic mice.
Mechanisms by which elevated intracellular calcium induces S49 cell membranes to become susceptible to the action of secretory phospholipase A2.
Plasma phospholipase A2 in children with malignant disorders.
Relationship between membrane permeability and specificity of human secretory phospholipase A(2) isoforms during cell death.
Role of membrane oxidation in controlling the activity of human group IIa secretory phospholipase A(2) toward apoptotic lymphoma cells.
Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
Susceptibility of S49 lymphoma cell membranes to hydrolysis by secretory phospholipase A(2) during early phase of apoptosis.
Lymphoma, B-Cell
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Effects of DMSO-induced differentiation on arachidonate mobilization in the human histiocytic lymphoma cell line U937: responsiveness to sub-micromolar calcium ionophore A23187 and phorbol esters.
Mass spectrometric analysis of arachidonyl-containing phospholipids in human U937 cells.
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Lymphoma, Large-Cell, Anaplastic
Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
Lymphopenia
Group X Secreted Phospholipase A2 Releases ?3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility.
PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients.
Macular Edema
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema: A 3-Month Placebo-Controlled Study.
Malaria
Antimalarial activity of human group IIA secreted phospholipase A2 in relation with enzymatic hydrolysis of oxidized lipoproteins.
Driving midgut-specific expression and secretion of a foreign protein in transgenic mosquitoes with AgAper1 regulatory elements.
In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
Induction of circulating group II phospholipase A2 expression in adults with malaria.
Phospholipid organization in monkey erythrocytes upon Plasmodium knowlesi infection.
Role of human group IIA secreted phospholipase A2 in malaria pathophysiology: Insights from a transgenic mouse model.
Selective elimination of malaria infected erythrocytes by a modified phospholipase A2 in vitro.
Short report: Lethal malaria in cytosolic phospholipase A2- and phospholipase A2IIA-deficient mice.
Malaria, Cerebral
Lipid metabolites of the phospholipase A2 pathway and inflammatory cytokines are associated with brain volume in paediatric cerebral malaria.
Malformations of Cortical Development
Differentially expressed proteins underlying childhood cortical dysplasia with epilepsy identified by iTRAQ proteomic profiling.
Malnutrition
Comparative changes between pancreas and pancreatic juice digestive enzyme contents during nutritional rehabilitation following severe protein malnutrition in the rat.
[Effect of a protein-deficient diet (5 p. 100 gluten) and of balanced refeeding (15 p. 100 casein) on potential lipase, colipase-dependent lipase and phospholipase A2 activities. II. In the pancreatic juice of the growing rat]
Mania
Lithium and the Other Mood Stabilizers Effective in Bipolar Disorder Target the Rat Brain Arachidonic Acid Cascade.
Mastitis
Application of pancreatic phospholipase A2 for treatment of bovine mastitis.
Exogenous phospholipase A2 affects inflammatory gene expression in primary bovine mammary epithelial cells.
Mastocytoma
Arachidonate release and eicosanoid generation by group IIE phospholipase A(2).
Arachidonic acid, a growth signal in murine P815 mastocytoma cells.
Characteristics and possible functions of mast cell phospholipases A2.
Characterization of cytosolic phospholipase A2 in rat mastocytoma RBL-2H3.
Detection of secretory phospholipase A2s related but not identical to type IIA isozyme in cultured mast cells.
Detection of three distinct phospholipases A2 in cultured mast cells.
Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms.
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells.
Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli.
[Activation of phospholipase hydrolysis in the process of oxidative cell damage]
[Pathobiochemical importance of phospholipases for the release of mast cell mediators]
Measles
Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins.
Meconium Aspiration Syndrome
Meconium aspiration syndrome: a role for phospholipase A2 in the pathogenesis?
Pancreatic phospholipase A2 contributes to lung injury in experimental meconium aspiration.
Secreted Phospholipase A2 is Increased in Meconium-Stained Amniotic Fluid of Term Gestations: Potential Implications for the Genesis of Meconium Aspiration Syndrome.
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Melanoma
Anticancer properties of phospholipase A2 from Daboia siamensis venom on human skin melanoma cells.
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Cloning of the human phospholipase A2 activating protein (hPLAP) gene on the chromosome 9p21 melanoma deleted region.
Comprehensive identification of novel post-translational modifications in cellular peroxiredoxin 6.
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.
Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2.
Increased sensitivity to TNF-mediated cytotoxicity of BL6 melanoma cells after H-2Kb gene transfection.
Influence of germline genetic variants on dermoscopic features of melanoma.
Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.
Partial characterization, in vitro antioxidant and antiproliferative activities of patatin purified from potato fruit juice.
Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling.
Phenotypic and Genotypic Analysis of Amelanotic and Hypomelanotic Melanoma Patients.
Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
Purification and characterization of a low molecular weight multifunctional cytotoxic phospholipase A2 from Russell's viper venom.
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells.
Melanoma, Experimental
Cellular responses to Pyrularia thionin are mediated by Ca2+ influx and phospholipase A2 activation and are inhibited by thionin tyrosine iodination.
Meningioma
Platelet-activating factor and human meningiomas.
Meningococcal Infections
[Lipid composition of erythrocyte membranes and blood serum in meningococcal infections in children]
Meningomyelocele
Amniotic fluid levels of phospholipase A2 in fetal rats with retinoic acid induced myelomeningocele: the potential "second hit" in neurologic damage.
Menorrhagia
Phospholipase activity in the endometrium of women with normal menstrual blood loss and women with proven ovulatory menorrhagia.
The activity of calcium dependent and calcium independent phospholipase A2 in normal endometrium and in endometrium from women suffering from menorrhagia and polycystic ovary syndrome.
Mesothelioma
Intraperitoneal mesotheliomas induced in mice by a polycyclic aromatic hydrocarbon.
Metabolic Diseases
Adiponutrin: A multimeric plasma protein.
Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.
Mechanistic insights into the urea-induced denaturation of a non-seleno thiol specific antioxidant human peroxiredoxin 6.
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Peroxiredoxin 6 overexpression regulates adriamycin-induced myocardial injury, oxidative stress and immune response in rats.
Phospholipase A2 enzymes in metabolic and cardiovascular diseases.
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
Metabolic Syndrome
17? Estradiol Modulates Perfusion Pressure and Expression of 5-LOX and CYP450 4A in the Isolated Kidney of Metabolic Syndrome Female Rats.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
An Inhibitor of Phospholipase A2 Group IIA Modulates Adipocyte Signaling and Protects Against Diet-Induced Metabolic Syndrome in Rats.
Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Inhibitory effects of various solvent extracts from Rhamnus frangula leaves on some inflammatory and metabolic enzymes.
Lipopolysaccharide promoted proliferation and adipogenesis of preadipocytes through JAK/STAT and AMPK-regulated cPLA2 expression.
Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.
Role of secretory phospholipase A? in women with metabolic syndrome.
Utility of metabolic syndrome as a risk enhancing factor in decision of statin use.
Mevalonate Kinase Deficiency
Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Microscopic Polyangiitis
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.
Miosis
[Effect of ultraviolet light on the hamster pupil]
Mitochondrial Diseases
Insights into Lewy body disease from rare neurometabolic disorders.
Mitochondrial Myopathies
Mitochondrial cytochemistry in experimental myopathies.
Mouth Neoplasms
Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX-2.
Movement Disorders
Dystonic opisthotonus: A "red flag" for neurodegeneration with brain iron accumulation syndromes?
The PLA2G6 gene in early-onset Parkinson's disease.
Mucositis
Ketoconazole attenuates radiation-induction of tumor necrosis factor.
Multiple Sclerosis
Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
Alterations in the activity of phospholipases A2 in postmortem white matter from patients with multiple sclerosis.
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.
Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
The role of phospholipase A2 in multiple Sclerosis: A systematic review and meta-analysis.
[On the activity of phospholipase A2 compared with 1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-glycerophosphatides in multiple sclerosis (author's transl)]
Multiple Sclerosis, Relapsing-Remitting
Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
Secretory Phospholipase A2 activity in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
Muscle Hypotonia
A Case of Infantile Neuroaxonal Dystrophy of Neonatal Onset.
Cerebellar atrophy without cerebellar cortex hyperintensity in infantile neuroaxonal dystrophy (INAD) due to PLA2G6 mutation.
Muscle Spasticity
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Muscle Weakness
Calcium-dependent phospholipase A2 Modulates Infection Induced Diaphragm Dysfunction.
Interactions between Cytosolic Phospholipase A2 Activation and Mitochondrial Reactive Oxygen Species Production in the Development of Ventilator-Induced Diaphragm Dysfunction.
Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports.
Muscular Atrophy
Genetic ablation of 12/15-lipoxygenase but not 5-lipoxygenase protects against denervation-induced muscle atrophy.
Inhibition of cPLA2 has neuroprotective effects on motoneuron and muscle atrophy following spinal cord injury.
Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein.
Sodium fluoride induced skeletal muscle changes: Degradation of proteins and signaling mechanism.
Targeting cPLA2 derived lipid hydroperoxides as a potential intervention for sarcopenia.
Muscular Diseases
Loss of Function Variants in Human PNPLA8 Encoding Calcium-Independent Phospholipase A2 ? Recapitulate the Mitochondriopathy of the Homologous Null Mouse.
Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy.
Patients with neutral lipid storage disease with myopathy (NLSDM) in Southwestern China.
Proteome and transcriptome profiling of equine myofibrillar myopathy identifies diminished peroxiredoxin 6 and altered cysteine metabolic pathways.
Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene.
Whole genome sequencing reveals biallelic PLA2G6 mutations in siblings with cerebellar atrophy and cap myopathy.
Muscular Dystrophies
Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Laser-inflicted injury of zebrafish embryonic skeletal muscle.
Notexin-induced muscle injury in the dog.
Muscular Dystrophies, Limb-Girdle
Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Muscular Dystrophy, Duchenne
Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Notexin-induced muscle injury in the dog.
Phospholipase A2 activity in dystrophinopathies.
Myalgia
Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
Mycoses
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Toll/IMD signal pathways mediate cellular immune responses via induction of intracellular PLA 2 expression.
Myocardial Infarction
A decrease in plasma factor which stimulates prostaglandin I2 synthesis in patients with acute myocardial infarction.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Association of PLA2G4A with myocardial infarction is modulated by dietary PUFAs.
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
Identification and characterization of human myocardial phospholipase A2 from transplant recipients suffering from end-stage ischemic heart disease.
Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction.
Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction?
Inhibition of type 2A secretory phospholipase A(2) reduces death of cardiomyocytes in acute myocardial infarction.
Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation.
Lack of phospholipase A2 receptor increases susceptibility to cardiac rupture after myocardial infarction.
Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction.
Neuroprotective effects of a nanocrystal formulation of sPLA(2) inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils.
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Phospholipase A2 expression in coronary thrombus is increased in patients with recurrent cardiac events after acute myocardial infarction.
Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-?-independent manner.
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
Plasma phospholipase A2 activity in clinical acute myocardial infarction.
Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice.
Roles of secreted phospholipases A? in the mammalian immune system.
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation.
Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction.
Serum phospholipase A2 and lysolecithin changes following myocardial infarction.
Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
Study on the relationship of cPLA2, CK-MB, and membrane phospholipid content in acute myocardial infarction.
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
Myocardial Ischemia
Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate.
Activation of myocardial cAMP-dependent protein kinase by lysoplasmenylcholine.
Analysis of myocardial plasmalogen and diacyl phospholipids and their arachidonic acid content using high-performance liquid chromatography.
Arrhythmogenic and antiarrhythmic effects of lipolytic factors on cultured heart cells.
Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.
Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition.
Electrospray ionization mass spectrometry analyses of nuclear membrane phospholipid loss after reperfusion of ischemic myocardium.
Hot topics in phospholipase A2 field.
Identification and characterization of human myocardial phospholipase A2 from transplant recipients suffering from end-stage ischemic heart disease.
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Purification and characterization of canine myocardial cytosolic phospholipase A2. A calcium-independent phospholipase with absolute f1-2 regiospecificity for diradyl glycerophospholipids.
Recent insights pertaining to sarcolemmal phospholipid alterations underlying arrhythmogenesis in the ischemic heart.
Role of phospholipase A2, C, and D activities during myocardial ischemia and reperfusion.
Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis.
Selective hydrolysis of plasmalogen phospholipids by Ca2+-independent PLA2 in hypoxic ventricular myocytes.
The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A2 during myocardial ischemia.
Thrombin activates a membrane-associated calcium-independent PLA2 in ventricular myocytes.
[Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease]
Myocardial Reperfusion Injury
Role of cytochrome P450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity.
Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury.
Myocarditis
Deficiency of Phospholipase A2 Receptor Exacerbates Autoimmune Myocarditis in Mice.
Secreted Phospholipase A2-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammation-Fibrosis Link.
Myoglobinuria
Establishment of an animal model for myoglobinuria by use of a myotoxin from Pseudechis australis (king brown snake) venom in mice.
Local necrotizing effect of snake venoms on skin and muscle: relationship to serum creatine kinase.
Morphological changes induced by a generalized myotoxin (myoglobinuria-inducing toxin) from the venom of Pseudechis australis (king brown snake) in skeletal muscle and kidney of mice.
Myoblast transplantation in whole muscle of nonhuman primates.
Pathologic changes induced by phospholipase A2 isolated from the venom of Collett's snake, Pseudechis colletti: a light and electron microscopic study.
Renal lesions in rhabdomyolysis caused by Pseudechis australis snake myotoxin.
Myotoxicity
A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A2s.
Ability of antiserum to myotoxin alpha from prairie rattlesnake (Crotalus viridis viridis) venom to neutralize local myotoxicity and lethal effects of myotoxin alpha and homologous crude venom.
Ability of rabbit antiserum against crotapotin to neutralize the neurotoxic, myotoxic and phospholipase A2 activities of crotoxin from Crotalus durissus cascavella snake venom.
ACP-TX-I and ACP-TX-II, Two Novel Phospholipases A2 Isolated from Trans-Pecos Copperhead Agkistrodon contortrix pictigaster Venom: Biochemical and Functional Characterization.
Alkylation of histidine residues of Bothrops jararacussu venom proteins and isolated phospholipases A2: a biotechnological tool to improve the production of antibodies.
Amino acid sequence and biological characterization of BlatPLA2, a non-toxic acidic phospholipase A2 from the venom of the arboreal snake Bothriechis lateralis from Costa Rica.
Ammodytin L, an inactive phospholipase A2 homologue with myotoxicity in mice, binds to the presynaptic acceptor of the beta-neurotoxic ammodytoxin C in Torpedo: an indication for a phospholipase A2 activity-independent mechanism of action of beta-neurotoxins in fish?
An Evaluation of 3-Rhamnosylquercetin, a Glycosylated Form of Quercetin, against the Myotoxic and Edematogenic Effects of sPLA 2 from Crotalus durissus terrificus.
Antibody neutralization of a myotoxin from the venom of Bothrops asper (terciopelo).
Antiophidic solanidane steroidal alkaloids from Solanum campaniforme.
Antitumoral potential of tunisian snake venoms secreted phospholipases A2.
Biochemical and functional studies of ColTx-I, a new myotoxic phospholipase A2 isolated from Crotalus oreganus lutosus (Great Basin rattlesnake) snake venom.
Biochemical characterization and pharmacological properties of a phospholipase A2 myotoxin inhibitor from the plasma of the snake Bothrops asper.
Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor.
Complete amino acid sequence of an acidic, cardiotoxic phospholipase A2 from the venom of Ophiophagus hannah (King Cobra): a novel cobra venom enzyme with "pancreatic loop".
Crotoxin: novel activities for a classic beta-neurotoxin.
Crystal structure of a phospholipase A(2) homolog complexed with p-bromophenacyl bromide reveals important structural changes associated with the inhibition of myotoxic activity.
Crystallization and preliminary X-ray analysis of cardiotoxic phospholipase A2 from Ophiophagus hannah (king cobra).
Daboia Russelli Venom Hyaluronidase: Purification, Characterization and Inhibition by ?-3-(3-Hydroxy-4-Oxopyridyl) ?-Amino-Propionic Acid.
Detection of antibodies to myotoxin a and prairie rattlesnake (Crotalus viridis viridis) venom in three antisera using enzyme-linked immunosorbent assay and immunodiffusion.
Differences in distribution of myotoxic proteins in venoms from different Bothrops species.
Elapid venom toxins: multiple recruitments of ancient scaffolds.
Exploring the binding mechanism and kinetics of Piperine with snake venom secretory Phospholipase A2.
Gallic acid anti-myotoxic activity and mechanism of action, a snake venom phospholipase A2 toxin inhibitor, isolated from the medicinal plant Anacardium humile.
Heterologous expression of the antimyotoxic protein DM64 in Pichia pastoris.
Immunochemical cross-reactivity of neurotoxic phospholipase A2 enzymes from Indian cobra (Naja naja naja) venom using polyclonal antibodies.
In vivo test of the ability of antiserum to myotoxin a from prairie rattlesnake (Crotalus viridis viridis) venom to neutralize local myonecrosis induced by myotoxin a and homologous crude venom.
Inhibition of the myotoxic and hemorrhagic activities of crotalid venoms by Eclipta prostrata (Asteraceae) extracts and constituents.
Intravascular hemolysis induced by the venom of the Eastern coral snake, Micrurus fulvius, in a mouse model: identification of directly hemolytic phospholipases A2.
Isolation and characterization of hyaluronidase a "spreading factor" from Indian cobra (Naja naja) venom.
Isolation and pharmacological characterization of a phospholipase A2 myotoxin from the venom of the Irian Jayan death adder (Acanthophis rugosus).
Isolation of a myotoxin from Bothrops asper venom: partial characterization and action on skeletal muscle.
Lapachol and synthetic derivatives: in vitro and in vivo activities against Bothrops snake venoms.
Mn(2+) ions reduce the enzymatic and pharmacological activities of bothropstoxin-I, a myotoxic Lys49 phospholipase A(2) homologue from Bothrops jararacussu snake venom.
Monoclonal antibodies to VRV-PL-VIIIa, a basic multitoxic phospholipase A2 from Vipera russelli venom.
Myotoxic activity of the toxic phospholipase, notexin, from the venom of the Australian tiger snake.
Myotoxic and cytolytic activities of dimeric Lys49 phospholipase A2 homologues are reduced, but not abolished, by a pH-induced dissociation.
Myotoxicity and physiological effects of three Trimeresurus flavoviridis phospholipases A2.
Neutralizing human anti crotoxin scFv isolated from a nonimmunized phage library.
Neutrophils do not contribute to local tissue damage, but play a key role in skeletal muscle regeneration, in mice injected with Bothrops asper snake venom.
New biological activity against phospholipase A2 by Turmerin, a protein from Curcuma longa L.
Occurrence of sulfated fucose branches in fucosylated chondroitin sulfate are essential for the polysaccharide effect preventing muscle damage induced by toxins and crude venom from Bothrops jararacussu snake.
Orthogonal optimization of prokaryotic expression of a natural snake venom phospholipase A2 inhibitor from Sinonatrix annularis.
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Production and partial characterization of monoclonal antibodies to Bothrops asper (terciopelo) myotoxin.
Purification and amino acid sequence of MP-III 4R D49 phospholipase A2 from Bothrops pirajai snake venom, a toxin with moderate PLA2 and anticoagulant activities and high myotoxic activity.
Purification and primary structure of a myotoxic lysine-49 phospholipase A2 with low lipolytic activity from Trimeresurus gramineus venom.
Purification and properties of hyaluronidase from Hippasa partita (funnel web spider) venom gland extract.
Purification, characterization and cytokine release function of a novel Arg-49 phospholipase A(2) from the venom of Protobothrops mucrosquamatus.
Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2 : insight from molecular docking studies.
Quercetin as an inhibitor of snake venom secretory phospholipase A2.
Shared structural determinants for the calcium-independent liposome membrane permeabilization and sarcolemma depolarization in Bothropstoxin-I, a LYS49-PLA(2) from the venom of Bothrops jararacussu.
Similarities and differences in mechanisms of cardiotoxins, melittin and other myotoxins.
Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity.
Snake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural molecules.
Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A2.
Systemic and local myotoxicity induced by snake venom group II phospholipases A2: comparison between crotoxin, crotoxin B and a Lys49 PLA2 homologue.
The detoxifying effects of structural elements of persimmon tannin on Chinese cobra phospholipase A2 correlated with their structural disturbing effects well.
The early expression of myotoxicity and localization of the binding sites of notexin in the soleus muscle of the rat. Notexin and muscle.
Toxicity of phospholipases A(2) D49 (6-1 and 6-2) and K49 (Bj-VII) from Bothrops jararacussu venom.
Unmasking Snake Venom of Bothrops leucurus: Purification and Pharmacological and Structural Characterization of New PLA2 Bleu TX-III.
Unveiling the elusive and exotic: Venomics of the Malayan blue coral snake (Calliophis bivirgata flaviceps).
Myxedema
Impaired inner medullary production of prostaglandin E2 in the kidney of the myxedematous rat.
Myxoma
Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma.
Effects of LDL lipids on activity of group IIA secretory phospholipase A2.
[Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease]
[Phospholipase A2, group IIa, as an earlier unknown immunohistological marker of cardiac myxoma]
Nasal Polyps
Age dictates a steroid resistant cascade of Wnt5a, transglutaminase-2 and leukotrienes in inflamed airways.
Group II subfamily secretory phospholipase A2 enzymes: expression in chronic rhinosinusitis with and without nasal polyps.
Phospholipase A2-dependent release of inflammatory cytokines by superantigen-stimulated nasal polyps of patients with chronic rhinosinusitis.
PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation.
Neonatal Sepsis
Premature labor. II. Bacterial sources of phospholipase.
Secretory phospholipase A(2) in newborn infants with sepsis.
Neoplasm Metastasis
Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis.
Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells.
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.
Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells.
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Group IIa sPLA2 inhibition attenuates NF-?B activity and promotes apoptosis of lung cancer cells.
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Knockout of PRDX6 induces mitochondrial dysfunction and cell cycle arrest at G2/M in HepG2 hepatocarcinoma cells.
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A? inhibition.
MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA.
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells.
Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis.
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+?? Treg polarization.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis.
Targeting cPLA2? inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/?-catenin pathways.
The effects of group II phospholipase A2 on ras-induced metastasis.
The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer.
Neoplasms
1,25-Dihydroxyvitamin D3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2.
1H MR spectroscopic imaging of phospholipase-mediated membrane lipid release in apoptotic rat glioma in vivo.
5-Lipoxygenase and endotoxin-induced microvascular albumin exchanges and leucocyte recruitment in guinea-pig lungs.
A blood biomarker for monitoring response to anti-EGFR therapy.
A Concise Update on the Relevance of Secretory phospholipase A2 group IIA and Its Inhibitors to Cancer.
A mitogen-activated protein kinase independent pathway involved in the phosphorylation and activation of cytosolic phospholipase A2 in human neutrophils stimulated with tumor necrosis factor-alpha.
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Absence of secretory phospholipase A2 gene alterations in human colorectal cancer.
Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer.
Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
Alterations in eicosanoid levels during U937 bcl-xL tumour growth suppression and recovery in NU/NU mice in vivo-Involvement of phospholipase A2.
Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy.
An echo-contrast agent, Levovist, lowers the ultrasound intensity required to induce apoptosis of human leukemia cells.
Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma.
Annexin I modulates cell functions by controlling intracellular calcium release.
Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression.
Anti-Cancer Effect of Thiacremonone through Down Regulation of Peroxiredoxin 6.
Anticancer double lipid prodrugs: liposomal preparation and characterization.
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis.
Antioxidant effects of N-acetylserotonin: possible mechanisms and clinical implications.
Antisense inhibition of 85-kDa cPLA2 blocks arachidonic acid release from airway epithelial cells.
Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphate.
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Antitumor potential of the myotoxin BthTX-I from Bothrops jararacussu snake venom: evaluation of cell cycle alterations and death mechanisms induced in tumor cell lines.
Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides.
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process.
Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes.
Arachidonic acid mobilization is suppressed during mitosis: role of cytosolic phospholipase A2 activation.
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells.
Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor.
Artocarpin attenuates ultraviolet B-induced skin damage in hairless mice by antioxidant and anti-inflammatory effect.
Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis.
Association of ?-glutamyl transferase with premature coronary artery disease.
Attenuation of atherosclerotic complications by modulating inflammatory responses in hypercholesterolemic rats with dietary Njavara rice bran oil.
Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta.
Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature.
Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome.
Bee venom in cancer therapy.
Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.
Bee venom secretory phospholipase A2 and phosphatidylinositol-homologues cooperatively disrupt membrane integrity, abrogate signal transduction and inhibit proliferation of renal cancer cells.
Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections.
Biomarkers of oxidative stress are associated with frailty: the Framingham Offspring Study.
Blood cytokine and complement levels in patients with sepsis.
Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor.
Bothrops moojeni myotoxin-II, a Lys49-phospholipase A2 homologue: an example of function versatility of snake venom proteins.
Bromoenol Lactone Attenuates Nicotine-Induced Breast Cancer Cell Proliferation and Migration.
BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation.
Cancer cells isolated from malignant pleural and peritoneal effusions inhibit phospholipase A2 activity in human polymorphonuclear leukocytes.
Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.
Cancer: restriction of chemical energy by fatty acids as the common pathway whereby various anti-tumour procedures selectively damage malignant cells in situ.
Carvedilol attenuates l-arginine induced acute pancreatitis in rats through modulation of oxidative stress and inflammatory mediators.
Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2.
Cathepsin B mediates tumor necrosis factor-induced arachidonic acid release in tumor cells.
Cell swelling activates phospholipase A2 in Ehrlich ascites tumor cells.
Ceramide-induced enhancement of secretory phospholipase A2 expression via generation of reactive oxygen species in tumor necrosis factor-alpha-stimulated mesangial cells.
Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin.
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate.
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
Chemopreventive Action of Anthocyanin-rich Black Soybean Fraction in APC (Min/+) Intestinal Polyposis Model.
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Clinical and biological significance of EZH2 expression in endometrial cancer.
Cloning and recombinant expression of a novel mouse-secreted phospholipase A2.
Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom.
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Contribution of Anoctamins to Cell Survival and Cell Death.
Control of angiogenesis by inhibitor of phospholipase A2.
Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2).
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A? and migration in prostate cancer cell RM-1.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
cPLA2a correlates with metastasis and poor prognosis of osteosarcoma by facilitating epithelial-mesenchymal transition.
Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines.
Crotoxin Inhibits Endothelial Cell Functions in Two- and Three-dimensional Tumor Microenvironment.
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Current insights into functions of phospholipase A2 receptor in normal and cancer cells: More questions than answers.
Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells.
Cycloheximide or nordihydroguaiaretic acid protects mice against the lethal and hepatocytolytic effects of a combined challenge with D-galactosamine and bacterial endotoxin.
Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate.
Cytokine- and forskolin-induced synthesis of group II phospholipase A2 and prostaglandin E2 in rat mesangial cells is prevented by dexamethasone.
Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells.
Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells.
Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407).
Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis.
Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells.
Cytosolic phospholipase A2 from human monocytic cells: characterization of substrate specificity and Ca(2+)-dependent membrane association.
Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts.
Cytosolic phospholipase A2 regulates alcohol-mediated astrocyte inflammatory responses in HIV-associated neurocognitive disorders.
Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours.
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.
Cytosolic phospholipase A2: targeting cancer through the tumor vasculature.
Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Damage to mitochondrial respiration chain is related to phospholipase A2 activation caused by tumor necrosis factor.
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.
Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis.
Deletion of phospholipase A2 group IVc induces apoptosis in rat mammary tumour cells by the nuclear factor-?B/lipocalin 2 pathway.
Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
Development- and age-associated expression pattern of peroxiredoxin 6, and its regulation in murine ocular lens.
Dietary Protein and Changes in Biomarkers of Inflammation and Oxidative Stress in the Framingham Heart Study Offspring Cohort.
Differential activation of keratinocyte phospholipase A2S by tumor promoters and other irritants.
Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.
Differential regulation of phospholipase A2 by cytokines inhibiting bone formation and mineralization.
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
Distinct regulation of cytosolic phospholipase A2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes.
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Dual Roles of Group IID Phospholipase A2 in Inflammation and Cancer.
Dysfunction of PLA2G6 and CYP2C44-associated network signals imminent carcinogenesis from chronic inflammation to hepatocellular carcinoma.
Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor-alpha in human intervertebral disc cells in vitro.
Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells.
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
Effects of a treatment with Se-rich rice flour high in resistant starch on enteric dysbiosis and chronic inflammation in diabetic ICR mice.
Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells.
Effects of Docosahexaenoic Acid and Its Peroxidation Product on Amyloid-? Peptide-Stimulated Microglia.
Effects of interleukin 1 beta, tumor necrosis factor alpha and transforming growth factor beta on group II phospholipase A2 activity in rat gingival fibroblasts.
Effects of lipopolysaccharide on phospholipase A2 activity and tumor necrosis factor expression in HL-60 cells.
Effects of swimming on pain and inflammatory factors in rats with lumbar disc herniation.
Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment.
EL-4 tumor cell-induced human and rabbit platelet aggregations.
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile.
Elevated phospholipase A2 activities in plasma samples from multiple cancers.
Elevation of serum group II phospholipase A2 in patients with cancers of digestive organs.
Elevation of serum group II phospholipase A2 levels in patients with advanced cancer.
Emerging roles for phospholipase A(2) enzymes in cancer.
Endothelial PKC?-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
Enhanced tissue expression and elevated circulating level of phospholipase A(2) receptor during murine endotoxic shock.
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate.
Enzymatic action of phospholipase A? on liposomal drug delivery systems.
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.
Epoxyeicosatrienoic acid ameliorates cerebral ischemia-reperfusion injury by inhibiting inflammatory factors and pannexin-1.
Evaluation of cytotoxic activities of snake venoms toward breast (MCF-7) and skin cancer (A-375) cell lines.
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice.
Exogenous surfactant in the treatment of neonatal meconium aspiration syndrome.
Exogenous type-II phospholipase A2 stimulates prostaglandin synthesis in rat liver-derived BRL-3A cells in the presence of tumor necrosis factor alpha.
Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis.
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Expression of cytosolic phospholipase A2 alpha in murine C12 cells, a variant of L929 cells, induces arachidonic acid release in response to phorbol myristate acetate and Ca2+ ionophores, but not to tumor necrosis factor-alpha.
Expression of group II phospholipase A2 in Paneth cells of an adenoma of the rectum. A case report.
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Expression of group XIIA phospholipase A2 in human digestive organs.
Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation.
Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells.
Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth.
Expression of type V secretory phospholipase A in myocardial remodelling after infarction.
Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action.
Fatty acids and expression of adipokines.
Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha- and interleukin-1beta-induced NF-kappa B activation.
Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.
Gene expression differences predict treatment outcome of merkel cell carcinoma patients.
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
Generation of ammodytoxin-anti-cathepsin B immuno-conjugate as a model for delivery of secretory phospholipase A(2) into cancer cells.
Glucocorticoids inhibit oncostatin M-induced phospholipase A2 gene expression in human hepatoma cells.
Glucocorticoids use in kidney transplant setting.
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Group II phospholipase A2 in human male reproductive organs and genital tumors.
Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer.
Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells.
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Group IVA Cytosolic Phospholipase A2 Regulates the G2-to-M Transition by Modulating the Activity of Tumor Suppressor SIRT2.
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.
Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.
Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival.
Growth inhibitory effects and molecular mechanisms of crotoxin treatment in esophageal Eca-109 cells and transplanted tumors in nude mice.
Half-life of interleukin-1 beta-induced group II phospholipase A2 in rat mesangial cells.
HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.
High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue.
High resolution mass spectrometry coupled with multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in Asian women.
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
Hypotonic cell swelling induces translocation of the alpha isoform of cytosolic phospholipase A2 but not the gamma isoform in Ehrlich ascites tumor cells.
Identification of a 27 bp 5'-flanking region element responsible for the low level constitutive expression of the human cytosolic phospholipase A2 gene.
Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry.
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Identification of novel cellular targets in biliary tract cancers using global gene expression technology.
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Identification of peroxiredoxin 6 as a potential lung-adenocarcinoma biomarker for predicting chemotherapy response by proteomic analysis.
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Identification of the transcription factor ARNTL2 as a candidate gene for the type 1 diabetes locus Idd6.
IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.
Immune modulation of glycosaminoglycan derived from P. lewisi in TNF-? stimulated cells.
Immunohistochemical localization of group II phospholipase A2 in the tumours and mucosa of the colon and rectum.
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester.
In vitro comparison of cytotoxic effects of crotoxin against three human tumors and a normal human epidermal keratinocyte cell line.
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells.
Increased gene expression of novel cytosolic and secretory phospholipase A(2) types in human airway epithelial cells induced by tumor necrosis factor-alpha and IFN-gamma.
Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats.
Increased resistance in splenectomized mice to a methylcholanthrene-induced tumour.
Increased serum phospholipase A2 activity after non-heart-beating donor liver transplantation and association with ischemia-reperfusion injury.
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
Induction of circulating group II phospholipase A2 expression in adults with malaria.
Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia.
Induction of cytosolic phospholipase A2 in human leukocytes by lipopolysaccharide.
Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes.
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
Inflammatory biomarkers in patients with sciatica: a systematic review.
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression.
Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.
Inflammatory Process and Molecular Targets for Antiinflammatory Nutraceuticals.
Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs.
Inhibited serum phospholipase A2 activity in hyperbilirubinemia.
Inhibition of 12-O-tetradecanoyl-phorbol-13-acetate-induced tumor promotion by nordihydroguaiaretic acid, a lipoxygenase inhibitor, and p-bromophenacyl bromide, a phospholipase A2 inhibitor.
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets.
Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism.
Inhibition of PLA2G4A Reduces the Expression of Lung Cancer-Related Cytokines.
Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Inhibitors of transcription and translation act synergistically with tumor necrosis factor to cause the activation of phospholipase A2.
Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory responses in both cellular and animal models.
Integrative analysis the characterization of peroxiredoxins in pan-cancer.
Interactions of PLA2-s from Vipera lebetina, Vipera berus berus and Naja naja oxiana venom with platelets, bacterial and cancer cells.
Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells.
Interleukin-1 and tumor necrosis factor stimulate arachidonic acid release and phospholipid metabolism in human myometrial cells.
Interleukin-1 beta, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells.
Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
Interleukin-4 inhibits the gene expression and biosyntheis of cytosolic phospholipase A2 in lipopolysaccharide stimulated U937 macrophage cell line and freshly prepared adherent rheumatoid synovial cells.
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.
Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus.
Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis.
Involvement of formyl peptide receptors in the stimulatory effect of crotoxin on macrophages co-cultivated with tumour cells.
Involvement of lipid mediators on cytokine signaling and induction of secretory phospholipase A2 in immortalized astrocytes (DITNC).
Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor.
Ischaemic preconditioning and TNF-alpha-mediated preconditioning is associated with a differential cPLA2 translocation pattern in early ischaemia.
Isolation and characterization of three inhibitors of thymidine incorporation into bovine fetal liver cells.
Ketoconazole attenuates radiation-induction of tumor necrosis factor.
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Knockout of PRDX6 induces mitochondrial dysfunction and cell cycle arrest at G2/M in HepG2 hepatocarcinoma cells.
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
Lactosylceramide-Induced Phosphorylation Signaling to Group IVA Phospholipase A2 via Reactive Oxygen Species in Tumor Necrosis Factor-?-Treated Cells.
Lentivirus-mediated Inhibition of Tumour Necrosis Factor-? improves motor function associated with PRDX6 in spinal cord contusion rats.
Liposomal formulation of retinoids designed for enzyme triggered release.
Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery.
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Liver diseases and cancer associated with lack of lymphocytic cortisol metabolism enhancing factor.
Long non?coding RNA SLNCR1 regulates non?small cell lung cancer migration, invasion and stemness through interactions with secretory phospholipase A2.
Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development.
Low back pain: pathophysiology and management.
Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A? inhibition.
Lung tumor growth-promoting function of peroxiredoxin 6.
Maleylated-BSA induces hydrolysis of PIP2, fluxes of Ca2+, NF-kappaB binding, and transcription of the TNF-alpha gene in murine macrophages.
Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid.
Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction.
Mercury Intoxication as a Rare Cause of Membranous Nephropathy in a Child.
Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.
Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids.
Metastatic intraperitoneal spread is initiated by phospholipase A2.
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2.
Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity.
Modulated mechanism of phosphatidylserine on the catalytic activity of Naja naja atra phospholipase A2 and Notechis scutatus scutatus notexin.
Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats.
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2).
Modulation of immune response and protective efficacy of recombinant outer-membrane protein F (rOmpF) of Aeromonas hydrophila in Labeo rohita.
Modulation of phospholipase A2 activity by the tumour promoters phorbol esters and teleocidin.
Molecular interactions of phospholipid monolayers with a model phospholipase.
Molecular Link Mechanisms between Inflammation and Cancer.
Momilactone sensitive proteins in Arabidopsis thaliana.
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Multivariate analysis of 9 disease-associated variables for outcome prediction in patients with sepsis.
Mutagenic and genotoxic activities of Phospholipase A2 Bothropstoxin-I from Bothrops jararacussu in Drosophila melanogaster and human cell lines.
MVL-PLA2, a phospholipase A2 from Macrovipera lebetina transmediterranea venom, inhibits tumor cells adhesion and migration.
Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer.
N-Acetylsphingosine stimulates phosphatidylglycerolphosphate synthase activity in H9c2 cardiac cells.
Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Nature of the spleen cell populations capable of releasing tumor enhancing factor.
Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier.
Neuroprotection of taurine through inhibition of 12/15 lipoxygenase pathway in cerebral ischemia of rats.
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
Non-Clinical Studies for Evaluation of 8-C-Rhamnosyl Apigenin Purified from Peperomia obtusifolia against Acute Edema.
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity.
Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas.
NPPR: Genetic Contributions of Inflammation to Depression.
Nucleophosmin Regulates Intracellular Oxidative Stress Homeostasis via Antioxidant PRDX6.
Nutritional factors (nutritional aspects) in biliary disorders: bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction.
Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terrificus venom.
Origin of circulating group II phospholipase A2 in hepatocytes in a patient with epitheloid hemangioendothelioma of the liver.
Over-expression of caveolin-1 aggravate LPS-induced inflammatory response in AT-1 cells via up-regulation of cPLA2/p38 MAPK.
Overexpression and biological function of PRDX6 in human cervical cancer.
Overexpression of major heat shock protein hsp70 inhibits tumor necrosis factor-induced activation of phospholipase A2.
Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma.
Overexpression of Prdx6 and resistance to peroxide-induced death in Hepa1-6 cells: Prdx suppression increases apoptosis.
Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.
Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.
Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells.
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation.
Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells.
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Partial characterization, in vitro antioxidant and antiproliferative activities of patatin purified from potato fruit juice.
Pathophysiology of pulmonary complications of acute pancreatitis.
Perfluorodecanoic acid (PFDA) promotes gastric cell proliferation via sPLA2-IIA.
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma.
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data.
Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factor-induced apoptosis.
Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Phospholipase A2 activating protein induces tumor regression.
Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor.
Phospholipase A2 activation in cultured mouse hepatocytes exposed to tumor necrosis factor-alpha.
Phospholipase A2 activities with a plasmalogen substrate in brain and in neural tumor cells: a sensitive and specific assay using pyrenesulfonyl-labeled plasmenylethanolamine.
Phospholipase A2 activity in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors of rats.
Phospholipase A2 activity in serum is induced during treatment with recombinant human interleukin-6 in patients with cancer.
Phospholipase A2 activity is not involved in the tumor necrosis factor-triggered apoptotic DNA fragmentation in bovine aortic endothelial cells.
Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells.
Phospholipase A2 Drives Tumorigenesis and Cancer Aggressiveness through Its Interaction with Annexin A1.
Phospholipase A2 expression in tumours: a target for therapeutic intervention?
Phospholipase A2 from krait Bungarus fasciatus venom induces human cancer cell death in vitro.
Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer.
Phospholipase A2 inhibitors regulate the proliferation of normal uterine cells.
Phospholipase A2 is a circulating mediator in typhoid fever.
Phospholipase A2 is activated by tumor necrosis factor-alpha in primary hepatocytes stimulated by a deleted form of hepatocyte growth factor.
Phospholipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells.
Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Phospholipase A2 superfamily in cancer.
Phospholipase A2-mediated inflammation induces regression of malignant gliomas.
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia.
Phospholipases A2 in ras-transformed and immortalized human mammary epithelial cells.
PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia.
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+?? Treg polarization.
Plasma Levels of Phospholipase A2-IIA in Patients with Different Types of Malignancies: Prognosis and Association with Inflammatory and Coagulation Biomarkers.
Plasma levels of type II phospholipase A2 and nitrite/nitrate in patients with burns.
Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis.
Plasma phospholipase A2 in children with malignant disorders.
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Platelet activating factor (PAF) antagonists on cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC).
Potentiation of TNF-alpha-stimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells.
Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
PRDX6 Overexpression Promotes Proliferation, Invasion, and Migration of A549 Cells in vitro and in vivo.
PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities.
PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model.
Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Proinflammatory mediator response in coronary bypass surgery using a centrifugal or a roller pump.
Prolactin release from MtTW15 and 7315a pituitary tumors is refractory to TRH and VIP stimulation.
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.
Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2.
Prostaglandin levels in stimulated macrophages are controlled by phospholipase A2-activating protein and by activation of phospholipase C and D.
Prostaglandins and cancer: further stereochemical studies on the molecule of phospholipase A2.
Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
Protective effect of Alpha-Linolenic acid on Lipopolysaccharide-Induced Orchitis in mice.
Protective effects and mechanisms of Baicalin and octreotide on renal injury of rats with severe acute pancreatitis.
Proteomic analysis reveals changes in the liver protein pattern of rats exposed to dietary folate deficiency.
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
Purification and characterization of a low molecular weight multifunctional cytotoxic phospholipase A2 from Russell's viper venom.
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease.
Rapid Screening and Identification of Antitumor Ingredients from the Mangrove Endophytic Fungus Using an Enzyme-Immobilized Magnetic Nanoparticulate System.
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease.
Reflections about Osteoarthritis and Curcuma longa.
Regional arterial infusion with lipoxin A4 attenuates experimental severe acute pancreatitis.
Regulation and inhibition of phospholipase A2.
Regulation of alpha 1-adrenoceptor on rat hepatocyte apoptosis induced by D-galactosamine and lipopolysaccharide.
Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TNFalpha, LPS and M-CSF in human monocytes and macrophages.
Regulation of phospholipase A2 gene expression by tumour necrosis factor alpha in human HepG2 cells.
Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth.
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.
Response of man to endotoxin.
Resveratrol nanoparticle system improves dissolution properties and enhances the hepatoprotective effect of resveratrol through antioxidant and anti-inflammatory pathways.
Role of phospholipase A2 and prostaglandin E in growth and differentiation of myeloid leukemic cells.
Role of the Ha-ras (RasH) oncogene in mediating progression of the tumor cell phenotype (review).
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Schlafen 3 knockout mice display gender-specific differences in weight gain, food efficiency, and expression of markers of intestinal epithelial differentiation, metabolism, and immune cell function.
Search of factors that intermediate cytokine-induced group IIA phospholipase A2 expression through the cytosolic phospholipase A2- and 12/15-lipoxygenase-dependent pathway.
Secreted phospholipase A2 of Clonorchis sinensis activates hepatic stellate cells through a pathway involving JNK signalling.
Secreted Phospholipases A2 Are Intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer.
Secreted phospholipases A2 in cancer: diverse mechanisms of action.
Secreted phospholipases A? are differentially expressed and epigenetically silenced in human breast cancer cells.
Secretory Phospholipase A(2) Inhibition Attenuates Intercellular Adhesion Molecule-1 Expression in Human Esophageal Adenocarcinoma Cells.
Secretory phospholipase A(2) responsive liposomes.
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis.
Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells.
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Secretory phospholipase A2-IIA overexpressing mice exhibit cyclic alopecia mediated through aberrant hair shaft differentiation and impaired wound healing response.
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis.
Secretory PLA(2) inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells.
Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa.
Selective inhibition of human group IIA secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes.
Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors.
Serum mannan-binding lectin (MBL) in patients with infection: clinical and laboratory correlates.
Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2.
Silibinin Down-regulates Expression of Secreted Phospholipase A2 Enzymes in Cancer Cells.
Singlet-Oxygen-Induced Phospholipase A2 Inhibition: A Major Role for Interfacial Tryptophan Dioxidation.
Solid and cystic pancreatic tumors. Clinical, histochemical, and electron microscopic features in ten cases.
Spatially resolved metabolomics combined with multicellular tumor spheroids to discover cancer tissue relevant metabolic signatures.
sPLA2 -IIA Overexpression in Mice Epidermis Depletes Hair Follicle Stem Cells and Induces Differentiation Mediated Through Enhanced JNK/c-Jun Activation.
Stimulation of different phospholipase A2 isoforms by TNF-alpha and IL-1beta in adult rat ventricular myocytes.
Stimulation of group II phospholipase A2 mRNA expression and release in an immortalized astrocyte cell line (DITNC) by LPS, TNF alpha, and IL-1 beta. Interactive effects.
Structural and Functional Aspects of Targeting the Secreted Human Group IIA Phospholipase A2.
Studies of synthetic chalcone derivatives as potential inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and pro-inflammatory cytokines.
Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer.
Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture.
Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells.
Synergistic Effects of Secretory Phospholipase A 2 from the Venom of Agkistrodon piscivorus piscivorus with Cancer Chemotherapeutic Agents.
Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy.
Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue.
Synthesis and catabolism of PGE2 by a nephroblastoma associated with hypercalcemia without bone metastases.
Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents.
Systemic phospholipase A2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure.
Targeting arachidonic acid pathway by natural products for cancer prevention and therapy.
Targeting cPLA2? inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/?-catenin pathways.
Targeting the enzymes involved in arachidonic acid metabolism to improve radiotherapy.
Telmisartan and N-acetylcysteine Suppress Group V Secretory Phospholipase A2 Expression in TNF?-stimulated Human Endothelial Cells and Reduce Associated Atherogenicity.
Temozolomide has anti-tumor effects through the phosphorylation of cPLA2 on glioblastoma cells.
The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor.
The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia - A Prospective Cohort Study.
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action.
The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition.
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
The expression of cytosolic phospholipase A2 and biosynthesis of leukotriene B4 in acute myeloid leukemia cells.
The high calcium ion uptake capacity of Ehrlich ascites tumour cell mitochondria is due to inhibition of the permeability transition and phospholipase A2 activity by magnesium.
The identification of a novel Paneth cell-associated antigen in a familial adenomatous polyposis mouse model.
The induction of cellular group II phospholipase A2 by cytokines and its prevention by dexamethasone.
The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function.
The influence of chronic ibuprofen treatment on proteins expressed in the mouse hippocampus.
The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions.
The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma.
The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approach.
The Molecular Basis for the Pharmacological Activity of Anthocyans.
The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone.
The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma.
The role of inducible nitric oxide synthase in aseptic loosening after total hip arthroplasty.
The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine.
The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia.
Therapeutic potential of arachidonyl trifluromethyl ketone, a cytosolic phospholipaseA2 IVA specific inhibitor, in cigarette smoke condensate-induced pathological conditions in alveolar type I & II epithelial cells.
Therapy with interleukin-2 induces the systemic release of phospholipase-A2.
Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli.
Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.
TNF alpha alters mitochondrial membrane potential in L929 but not in TNF alpha-resistant L929.12 cells: relationship with the expression of stress proteins, annexin 1 and superoxide dismutase activity.
TNF-? Induces Cytosolic Phospholipase A2 Expression in Human Lung Epithelial Cells via JNK1/2- and p38 MAPK-Dependent AP-1 Activation.
TNF-? induces cytosolic phospholipase A2 expression via Jak2/PDGFR-dependent Elk-1/p300 activation in human lung epithelial cells.
TNF-?-Induced cPLA2 Expression via NADPH Oxidase/Reactive Oxygen Species-Dependent NF-?B Cascade on Human Pulmonary Alveolar Epithelial Cells.
TNF-alpha-induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling.
Towards novel radiosensitizing agents: the role of cytosolic PLA2? in combined modality cancer therapy.
Transforming growth factor beta 2 differentially modulates interleukin-1 beta- and tumour-necrosis-factor-alpha-stimulated phospholipase A2 and prostaglandin E2 synthesis in rat renal mesangial cells.
Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition.
Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines.
Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle.
Tumor necrosis factor stimulates human neutrophils to release leukotriene B4 and platelet-activating factor. Induction of phospholipase A2 and acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase activity and inhibition by antiproteinase.
Tumor necrosis factor-alpha and interleukin-1 alpha enhance glucose utilization by astrocytes: involvement of phospholipase A2.
Tumor necrosis factor-alpha induces the 85-kDa cytosolic phospholipase A2 gene expression in human bronchial epithelial cells.
Tumor necrosis factor-alpha priming of phospholipase A2 activation in human neutrophils. An alternative mechanism of priming.
Tumor necrosis factor-alpha stimulates prostaglandin F2alpha secretion by bovine luteal cells via activation of mitogen-activated protein kinase and phospholipase A2 pathways.
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells.
Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A2 in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor.
Tumour necrosis factor-alpha-induced phosphorylation and activation of cytosolic phospholipase A2 are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in human neutrophils.
Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
Using PCR-RFLP technology to teach single nucleotide polymorphism for undergraduates.
VRCTC-310--a novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity.
Walker 256 Tumor Growth Suppression by Crotoxin Involves Formyl Peptide Receptors and Lipoxin A?.
Women with reduced ovarian reserve or advanced maternal age have an altered follicular environment.
[Activation of phospholipase hydrolysis in the process of oxidative cell damage]
[Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]
[Diagnostic effect of bronchoalveolar lavage in early lung injury caused by enterogenic infection in rat]
[Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis]
[Growth inhibition and induction of tumor cell death by phospholipase A2 and lipoxygenase inhibitors]
[Immunologic theory investigation and discussion of pain cause by lumbar intervertebral disc herniation (LDH)]
[Physiopathology of lung injury in acute pancreatitis]
[Purification and anticancer activity of cytotoxin-14 from venom of Naja naja atra]
[Some probable therapeutic effects of the treatment of malignant neoplasms with a combination of lecithinase A, gamma globulin and hyaluronidase.]
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
[The cytotoxic mechanism of tumor necrosis factor (TNF) in human osteosarcoma cell line TE85--(1). Implication of phospholipase A2 activity in cytotoxicity]
[The peripheral blood levels of TNF alpha and PLA2 activities in dialysis and non-dialysis patients with uremia]
[The relationship between opsonin, endotoxin and chemical mediators in postoperative complications after surgery]
[Tumor necrosis factor induced enhancement of neutrophil chemotaxis and adhesion through mediating of phospholipase A2 activation]
Nephritis
Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Nephrosis, Lipoid
[Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy].
Nephrotic Syndrome
Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy.
Antiphospholipase A? receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.
Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis?.
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.
Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine.
Nervous System Diseases
Case report of a novel homozygous splice site mutation in PLA2G6 gene causing infantile neuroaxonal dystrophy in a Sudanese family.
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.
Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.
Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders.
Mitochondria from a mouse model of the human infantile neuroaxonal dystrophy (INAD) with genetic defects in VIA iPLA2 have disturbed Ca(2+) regulation with reduction in Ca(2+) capacity.
Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: Implications for molecular diagnosis.
New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2.
Phospholipases A2 and Inflammatory Responses in the Central Nervous System.
Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Nervous System Neoplasms
Phospholipase A2-mediated inflammation induces regression of malignant gliomas.
Neuralgia
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury.
AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis.
Calcium-independent phospholipase A2 inhibitor produces an analgesic effect in a rat model of neuropathic pain by reducing central sensitization in the dorsal horn.
Crotoxin Conjugated to SBA-15 Nanostructured Mesoporous Silica Induces Long-Last Analgesic Effect in the Neuropathic Pain Model in Mice.
Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Phospholipase A2 Inhibitor-Loaded Phospholipid Micelles Abolish Neuropathic Pain.
Suppressive Effects of Bee Venom-Derived Phospholipase A2 on Mechanical Allodynia in a Rat Model of Neuropathic Pain.
The analgesic effect of crotoxin on neuropathic pain is mediated by central muscarinic receptors and 5-lipoxygenase-derived mediators.
Neuritis
The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats.
Neuritis, Autoimmune, Experimental
The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats.
Neuroaxonal Dystrophies
A Case of Infantile Neuroaxonal Dystrophy of Neonatal Onset.
A new PLA2G6 mutation in a family with infantile neuroaxonal dystrophy.
A novel mitofusin 2 mutation causes canine fetal-onset neuroaxonal dystrophy.
Case report of a novel homozygous splice site mutation in PLA2G6 gene causing infantile neuroaxonal dystrophy in a Sudanese family.
Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.
Cerebellar atrophy without cerebellar cortex hyperintensity in infantile neuroaxonal dystrophy (INAD) due to PLA2G6 mutation.
Characterization of PLA2G6 as a locus for dystonia-parkinsonism.
Clinical and genetic delineation of neurodegeneration with brain iron accumulation.
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy.
Compound heterozygous PLA2G6 loss-of-function variants in Swaledale sheep with neuroaxonal dystrophy.
Differential cerebral cortex transcriptomes of baboon neonates consuming moderate and high docosahexaenoic acid formulas.
Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations.
Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A(2)-VIA (iPLA(2)?)-knockout mice.
Downbeat nystagmus as the presenting symptom of infantile neuroaxonal dystrophy: A case report.
Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6.
Expression of PLA2G6 in human fetal development: Implications for infantile neuroaxonal dystrophy.
Extensive aggregation of ?-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site.
Fetal akinesia deformation sequence and neuroaxonal dystrophy without PLA2G6 mutation.
Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.
Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations.
Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex.
Homozygous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: Further evidence of a fourth phenotype of PLA2G6-associated neurodegeneration.
Identification of the PLA2G6 c.1579G>A Missense Mutation in Papillon Dog Neuroaxonal Dystrophy Using Whole Exome Sequencing Analysis.
Impaired iPLA2? activity affects iron uptake and storage without iron accumulation: an in vitro study excluding decreased iPLA2? activity as the cause of iron deposition in PLAN.
Infantile and childhood onset PLA2G6-associated neurodegeneration in a large North African cohort.
Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: An update for the diagnosis.
Infantile neuroaxonal dystrophy caused by PLA2G6 gene mutation in a Chinese patient: A case report.
Infantile neuroaxonal dystrophy caused by uniparental disomy.
Infantile neuroaxonal dystrophy: what's most important for the diagnosis?
Inherited neuroaxonal dystrophy in dogs causing lethal, fetal-onset motor system dysfunction and cerebellar hypoplasia.
Initial survey of PLA2G6 missense variant causing neuroaxonal dystrophy in Papillon dogs in North America and Europe.
Insights into Lewy body disease from rare neurometabolic disorders.
iPLA2-VIA is required for healthy aging of neurons, muscle, and the female germline in Drosophila melanogaster.
Iron Accumulation in Syndromes of Neurodegeneration with Brain Iron Accumulation 1 and 2 - causative or consequential?
Loss of Function Variants in Human PNPLA8 Encoding Calcium-Independent Phospholipase A2 ? Recapitulate the Mitochondriopathy of the Homologous Null Mouse.
Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.
Mitochondria from a mouse model of the human infantile neuroaxonal dystrophy (INAD) with genetic defects in VIA iPLA2 have disturbed Ca(2+) regulation with reduction in Ca(2+) capacity.
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism.
Mutations in the Drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration.
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.
Neuroaxonal Dystrophy in Calcium-Independent Phospholipase A2{beta} Deficiency Results from Insufficient Remodeling and Degeneration of Mitochondrial and Presynaptic Membranes.
Neuroaxonal dystrophy in PLA2G6 knockout mice.
Neurodegeneration associated with genetic defects in phospholipase A(2).
Neurodegeneration with brain iron accumulation.
Neurons and astrocytes in an infantile neuroaxonal dystrophy (INAD) mouse model show characteristic alterations in glutamate-induced Ca(2+) signaling.
New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations.
Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.
Novel PLA2G6 mutations associated with an exonic deletion due to non-allelic homologous recombination in a patient with infantile neuroaxonal dystrophy.
Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy.
Pantothenate kinase-associated neurodegeneration is not a synucleinopathy.
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to ?-Synuclein Gain.
PLA2G6 mutation underlies infantile neuroaxonal dystrophy.
Pla2g6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia.
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.
PLA2G6-associated Dystonia-Parkinsonism: Case Report and Literature Review.
PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease.
R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family.
Reevaluating the pathogenicity of the variations c.439 G>A and c.2132 C>T in the PLA2G6 gene.
Severe disturbance in the Ca2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6.
Treatment of infantile neuroaxonal dystrophy with RT001: A di-deuterated ethyl ester of linoleic acid: Report of two cases.
Typical MRI features of PLA2G6 mutation-related phospholipase-associated neurodegeneration (PLAN)/infantile neuroaxonal dystrophy (INAD).
Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis.
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.
[A novel homozygous mutation in PLA2G6 gene causes infantile neuroaxonal dystrophy in a case].
[Clinical features of infantile neuroaxonal dystrophy and PLA2G6 gene testing].
[PLA2G6 compound complicated mutation in an atypical neuroaxonal dystrophy pedigree].
Neuroblastoma
Activation of arachidonic acid-specific phospholipase A2 in human neuroblastoma cells after chronic alcohol exposure: prevention by GM1 ganglioside.
Activation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.
Arachidonate release and c-fos expression in various models of hypoxia and hypoxia-hypoglycemia in retinoic acid differentiated neuroblastoma cells.
Astrocytes regulate ?-secretase-cleaved soluble amyloid precursor protein secretion in neuronal cells: Involvement of group IIA secretory phospholipase A2.
Bicuculline induces free fatty acid release from phospholipids in neuro-2A cells in culture.
Clinacanthus nutans Extracts Modulate Epigenetic Link to Cytosolic Phospholipase A2 Expression in SH-SY5Y Cells and Primary Cortical Neurons.
Cytosolic phospholipase A2 and lipoxygenase are involved in cell cycle progression in neuroblastoma cells.
Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells.
Interferon-gamma induces the synthesis and activation of cytosolic phospholipase A2.
Kainate Receptors Mediate Regulated Exocytosis of Secretory Phospholipase A(2) in SH-SY5Y Neuroblastoma Cells.
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
Molecular analysis of the secretory phospholipase A2 gene, a candidate of Mom1 gene, in neuroblastomas.
Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties.
Notexin upregulates Fas and FasL protein expression of human neuroblastoma SK-N-SH cells through p38 MAPK/ATF-2 and JNK/c-Jun pathways.
p38 MAPK activation and mitochondrial depolarization mediate the cytotoxicity of Taiwan cobra phospholipase A2 on human neuroblastoma SK-N-SH cells.
Regulation of the cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells.
Stimulation of receptor-coupled phospholipase A2 by interferon-gamma.
Swelling-induced arachidonic acid release via the 85-kDa cPLA2 in human neuroblastoma cells.
Taiwan cobra phospholipase A2 elicits posttranscriptional up-regulation of ADAM17 in human neuroblastoma SK-N-SH cells.
The neuromuscular activity of Bothriopsis bilineata smaragdina (forest viper) venom and its toxin Bbil-TX (Asp49 phospholipase A2) on isolated mouse nerve-muscle preparations.
Neurodegenerative Diseases
25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR.
Acceleration of the Development of Alzheimer's Disease in Amyloid Beta-Infused Peroxiredoxin 6 Overexpression Transgenic Mice.
An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.
Arachidonic Acid Induces ARE/Nrf2-Dependent Heme Oxygenase-1 Transcription in Rat Brain Astrocytes.
Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.
Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review.
Gold/Phospholipid nanoconstructs as label-free optical probes for evaluating phospholipase A2 activity.
Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics.
Homozygous PLA2G6 (PARK 14) gene mutation associated neuropsychiatric phenotypes from southern India.
Infantile neuroaxonal dystrophy caused by uniparental disomy.
Inhibition of cytosolic phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III tubulin.
Kainate Receptors Mediate Regulated Exocytosis of Secretory Phospholipase A(2) in SH-SY5Y Neuroblastoma Cells.
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Moving Beyond Syndromic Classifications in Neurodegenerative Disease: The Example of PLA2G6.
Mutations in the Drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration.
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.
Neuroaxonal Dystrophy in Calcium-Independent Phospholipase A2{beta} Deficiency Results from Insufficient Remodeling and Degeneration of Mitochondrial and Presynaptic Membranes.
Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration.
New Insights of Phospholipase A2 Associated Neurodegeneration Phenotype Based on the Long-Term Follow-Up of a Large Hungarian Family.
Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.
Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports.
Other proteins involved in Parkinson's disease and related disorders.
Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases.
Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to ?-Synuclein Gain.
Phospholipases A2 and Inflammatory Responses in the Central Nervous System.
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma.
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.
PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes.
Plasmalogens, phospholipases A2 and signal transduction.
PRDX6 Inhibits Neurogenesis through Downregulation of WDFY1-Mediated TLR4 Signal.
Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells.
R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family.
Role of Cytosolic Phospholipase A2 in Oxidative and Inflammatory Signaling Pathways in Different Cell Types in the Central Nervous System.
Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachadonic acid release in primary murine astrocytes.
Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6.
Secreted phospholipase A2 involvement in neurodegeneration: differential testing of prosurvival and anti-inflammatory effects of enzyme inhibition.
Sphingomyelin Regulates the Activity of Secretory Phospholipase A2 in the Plasma Membrane.
The Roles of Peroxiredoxin 6 in Brain Diseases.
Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis.
Neuroinflammatory Diseases
Arachidonic Acid Derivatives and Neuroinflammation.
Bee venom phospholipase A2 ameliorates amyloidogenesis and neuroinflammation through inhibition of signal transducer and activator of transcription-3 pathway in Tg2576 mice.
Botanical Polyphenols Mitigate Microglial Activation and Microglia-Induced Neurotoxicity: Role of Cytosolic Phospholipase A2.
Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder.
Brain phospholipases A2: a perspective on the history.
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4.
Genetic ablation of PLA2G6 in mice leads to cerebellar atrophy characterized by Purkinje cell loss and glial cell activation.
Involvement of oxidative pathways in cytokine-induced secretory phospholipase A2-IIA in astrocytes.
Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.
Oleanolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 IIA-activated calcium signals.
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption.
Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding.
Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer's disease.
Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.
Neutropenia
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
Nevus
Influence of germline genetic variants on dermoscopic features of melanoma.
Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
Niemann-Pick Diseases
Role of sphingomyelinases in neurological disorders.
Non-alcoholic Fatty Liver Disease
A common variant in the adiponutrin gene influences liver enzyme levels.
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease.
A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.
Absence of adipose triglyceride lipase protects from hepatic ER stress.
Adiponutrin: A multimeric plasma protein.
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.
Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers.
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population.
Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease.
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
Identification and Optimization of a Minor Allele-Specific Small Interfering RNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
iPLA2? deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
iPla2? deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.
Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant.
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function.
Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis.
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms.
The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population.
The ménage à trois of autophagy, lipid droplets and liver disease.
The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression.
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes.]
Obesity
A collective diabetes cross in combination with a computational framework to dissect the genetics of human obesity and Type 2 diabetes.
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells.
A Representative GIIA Phospholipase A2 Activates Preadipocytes to Produce Inflammatory Mediators Implicated in Obesity Development.
A single nucleotide polymorphism (SNP) rs2072907 in the adiponutrin gene (ADPN) was not associated with obesity and type 2 diabetes in Chinese population.
Activation of phospholipase A2 is associated with generation of placental lipid signals and fetal obesity.
Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage.
AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency.
Association between polymorphisms in SLC15A1 and PLA2G16 genes and development of obesity in Chinese subjects.
Cold exposure down-regulates adiponutrin/PNPLA3 mRNA expression and affects its nutritional regulation in adipose tissues of lean and obese Zucker rats.
Comprehensive identification of novel post-translational modifications in cellular peroxiredoxin 6.
Correlative studies on the effects of obesity, diabetes and hypertension on gene expression in omental adipose tissue of obese women.
Critical role for cytosolic group IVA phospholipase A2 in early adipocyte differentiation and obesity.
Diet-induced obesity affects expression of adiponutrin/PNPLA3 and adipose triglyceride lipase, two members of the same family.
Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids.
Genetic Evidence for a Role of Adiponutrin in the Metabolism of Apolipoprotein B-Containing Lipoproteins.
Genetic variance in the adiponutrin gene family and childhood obesity.
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Group 1B phospholipase A? deficiency protects against diet-induced hyperlipidemia in mice.
Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
Haplotype combinations of AdPLA gene polymorphisms associate with growth traits in Chinese cattle.
Isoproterenol, TNFalpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.
Lipopolysaccharide promoted proliferation and adipogenesis of preadipocytes through JAK/STAT and AMPK-regulated cPLA2 expression.
Mice Deficient in Group VIB Phospholipase A2 (iPLA2{gamma}) Exhibit Relative Resistance to Obesity and Metabolic Abnormalities Induced by a Western Diet.
Pancreatic acinar cell-specific overexpression of group 1B phospholipase A(2) exacerbates diet-induced obesity and insulin resistance in mice.
Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism.
Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity.
Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.
Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.
Secreted Phospholipase PLA2G2D Contributes to Metabolic Health by Mobilizing ?3 Polyunsaturated Fatty Acids in WAT.
Targeting of adipose tissue macrophages by bee venom phospholipase A2 attenuates high-fat diet-induced obesity.
The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity.
The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice.
The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.
The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease.
Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.
Variation in the adiponutrin gene influences its expression and associates with obesity.
Obesity, Abdominal
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.
Obesity, Metabolically Benign
Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids.
Obstetric Labor, Premature
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Elevations of group II phospholipase A2 concentrations in serum and amniotic fluid in association with preterm labor.
Group I and group II phospholipase A2 in serum during normal and pathological pregnancy.
Microorganisms and premature labor.
Premature labor. II. Bacterial sources of phospholipase.
Preterm labor and bacterial intra-amniotic infection: arachidonic acid liberation by the action of phospholipase A2.
Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of Fusobacterium nucleatum.
Pulmonary phospholipid saturation increases with glucocorticoid receptor mRNAs in late gestation but not due to labor in the fetal rhesus monkey.
The expression of cytosolic phospholipase A2 and prostaglandin endoperoxide synthase in ovine maternal uterine and fetal tissues during late gestation and labor.
Oligodendroglioma
Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.
Opisthorchiasis
Proteomic identification of peroxiredoxin 6 for host defence against Opisthorchis viverrini infection.
Osteitis Deformans
Secreted phospholipase A2 type II is present in Paget's disease of bone and modulates osteoclastogenesis, apoptosis and bone resorption of human osteoclasts independently of its catalytic activity in vitro.
Osteoarthritis
Cellular activation products in osteoarthritis synovial fluid.
Group II phospholipase A2 in synovial fluid and serum in acute arthritis.
Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium.
Interleukin-1 activates phospholipase A2 in human synovial cells.
Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids.
Multiple phospholipase A2 enzymes participate in the inflammatory process in osteoarthritic cartilage.
Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme.
Phospholipase A2 inhibitor-loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis progression.
Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.
Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis.
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis.
The role of phospholipase A2 in the physiopathology of osteoarthritis.
[Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]
[Serum phospholipase A2 activity in osteoarthritis]
Osteosarcoma
Acetone immersion enhanced MALDI-MS imaging of small molecule metabolites in biological tissues.
Adenylate cyclase enhancing factor from rat osteosarcoma cytosol.
Stimulation of matrix vesicle enzyme activity in osteoblast-like cells by 1,25(OH)2D3 and transforming growth factor beta (TGF beta).
[The cytotoxic mechanism of tumor necrosis factor (TNF) in human osteosarcoma cell line TE85--(1). Implication of phospholipase A2 activity in cytotoxicity]
Otitis
Tissue Damage Signaling Is a Prerequisite for Protective Neutrophil Recruitment to Microbial Infection in Zebrafish.
Ovarian Neoplasms
Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate.
Caspase-3-dependent Activation of Calcium-independent Phospholipase A2 Enhances Cell Migration in Non-apoptotic Ovarian Cancer Cells.
Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.
Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.
Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.
Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A2 in ovarian cancer cells.
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells.
Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells.
The prognostic values of the peroxiredoxins family in ovarian cancer.
Pancreatic Cyst
Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.
Pancreatic Diseases
Clinical usefulness of serum phospholipase A2 determination in patients with pancreatic diseases.
Serum levels of six pancreatic enzymes as related to the degree of renal dysfunction.
Serum phospholipase A2 activity in chronic pancreatic diseases.
Simultaneous determinations of pancreatic phospholipase A2 and prophospholipase A2 in various pancreatic diseases.
The diagnostic value of serum pancreatic phospholipase A2 (PLA2) in pancreatic diseases.
Urinary phospholipase A2 excretion in chronic pancreatic diseases.
[Usefulness of serum pancreatic phospholipase A2 determination in patients with various pancreatic diseases]
Pancreatic Neoplasms
Activation of MAP kinase cascade induced by human pancreatic phospholipase A2 in a human pancreatic cancer cell line.
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines.
Deoxyribonuclease I serum activity in pancreatic cancer.
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
Flavonoids Identified from Korean Scutellaria baicalensis Induce Apoptosis by ROS Generation and Caspase Activation on Human Fibrosarcoma Cells.
Human pancreatic phospholipase A2 stimulates the growth of human pancreatic cancer cell line.
Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer.
Serum phospholipases A2 in inflammatory diseases.
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Pancreatic Pseudocyst
Characterization of phospholipase A2 activity in aspirates of human pancreatic pseudocysts after isolation by reversed-phase high performance liquid chromatography.
Pancreaticobiliary Maljunction
Nutritional factors (nutritional aspects) in biliary disorders: bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction.
Partial characterization of proapoptotic action of biliary deteriorated lipids on biliary epithelial cells in pancreaticobiliary diseases.
Pancreatitis
A randomized double-blind study using CaNa2EDTA, a phospholipase A2 inhibitor, in the management of human acute pancreatitis.
Abdominal hyperalgesia in secretory phospholipase A(2)-induced rat pancreatitis: Distinct roles of NK(1) receptors.
Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.
Acute lung injury induced by phospholipase A2. Structural and functional changes.
Acute pancreatitis as a model of sepsis.
Acute pancreatitis in transgenic mice expressing human group IIA phospholipase A2.
Advances in the enzyme diagnosis of pancreatic diseases.
Application of a new monoclonal antibody for time-resolved fluoroimmunoassay of human pancreatic phospholipase A2.
Aprotinin and Na2CaEDTA in experimental hemorrhagic pancreatitis in pigs.
Bactericidal/permeability-increasing protein and group I and II phospholipase A2 during the induction phase of human acute pancreatitis.
Behavior of plasma phospholipase A2 activity in experimental acute pancreatitis according to diet.
Beneficial effect of iloprost on the course of acute taurocholate pancreatitis in rats and its limitation by antecedent acute ethanol intake.
C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis.
Catalytic activity of phospholipase A2 in blood plasma and pancreatic tissue perfusion in early experimental acute pancreatitis.
Changes of gastric and intestinal blood flow, serum phospholipase A2 and interleukin-1beta in rats with acute necrotizing pancreatitis.
Changes of Inflammation and Apoptosis in Adrenal Gland After Experimental Injury in Rats with Acute Necrotizing Pancreatitis.
Characterization of two phospholipases A2 in serum of patients with sepsis and acute pancreatitis.
Chlorpromazine treatment of experimental acute fulminant pancreatitis in pigs.
Crucial role of group IIA phospholipase A2 in pancreatitis-associated adrenal injury in acute necrotizing pancreatitis.
Dexamethasone Affects Inflammation but Not Trypsinogen Activation in Experimental Acute Pancreatitis.
Diagnostic and prognostic utility of phospholipase A activity in patients with acute pancreatitis: comparison with amylase and lipase.
Diagnostic value of immunoreactive phospholipase A2 in acute pancreatitis.
Differentiation of human phospholipase A2 isoenzymes in serum and other body fluids with use of monoclonal antibodies.
Duodenal secretion of phospholipase A2, amylase, and bicarbonate in chronic pancreatitis.
Early assessment of acute pancreatitis. A comparative study of computed tomography and laboratory tests.
Early bacterial infection of the pancreas and course of disease in cerulein-induced acute pancreatitis in rats.
Effect of a new inhibitor of type II phospholipase A2 on experimental acute pancreatitis in rats.
Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats.
Effect of IS-741 (a new synthetic antiinflammatory agent) on acute necrotizing pancreatitis in dogs. Significance of its inhibitory effect on cytosolic phospholipase A2.
Effect of phospholipase A2 silencing on acute experimental pancreatitis.
Effect of procainhydrochloride on phospholipase A2 catalytic activity in sodium taurocholate-induced acute experimental pancreatitis in rats.
Effects of gabexate mesilate (FOY) on amylase and phospholipase A2 in human serum and pancreatic juice.
Effects of Snake-Derived Phospholipase A2 Inhibitors on Acute Pancreatitis: In vitro and in vivo Characterization.
Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2.
Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis.
Evaluation of phospholipase A2 measurement for early prediction of the severity of acute pancreatitis.
Experimental pancreatitis in the rat. Changes in pulmonary phospholipids during sodium taurocholate-induced acute pancreatitis.
Experimental pancreatitis in the rat. Light and electron microscopical observations on early pancreatic lesions induced by intraductal injection of trypsin, phospholipase A2, lysolecithin and non-ionic detergent.
Experimental study of a novel phospholipase A2 inhibitor in acute pancreatitis.
Expression of group II phospholipase A2 in the liver in acute pancreatitis.
Fat necrosis in human acute pancreatitis. An immunohistological study.
Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.
Hepatic involvement in pancreatitis-induced lung damage.
Human pancreatic phospholipase A2 in acute necrotizing pancreatitis.
Hydrocortisone treatment of early SIRS in acute experimental pancreatitis.
Hydrolytic activities of human pancreatic phospholipase A2 and endotoxin-stimulated endogenous phospholipase A2 toward membrane phospholipids of erythrocytes.
Immunoreactive pancreatic phospholipase A2 and catalytically active phospholipases A2 in serum from patients with acute pancreatitis.
Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer.
Improved method for the determination of phospholipase A2 catalytic activity concentration in human serum and ascites.
In vivo effect of pancreatic phospholipase A2 on the arachidonic acid cascade.
Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.
Increased concentrations of synovial-type phospholipase A2 in serum and pulmonary and renal complications in acute pancreatitis.
Increased peritoneal permeability in acute experimental pancreatitis.
Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline.
Inhibition of inducible nitric oxide synthase-derived nitric oxide as a therapeutical target for acute pancreatitis induced by secretory phospholipase A2.
Inhibition of pulmonary surfactant function by phospholipases.
Interleukin-6 and Phospholipase A2 isoenzymes during acute pancreatitis.
Involvement of oxygen radicals and phospholipase A2 in acute pancreatitis of the rat.
IS-741 (Ishihara Sangyo).
Kinetics of group IB and IIA phospholipase A2 during low-volume continuous hemodiafiltration in severe acute pancreatitis.
Long-term ethanol ingestion causes an increase of phospholipase A2 activity in acute experimental pancreatitis in rats.
Lysophosphatidylcholine activates transcription factor NF-kappaB and AP-1 in AR42J cells.
Lysophosphatidylcholine induces apoptosis in AR42J cells.
Natural disruption of group 2 phospholipase A2 gene protects against choline-deficient ethionine-supplemented diet-induced acute pancreatitis and lung injury.
Oxidative stress as an early prognostic factor in acute pancreatitis (AP): its correlation with serum phospholipase A2 (PLA2) and plasma polymorphonuclear elastase (PMN-E) in different-severity forms of human AP.
Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis.
Pancreatic phospholipase A2 activity in acute pancreatitis: a prognostic marker for early identification of patients at risk.
Pancreatic phospholipase A2 in cerulein-induced acute pancreatitis in the rat.
Pancreatic phospholipase A2 in human acute pancreatitis.
Pancreatic phospholipase A2 in proximal tubules of rat kidney in experimental acute pancreatitis and after intravenous injection of the enzyme.
Pancreatic phospholipase A2 induces bacterial translocation in rats.
Pancreaticobiliary maljunction-associated pancreatitis: an experimental study on the activation of pancreatic phospholipase A2.
Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats.
Phospholipase A2 activity and concentration in several body fluids in patients with acute pancreatitis.
Phospholipase A2 activity in body fluids and pancreatic tissue in patients with acute necrotising pancreatitis.
Phospholipase A2 activity in taurocholate-induced acute pancreatitis in the rat model.
Phospholipase A2 and acute pancreatitis in rats.
Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase.
Phospholipase A2 in acute pancreatitis.
Phospholipase A2 in acute pancreatitis: new biochemical and pathological aspects.
Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Phospholipase A2 in serum and ascitic exudate in experimental acute haemorrhagic pancreatitis in pigs.
Phospholipase A2 inhibitors and their possible clinical use in the treatment of acute pancreatitis.
Phospholipase A2 is associated with albumin in patients with acute pancreatitis.
Phospholipase A2 isoforms in acute pancreatitis.
Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis.
Plasma type II phospholipase A2 levels in patients with acute pancreatitis.
Prognostic value of serum phospholipase A in acute pancreatitis.
Purification and characterization of human pancreatic phospholipase A2 and development of a radioimmunoassay.
Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial.
Renal tubular cell injury and serum phospholipase A2 activity in acute pancreatitis.
Role of pancreatic enzymes and their substrates in autodigestion of the pancreas. In vitro studies with isolated rat pancreatic acini.
Role of phospholipase A2 in human acute pancreatitis.
Role of phospholipase A2 in pancreatic acinar cell damage and possibilities of inhibition: studies with isolated rat pancreatic acini.
Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat.
Role of substance P and bradykinin in acute pancreatitis induced by secretory phospholipase A2.
Secretory phospholipase A2 in patients with infected pancreatic necroses in acute pancreatitis.
Serum pancreatic phospholipase A2 and prophospholipase A2 in acute pancreatitis and after endoscopic retrograde pancreatography.
Serum phospholipase A2 activity in acute pancreatitis: an early guide to severity.
Serum phospholipase A2 and free fatty acid levels in acute pancreatitis.
Serum phospholipase A2 and pulmonary changes in acute fulminant pancreatitis.
Serum phospholipase A2 in canine acute pancreatitis.
Serum phospholipase A2 in diet-induced pancreatitis.
Serum phospholipase A2 in human acute pancreatitis.
Serum phospholipase A2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis.
Serum phospholipase A2, amylase, lipase, and urinary amylase activities in relation to the severity of acute pancreatitis.
Serum phospholipase A2, immunoreactive trypsin, and trypsin inhibitors during human acute pancreatitis.
Serum phospholipases A2 in inflammatory diseases.
Severe acute pancreatitis is related to increased early urinary levels of the activation Peptide of pancreatic phospholipase A(2).
The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats.
The role of ascites and phospholipase A2 on peritoneal permeability changes in acute experimental pancreatitis.
The role of phospholipase A2 in acute pancreatitis.
The role of phospholipase A2 in human acute pancreatitis.
The role of phospholipase A2 in respiratory failure of acute pancreatitis.
The role of phospholipase A2 in the pathogenesis of respiratory damage in hemorrhagic necrotizing pancreatitis--assessment of a new experimental model.
Time-resolved fluoroimmunoassay of human pancreatic phospholipase A2.
Time-resolved fluoroimmunoassay of pancreatic phospholipase A2.
Toward routine use of nonsteroidal anti-inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography.
Toxic effects of human pancreatic and snake and bee venom phospholipases A2 on MCF-7 cells in culture.
Usefulness of determination of serum immunoreactive pancreatic phospholipase A2 content for early identification of severe acute pancreatitis.
What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study.
Zerumbone attenuates the severity of acute necrotizing pancreatitis and pancreatitis-induced hepatic injury.
[Acute purulent parotitis as a sequela of alkylphosphate (E 605) poisoning]
[Biochemical diagnostics in acute pancreatitis recognition and outcome predicition]
[Effect of phospholipase A2 on pancreatic parenchymal necrosis in acute pancreatitis in rats]
[Experimental studies on pathophysiology of acute pancreatitis, with special reference to pancreatic phospholipase A2 and the effect of CDP-choline]
[In vitro examination of the influence of lipase and amylase on dog's pancreas tissue incubated with endotoxins, phospholipase A2 or cytokines]
[Influences of BN50739 on neutrophil elastase and phospholipase A2 in lung and tracheal mucosa of pigs with acute severe pancreatitis]
[Mexidol-induced modification of lipid metabolism in pancreatitis]
[Phospholipase A2 inhibitors in hemorrhagic-necrotizing pancreatitis. Animal experiment evaluation of a new treatment concept]
[Role of phospholipase A2 in injury of lung complicated by acute pancreatitis and the therapeutic effect and mechanism of verapamil on it]
[Serum and ascitic phospholipase A2 activities and their heat stabilities in taurocholate induced rat acute pancreatitis]
[Study of phospholipase A2 in serum, ascitic exudate and pancreatic tissue in acute pancreatitis in rats]
[The role of phospholipase A2 in acute pancreatitis]
[Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate]
Pancreatitis, Acute Hemorrhagic
Phospholipase A2 in sodium taurocholate-induced experimental hemorrhagic pancreatitis in the rat.
The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs.
Pancreatitis, Acute Necrotizing
Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.
Changes of gastric and intestinal blood flow, serum phospholipase A2 and interleukin-1beta in rats with acute necrotizing pancreatitis.
Crucial role of group IIA phospholipase A2 in pancreatitis-associated adrenal injury in acute necrotizing pancreatitis.
Effect of IS-741 (a new synthetic antiinflammatory agent) on acute necrotizing pancreatitis in dogs. Significance of its inhibitory effect on cytosolic phospholipase A2.
Human pancreatic phospholipase A2 in acute necrotizing pancreatitis.
Pathomorphological study of the pancreas during phospholipase A2-induced experimental pancreatic necrosis.
Phospholipase A2 in acute pancreatitis: new biochemical and pathological aspects.
Phospholipase A2 isoforms in acute pancreatitis.
Role of pancreatic enzymes and their substrates in autodigestion of the pancreas. In vitro studies with isolated rat pancreatic acini.
Role of phospholipase A2 in human acute pancreatitis.
Secretory phospholipase A2 in patients with infected pancreatic necroses in acute pancreatitis.
The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats.
[Preventive therapy with mexidol in toxic damage to the heart].
Pancreatitis, Alcoholic
Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer.
Pancreatitis, Chronic
Deoxyribonuclease I serum activity in pancreatic cancer.
Duodenal secretion of phospholipase A2, amylase, and bicarbonate in chronic pancreatitis.
Immunocytochemical evidence of phospholipase A2 in pancreatic tumors--diagnostic values.
Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
Immunohistochemical localization of phospholipase A2 in human pancreas in acute and chronic pancreatitis.
Phospholipase A2 isoforms are altered in chronic pancreatitis.
[A new pathophysiologic concept in chronic pancreatitis: tissue destruction induced via inflammatory mediators]
[The role of phospholipase A2 in pathogenesis of acute and chronic pancreatitis, its significance in diagnosis of the disease]
Pantothenate Kinase-Associated Neurodegeneration
Childhood disorders of neurodegeneration with brain iron accumulation (NBIA).
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.
Extensive aggregation of ?-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site.
Iron Accumulation in Syndromes of Neurodegeneration with Brain Iron Accumulation 1 and 2 - causative or consequential?
Neurodegeneration with brain iron accumulation.
Papilledema
Epac2-deficiency leads to more severe retinal swelling, glial reactivity and oxidative stress in transient middle cerebral artery occlusion induced ischemic retinopathy.
Papilloma
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Elevated prostaglandin E2 level via cPLA2--COX-2--mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats.
Type II phospholipase A2 recombinant overexpression enhances stimulated arachidonic acid release.
[Factors controlling tumor promotion induced by TPA]
Paralysis
Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins.
An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomation.
Crotoxin in humans: analysis of the effects on extraocular and facial muscles.
Facial diplegia, pharyngeal paralysis, and ophthalmoplegia after a timber rattlesnake envenomation.
Heparin at low concentration acts as antivenom against Bothrops jararacussu venom and bothropstoxin-I neurotoxic and myotoxic actions.
Influence of temperature upon paralyzing and myotoxic effects of bothropstoxin-I on mouse neuromuscular preparations.
Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins.
Nerve terminal damage by beta-bungarotoxin: its clinical significance.
Neuromuscular paralysis by the basic phospholipase A2 subunit of crotoxin from Crotalus durissus terrificus snake venom needs its acid chaperone to concurrently inhibit acetylcholine release and produce muscle blockage.
Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach.
Quantification of crotamine, a small basic myotoxin, in South American rattlesnake (Crotalus durissus terrificus) venom by enzyme-linked immunosorbent assay with parallel-lines analysis.
Reversible skeletal neuromuscular paralysis induced by different lysophospholipids.
Study of crotoxin on the induction of paralysis in extraocular muscle in animal model.
Understanding Biological Roles of Venoms Among the Caenophidia: The Importance of Rear-Fanged Snakes.
Paraplegia
PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia.
Rare causes of dystonia parkinsonism.
Parkinson Disease
A Han Chinese Family With Early-Onset Parkinson's Disease Carrying Novel Frameshift Mutation and Compound Heterozygous Mutation of PRKN Appearing Incompatible With MDS Clinical Diagnostic Criteria.
Association between PLA2G6 gene polymorphisms and Parkinson's disease in the Chinese Han population.
Association of rare heterozygous PLA2G6 variants with the risk of Parkinson's disease.
Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson's disease alpha-synuclein transgenic mice.
Bee Venom Phospholipase A2, a Novel Foxp3+ Regulatory T Cell Inducer, Protects Dopaminergic Neurons by Modulating Neuroinflammatory Responses in a Mouse Model of Parkinson's Disease.
Comparison of Administration Routes on the Protective Effects of Bee Venom Phospholipase A2 in a Mouse Model of Parkinson's Disease.
Comparison of the Protective Effects of Bee Venom Extracts with Varying PLA2 Compositions in a Mouse Model of Parkinson's Disease.
Dose-Dependent Neuroprotective Effect of Standardized Bee Venom Phospholipase A2 Against MPTP-Induced Parkinson's Disease in Mice.
Early-Onset Parkinson's Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review.
Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease.
Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.
Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations.
Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
Genetic analysis of ATP13A2, PLA2G6 and FBXO7 in a cohort of Chinese patients with early-onset Parkinson's disease.
Heterozygous PLA2G6 Mutation Leads to Iron Accumulation Within Basal Ganglia and Parkinson's Disease.
iPLA2? knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology.
Lack of Association Between PLA2G6 Genetic Variation and Parkinson's Disease: A Systematic Review.
Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson's Disease.
Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity.
Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.
Novel therapeutic approaches for Parkinson's disease by targeting brain cholesterol homeostasis.
PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model.
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Phospholipase iPLA2? averts ferroptosis by eliminating a redox lipid death signal.
PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease.
Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased ?-Synuclein Expression, and Defects in Brain Functions and Pathways.
PLA2G6 mutations and Parkinson's disease.
PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease.
PLA2G6 variant in Parkinson's disease.
PLA2G6 variants associated with the number of affected alleles in Parkinson's disease in Japan.
Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci.
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Reprogramming of a human induced pluripotent stem cell (iPSC) line (IBMSi012-A) from an early-onset Parkinson's disease patient harboring a homozygous p.D331Y mutation in the PLA2G6 gene.
Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.
Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action.
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
The PLA2G6 gene in early-onset Parkinson's disease.
The role of genetics in Parkinson's disease: a large cohort study in Chinese mainland population.
Parkinsonian Disorders
A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population.
Aripiprazole in a Patient of PLA2G6-Associated Neurodegeneration With Psychosis.
Autosomal recessive parkinsonism.
Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families.
Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes.
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.
Early-Onset Parkinson's Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review.
Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex.
Homozygous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: Further evidence of a fourth phenotype of PLA2G6-associated neurodegeneration.
Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism.
Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.
Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
MPP+ induced SH-SY5Y apoptosis is potentiated by cyclosporin A and inhibited by aristolochic acid.
Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism.
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background.
Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism.
Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to ?-Synuclein Gain.
PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort.
PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical features and neuropathology.
PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease.
PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism.
Progressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A2? Knockout Mice.
Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
Rare causes of dystonia parkinsonism.
Severe Early-Onset Parkinsonian Syndrome Caused by PLA2G6 Heterozygous Variants.
Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action.
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.
Pectus Carinatum
Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism.
Pediatric Obesity
Genetic variance in the adiponutrin gene family and childhood obesity.
Peptic Ulcer
Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers.
Helicobacter pylori associated phospholipase A2 activity: a factor in peptic ulcer production?
PH-activated phospholipase A2: an important mucosal barrier breaker in peptic ulcer disease.
peptidylprolyl isomerase deficiency
Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress.
Periodontal Diseases
IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
Periodontitis
The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.
Peripheral Nerve Injuries
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury.
Intracellular phospholipase A2 group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury.
Peripheral Nervous System Diseases
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Peritonitis
Ac2-26 Mimetic Peptide of Annexin A1 Inhibits Local and Systemic Inflammatory Processes Induced by Bothrops moojeni Venom and the Lys-49 Phospholipase A2 in a Rat Model.
Alterations of the composition and metabolism of pulmonary surfactant phospholipids induced by experimental peritonitis in rats.
Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis?
Assessment of inflammatory mediators in patients with generalized peritonitis.
Characterization and pharmacological modulation of soluble phospholipase A2 generated during glycogen-induced rat peritonitis.
Extracellular phospholipase A2 activity in cell free peritoneal lavage fluid from mice with zymosan peritonitis.
Kinetics of phospholipase A2, arachidonic acid, and eicosanoid appearance in mouse zymosan peritonitis.
Opuntia dillenii cladode: Opuntiol and opuntioside attenuated cytokines and eicosanoids mediated inflammation.
Phospholipase-resistant phosphatidylcholine reduces intra-abdominal adhesions induced by bacterial peritonitis.
Pro-inflammatory activity of phospholipase A2 in CAPD patients with and without peritonitis.
Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis.
Serum phospholipase A2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis.
[Changes in phospholipase A2 activity and lipid peroxidation in endotoxicosis during experimental peritonitis]
Persistent Infection
Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
Role of cytosolic and calcium independent phospholipases A2 in insulin secretion impairment of INS-1E cells infected by S. aureus.
Pheochromocytoma
Arachidonic acid release and prostaglandin F2alpha formation induced by phenylarsine oxide in PC12 cells: possible involvement of secretory phospholipase A2 activity.
Function of type II phospholipase A2 in dopamine secretion by rat neuronal PC12 cells.
Influence of phospholipases A2 from snake venoms on survival and neurite outgrowth in pheochromocytoma cell line PC12.
Inhibition by protein kinase C activation of melittin-induced arachidonic acid release in PC12 pheochromocytoma cells.
Release of secretory phospholipase A2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion.
Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor.
The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid.
phosphatidylinositol deacylase deficiency
Group X secretory phospholipase A2 can induce arachidonic acid release and eicosanoid production without activation of cytosolic phospholipase A2 alpha.
phospholipase a2 deficiency
Choline and choline-related nutrients in regular and preterm infant growth.
Curcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-?B regulation.
Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice.
Deficiency of Prdx6 in lens epithelial cells induces ER stress-response-mediated impaired homeostasis and apoptosis.
Detection of secretory phospholipase A2s related but not identical to type IIA isozyme in cultured mast cells.
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Dual Roles of Group IID Phospholipase A2 in Inflammation and Cancer.
Group IVA phospholipase A2 deficiency prevents CCl4-induced hepatic cell death through the enhancement of autophagy.
Group V Secretory Phospholipase A(2) Enhances the Progression of Angiotensin II-Induced Abdominal Aortic Aneurysms but Confers Protection against Angiotensin II-Induced Cardiac Fibrosis in ApoE-Deficient Mice.
Group VIA phospholipase A2 deficiency in mice chronically fed with high-fat-diet attenuates hepatic steatosis by correcting a defect of phospholipid remodeling.
Group X Secreted Phospholipase A2 Releases ?3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility.
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation.
Mouse models of human INAD by Pla2g6 deficiency.
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease.
Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis.
Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased ?-Synuclein Expression, and Defects in Brain Functions and Pathways.
Prdx6 deficiency ameliorates DSS colitis: relevance of compensatory antioxidant mechanisms.
Restoration of On-Time Embryo Implantation Corrects the Timing of Parturition in Cytosolic Phospholipase A2 Group IVA Deficient Mice.
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
The enteropathy of prostaglandin deficiency.
Pick Disease of the Brain
Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6.
Saitohin, which is nested within the tau gene, interacts with tau and Abl and its human-specific allele influences Abl phosphorylation.
Picornaviridae Infections
Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.
Pituitary Neoplasms
12-O-tetradecanoyl-phorbol-13-acetate-induced ACTH secretion in pituitary tumor cells.
Evidence supporting a correlation between arachidonic acid release and prolactin secretion from GH3 cells.
Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated prolactin production without modifying the production of inositolphosphates in GH4C1 pituitary cells.
Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid.
Pityriasis
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.
Pityriasis Rubra Pilaris
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.
Plague
Inactivation of Peroxiredoxin 6 by the Pla Protease of Yersinia pestis.
Pleural Effusion
Detection and characterization of extracellular phospholipase A2 in pleural effusion of patients with tuberculosis.
Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer.
Pleurisy
A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation.
Antiinflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy.
Cellular and extracellular phospholipase A2 activity in zymosan pleurisy in rat.
Characterization of phospholipase A2 activity in rat RPAR-induced pleurisy.
Dynamics and participation of type II phospholipase A2 in rat zymosan-induced pleurisy.
Phospholipase A2 acyl-hydrolytic activity in rat RPAR-induced pleurisy.
Role of type II phospholipase A2 in the inflammatory process of carrageenan-induced pleurisy in rats.
Sequential release of TNFalpha and phospholipase A(2) in a rat model of LPS-induced pleurisy.
[Relationship between effect of tetrandrine on pleurisy and phospholipase A2]
Pneumonia
AdipoR-increased intracellular ROS promotes cPLA2 and COX-2 expressions via activation of PKC and p300 in adiponectin-stimulated human alveolar type II cells.
Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice.
Cytosolic phospholipase A2? promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.
Deficiency of phospholipase A2 receptor exacerbates ovalbumin-induced lung inflammation.
Drastic changes in the tissue-specific expression of secreted phospholipases A2 in chicken pulmonary disease.
Effects of inflammatory stimuli on responses of macrophages to Mycoplasma bovis infection.
Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells.
Factors controlling vascular permeability: transmitting mechanical signals. Focus on "mechanical induction of group V phospholipase A2 causes lung inflammation and acute lung injury".
Genetic inactivation of the phospholipase A2 activity of peroxiredoxin 6 in mice protects against LPS-induced acute lung injury.
Group 1B phospholipase A2 in metabolic and inflammatory disease modulation.
Group V Phospholipase A2 in bone marrow derived myeloid cells and bronchial epithelial cells promote bacterial clearance after E. coli pneumonia.
Group V secretory phospholipase A2 is involved in macrophage activation and is sufficient for macrophage effector functions in allergic pulmonary inflammation.
Group V secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function.
Increased group IV cytosolic phospholipase A2 activity in lungs of sheep after smoke inhalation injury.
Inflammatory signalings involved in airway and pulmonary diseases.
Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
Mechanical induction of Group V phospholipase A2 causes lung inflammation and acute lung injury.
Peroxiredoxin 6 differentially regulates acute and chronic cigarette smoke–mediated lung inflammatory response and injury.
Phospholipase A2 levels in acute chest syndrome of sickle cell disease.
Phospholipases A2 as biomarkers in ARDS.
Polydatin up-regulates Clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro.
Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia.
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase.
Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.
Secreted Phospholipase A2 is Increased in Meconium-Stained Amniotic Fluid of Term Gestations: Potential Implications for the Genesis of Meconium Aspiration Syndrome.
Secretory Phospholipase A2-IIA Protein and mRNA Pools in Extracellular Vesicles of Bronchoalveolar Lavage Fluid from Patients with Early Acute Respiratory Distress Syndrome: A New Perception in the Dissemination of Inflammation?
Serum ferritin elevation and acute lung injury in rats subjected to hemorrhage: reduction by mepacrine treatment.
Surface properties after a simulated PLA2 hydrolysis of pulmonary surfactant's main component, DPPC.
Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Pneumonia, Pneumocystis
Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Pneumonia, Ventilator-Associated
Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration.
Polycystic Kidney Diseases
Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease.
Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease.
Polycystic Ovary Syndrome
A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
The activity of calcium dependent and calcium independent phospholipase A2 in normal endometrium and in endometrium from women suffering from menorrhagia and polycystic ovary syndrome.
The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
Porphyria Cutanea Tarda
Hepatic arachidonic acid metabolism is disrupted after hexachlorobenzene treatment.
Porphyrias
Hepatic arachidonic acid metabolism is disrupted after hexachlorobenzene treatment.
[Epidemiology and risk factors of hepatocellular carcinoma].
Pre-Eclampsia
Activities of phospholipase A2, cyclooxygenase, and PGI2 synthase of umbilical venous endothelial cells in preeclamptic women.
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Group I and group II phospholipase A2 in serum during normal and pathological pregnancy.
Increased placental phospholipase A2 activities in pre-eclampsia.
Increased placental phospholipase A2 gene expression and free F2-isoprostane levels in response to oxidative stress in preeclampsia.
Placental phospholipase A2 activities in pre-eclampsia.
Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy.
Plasma from preeclamptic women increases human endothelial cell prostacyclin production without changes in cellular enzyme activity or mass.
Plasma type II phospholipase A2 levels are elevated in severe preeclampsia.
Synovial phospholipase A2 serum levels in pregnancy and preeclampsia.
The role of the endogenous anti-inflammatory compound gravidin in pre-eclampsia.
Premature Birth
Associations of maternal PLA2G4C and PLA2G4D polymorphisms with the risk of spontaneous preterm birth in a Chinese population.
Primate-specific evolution of noncoding element insertion into PLA2G4C and human preterm birth.
Priapism
Mycoplasma-enhanced priapism in mice.
Prion Diseases
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.
Progeria
Targeting the phospholipase A2 receptor ameliorates premature aging phenotypes.
The role of lipid metabolism in aging, lifespan regulation, and age-related disease.
Prostatic Hyperplasia
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro.
Prostatic Intraepithelial Neoplasia
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Prostatic Neoplasms
Association of 5'UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis.
Bee Venom Components as Therapeutic Tools against Prostate Cancer.
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.
Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo.
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer.
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy.
Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Oncogenic action of phospholipase A2 in prostate cancer.
Oncogenic action of secreted phospholipase A2 in prostate cancer.
Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Phospholipase A2-Responsive Phosphate Micelle-Loaded UCNPs for Bioimaging of Prostate Cancer Cells.
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.
Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis.
The arachidonic Acid pathway and its role in prostate cancer development and progression.
Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
[Botulinum toxin type-A toxin activity in prostate cancer cell lines].
Protein-Energy Malnutrition
[Comparative study of the effects of 2 types of protein-energy malnutrition followed by a balanced refeeding, on the lipase, phospholipase A2 and amylase activities of the pancreas and pancreatic juice in the growing rat]
Proteinuria
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy.
Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy.
sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1ser757 signaling pathway.
sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy.
Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
Pruritus
TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase.
Psoriasis
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes.
Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema.
Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin.
Confirmation of raised phospholipase A2 activity in the uninvolved skin of psoriasis.
cPLA2? Enzyme Inhibition Attenuates Inflammation and Keratinocyte Proliferation.
Current knowledge on autoantigens and autoantibodies in psoriasis.
Dermal and ocular safety of the new phospholipase A2 inhibitors PX-18 and PX-13 formulated as drug nanosuspension.
Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue.
Epidermal phospholipase A2 activity is raised in the uninvolved skin of psoriasis.
Expression and Function of Group IIE Phospholipase A2 in Mouse Skin.
Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation.
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Phospholipase A2 activity of peripheral-blood mononuclear leukocytes in psoriasis.
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.
Secretory and cytosolic phospholipase A(2)regulate the long-term cytokine-induced eicosanoid production in human keratinocytes.
Structure of Human GIVD Cytosolic Phospholipase A2 Reveals Insights into Substrate Recognition.
The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases.
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch.
The level of phospholipase A2 activity is raised in the uninvolved epidermis of psoriasis.
[Phospholipase A2 activating factor in sera of patients with psoriasis vulgaris]
[The lipid spectrum of the skin in psoriasis]
Pulmonary Arterial Hypertension
Role of Secretory Phospholipase A2 in Rhythmic Contraction of Pulmonary Arteries of Rats With Monocrotaline-Induced Pulmonary Arterial Hypertension.
The study of the relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure.
[The relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure]
Pulmonary Atelectasis
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
Pulmonary Disease, Chronic Obstructive
A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease.
Gly80Ser Polymorphism of Phospholipase A2-IID Is Associated with Cytokine Inducibility in A549 Cells.
Molecular modeling of Gly80 and Ser80 variants of human group IID phospholipase A2 and their receptor complexes: potential basis for weight loss in chronic obstructive pulmonary disease.
Peroxiredoxins and Immune Infiltrations in Colon Adenocarcinoma: Their Negative Correlations and Clinical Significances, an In Silico Analysis.
Toxicological effects of ambient fine (PM2.5-0.18) and ultrafine (PM0.18) particles in healthy and diseased 3D organo-typic mucocilary-phenotype models.
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Pulmonary Edema
Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.
Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice.
Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction.
Phospholipase A2 induced diffuse alveolar damage--effect of indomethacin and dexamethasone upon morphology and plasma-histamine level.
[Effects of phospholipase A2 on the etiology of pulmonary edema hemodynamics of lesser circulation in intact and vagotomized animals]
[Experimental study on the pathogenesis of pulmonary insufficiency in acute pancreatitis and changes in the pulmonary surfactant]
[Physiopathology of lung injury in acute pancreatitis]
Pulmonary Eosinophilia
Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia.
Pulmonary Fibrosis
AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis.
Telomere shortening activates TGF-?/Smads signaling in lungs and enhances both lipopolysaccharide and bleomycin-induced pulmonary fibrosis.
Radiculopathy
Immediate inhibition of spinal secretory phospholipase A2 prevents the pain and elevated spinal neuronal hyperexcitability and neuroimmune regulatory genes that develop with nerve root compression.
Possible mechanism of painful radiculopathy in lumbar disc herniation.
The role of steroids and their effects on phospholipase A2. An animal model of radiculopathy.
Rectal Neoplasms
Identification of Metabolic-Associated Genes for the Prediction of Colon and Rectal Adenocarcinoma.
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia.
PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
PLA2G4A mutants modified protective effect of tea consumption against colorectal cancer.
Renal Insufficiency, Chronic
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Reperfusion Injury
Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722.
Blood lipid profile in ischaemia reperfusion injury.
Calcium in renal cells. Modulation of calcium-dependent activation of phospholipase A2.
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model.
Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.
In vitro studies on the influence of L-ascorbic acid 2-[3,4-dihydro- 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6yl-hy drogen phosphate] potassium salt on lipid peroxidation and phospholipase A2 activity.
Increased serum phospholipase A2 activity after non-heart-beating donor liver transplantation and association with ischemia-reperfusion injury.
Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury.
Phospholipase A2 is activated in the kidney, but not in the liver during ischemia-reperfusion.
Phospholipase A2 secretion during intestinal graft ischemia.
Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats.
Protective effect of N-(p-amylcinnamoyl) anthranilic acid, phospholipase A2 enzyme inhibitor, and transient receptor potential melastatin-2 channel blocker against renal ischemia-reperfusion injury.
Protective role of exogenous recombinant peroxiredoxin 6 under ischemia-reperfusion injury of kidney.
Regulation of Prdx6 by Nrf2 Mediated Through aiPLA2 in White Matter Reperfusion Injury.
Reperfusion injury after intestinal ischemia.
Reperfusion mucosal damage after complete intestinal ischemia in the dog: the effects of antioxidant and phospholipase A2 inhibitor therapy.
Retraction. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury.
Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury.
The contribution of phospholipase A2 to the cochlear dysfunction induced by transient ischemia.
Tissular prostanoid release, phospholipase A2 activity, and lipid peroxidation in pancreas transplantation.
Reproductive Tract Infections
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
Respiratory Distress Syndrome
A diether phosphonolipid surfactant analog, DEPN-8, is resistant to phospholipase-C cleavage.
Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome.
Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia.
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Effect of cooling on lung secretory phospholipase A2 activity in vitro, ex vivo, and in vivo.
Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis.
Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
Interaction of secreted phospholipase A2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome.
Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin.
Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins.
Phospholipase A2 is present in meconium and inhibits the activity of pulmonary surfactant: an in vitro study.
Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury.
Pulmonary Secretory Phospholipase A(2) in Infants with Respiratory Distress Syndrome Stimulates in vitro Neutrophil Migration.
Secretory phospholipase A(2) in newborn infants with sepsis.
Secretory Phospholipase A2 Enzymes in Acute Lung Injury.
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Secretory Phospholipase A2-IIA Protein and mRNA Pools in Extracellular Vesicles of Bronchoalveolar Lavage Fluid from Patients with Early Acute Respiratory Distress Syndrome: A New Perception in the Dissemination of Inflammation?
Secretory Phospholipase A2-Mediated Depletion of Phosphatidylglycerol in Early Acute Respiratory Distress Syndrome.
Systemic phospholipase A2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure.
Therapeutic use of a group IIA phospholipase A2 inhibitor in acute respiratory distress syndrome: time is of the essence.
Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury.
Respiratory Insufficiency
Crotoxin-Induced Mice Lung Impairment: Role of Nicotinic Acetylcholine Receptors and COX-Derived Prostanoids.
Frequency-dependent neuromuscular blockade by textilotoxin in vivo.
Inhibition of pulmonary surfactant function by phospholipases.
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study.
The role of phospholipase A2 in respiratory failure of acute pancreatitis.
The role of phospholipase A2 in the pathogenesis of respiratory damage in hemorrhagic necrotizing pancreatitis--assessment of a new experimental model.
Tourniquet ineffectiveness to reduce the severity of envenoming after Crotalus durissus snake bite in Belo Horizonte, Minas Gerais, Brazil.
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction.
[Experimental study on the pathogenesis of pulmonary insufficiency in acute pancreatitis and changes in the pulmonary surfactant]
Respiratory Paralysis
Anticrotalic and antitumoral activities of gel filtration fractions of aqueous extract from Tabernaemontana catharinensis (Apocynaceae).
Respiratory Syncytial Virus Infections
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Respiratory Tract Infections
Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection.
Retinal Degeneration
Functional role of peroxiredoxin 6 in the eye.
Specific roles for Group V secretory PLA? in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.
Retinal Neovascularization
The Role of Cytosolic Phospholipase A2 in Retinal Neovascularization.
Retinoblastoma
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Retinopathy of Prematurity
The Role of Cytosolic Phospholipase A2 in Retinal Neovascularization.
Rhabdomyolysis
Cytotoxic fungi--an overview.
Phospholipases A2 From Viperidae Snake Venoms: How do They Induce Skeletal Muscle Damage?
Renal lesions in rhabdomyolysis caused by Pseudechis australis snake myotoxin.
Severe and fatal mass attacks by 'killer' bees (Africanized honey bees--Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations.
Rheumatic Heart Disease
[Changes of lipid metabolism in cardiac failure patients with rheumatic heart disease]
Rhinitis
Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine.
The role of mast cell-derived secreted phospholipases A(2) in respiratory allergy.
Rhinitis, Allergic, Seasonal
Phospholipase A2 mRNA expression in the nasal mucosa of healthy subjects and patients with seasonal allergic rhinitis.
Rickets
The Phospholipin of the Blood and Liver in Experimental Rickets in Dogs.
Rosacea
Tetracycline Actions Relevant to Rosacea Treatment.
Salmonella Infections
Calcium-independent phospholipase A2 beta is dispensable in inflammasome activation and its inhibition by bromoenol lactone.
Sarcoidosis
Extracellular phospholipase A2 expression in sarcoidosis.
Sarcoma
Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms.
Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells.
Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells.
Sarcoma, Avian
Enhancing factor for Rous sarcoma virus: in vitro assay and action on both cells and virus.
Hexose uptake enhancing factor released from Rous sarcoma cells.
The tyrosine phosphorylation substrate p36 is developmentally regulated in embryonic avian limb and is induced in cell culture.
Sarcoma, Yoshida
Influence of charge on the inactivation of membrane bound (Na+ + K+)-ATPase of Yoshida sarcoma cells by inhibitor proteins from cobra venom.
Sarcopenia
Prdx6 Plays a Main Role in the Crosstalk Between Aging and Metabolic Sarcopenia.
Targeting cPLA2 derived lipid hydroperoxides as a potential intervention for sarcopenia.
Sciatica
A controlled biochemical and immunohistochemical study of human synovial-type (group II) phospholipase A2 and inflammatory cells in macroscopically normal, degenerated, and herniated human lumbar disc tissues.
Chymopapain-induced reduction of proinflammatory phospholipase A2 activity and amelioration of neuropathic behavioral changes in an in vivo model of acute sciatica.
Mechanisms of low back pain: a neurophysiologic and neuroanatomic study.
Phospholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam.
Phospholipase A2 sensitivity of the dorsal root and dorsal root ganglion.
Scleroderma, Systemic
Hypophospholipasemia A2 in systemic sclerosis.
Scoliosis
Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism.
Seizures
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Hippocampal Gene Network Analysis in an Experimental Model of Posttraumatic Epilepsy.
Human secretory phospholipase A(2), group IB in normal eyes and in eye diseases.
Ketogenic diet change cPLA2/clusterin and autophagy related gene expression and correlate with cognitive deficits and hippocampal MFs sprouting following neonatal seizures.
Leptin-regulated autophagy plays a role in long-term neurobehavioral injury after neonatal seizures and the regulation of zinc/cPLA2 and CaMK II signaling in cerebral cortex.
Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy.
Modulation of DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/quisqualate receptors by phospholipase A2: a necessary step in long-term potentiation?
Neuro-Behavioral Status and the Hippocampal Expression of Metabolic Associated Genes in Wild-Type Rat Following a Ketogenic Diet.
Reciprocal regulation of fatty acid release in the brain by GABA and glutamate.
Secreted phospholipase A2-induced neurotoxicity and epileptic seizures after intracerebral administration: an unexplained heterogeneity as emphasized with paradoxin and crotoxin.
Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
The accumulation of free arachidonic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy.
The neuromessenger platelet-activating factor in plasticity and neurodegeneration.
Sepsis
A continuous fluorescence assay for the determination of calcium-dependent secretory phospholipase A2 activity in serum.
Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2.
Acute lung injury induced by phospholipase A2. Structural and functional changes.
Acute pancreatitis as a model of sepsis.
Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice with Experimental Sepsis.
An Amperometric Biosensor for the Determination of Bacterial Sepsis Biomarker, Secretory Phospholipase Group 2-IIA Using a Tri-Enzyme System.
Antibacterial actions of secreted phospholipases A2. Review.
Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis*.
Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome.
CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.
Characterization of cellular and elevated serum phospholipase A2 activities with a comparison of two methods.
Characterization of phospholipase A2 from human nasal lavage.
Characterization of two phospholipases A2 in serum of patients with sepsis and acute pancreatitis.
Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.
Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia.
Early changes in organ function predict eventual survival in severe sepsis.
Effect of azithromycin on the LPS-induced production and secretion of phospholipase A2 in lung cells.
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Enhancement of leukocyte response to lipopolysaccharide by secretory group IIA phospholipase A2.
Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A(2) responsive liposome in prostate cancer.
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Group II phospholipase A2 gene expression is transcriptionally regulated in rat liver during sepsis.
Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections.
Group IIA secretory phospholipase 2 independently predicts mortality and positive blood culture in emergency department sepsis patients.
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
Heterogeneous models for an early discrimination between sepsis and non-infective SIRS in medical ward patients: a pilot study.
High sPLA2-IIA level is associated with eicosanoid metabolism in patients with bacterial sepsis syndrome.
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome.
Interleukin-6 and phospholipase A2 in sepsis.
Is circulating phospholipase A2 removed by large-pore continuous venovenous hemodiafiltration in septic acute renal failure?
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.
Measurement of a Novel Biomarker, Secretory Phospholipase A2 Group IIA as a Marker of Sepsis: A Pilot Study.
Mediators of injury and inflammation.
Modulation of lipid and protein mediators of inflammation by cytosolic phospholipase A2alpha during experimental sepsis.
Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock.
Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department.
Phospholipase A in acute lung injury after trauma and sepsis: its relation to the inflammatory mediators PMN-elastase, C3a, and neopterin.
Phospholipase A2 activities are decreased during early but increased during late phases of sepsis in rat heart.
Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis.
Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis.
Plasma secretory phospholipase A2 as an early marker for late-onset sepsis in preterm infants-a pilot study.
Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis.
Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis.
Roles of secreted phospholipases A? in the mammalian immune system.
Secretory non-pancreatic phopholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2.
Secretory phospholipase A(2) in newborn infants with sepsis.
Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms.
Surgical trauma induces group II phospholipase A2 production by neutrophils at a local site after surgery.
The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.
Transcriptional Regulation of the Group IIA Secretory Phospholipase A2 Gene by C/EBP? in Rat liver and its Relationship to Hepatic Gluconeogenesis during Sepsis.
Venous and arterial thromboembolism in severe sepsis.
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis].
[Secreted phospholipases A2 (sPLA2): friends or foes? Are they actors in antibacterial and anti-HIV resistance?]
Severe Dengue
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Shock, Septic
A predictive model for the clearance of soluble phospholipase A2 during septic shock.
Altered ryanodine receptor of canine cardiac sarcoplasmic reticulum and its underlying mechanism in endotoxin shock.
Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion.
Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.
Comparison of the enterotoxigenic types, toxic shock syndrome toxin I (TSST-1) strains and antibiotic susceptibilities for enterotoxigenic Staphylococcus aureus strains isolated from food and clinical samples.
Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study.
Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032.
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.
Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid.
Expression and purification of recombinant toxicshock-syndrome toxin I.
Glutamine inhibits lipopolysaccharide-induced cytoplasmic phospholipase A2 activation and protects against endotoxin shock in mouse.
Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid.
Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.
Increased concentrations of synovial-type phospholipase A2 in serum and pulmonary and renal complications in acute pancreatitis.
Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes.
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response.
Inhibition of human group II phospholipase A2 by C-reactive protein in vitro.
Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.
Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock.
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.
PCR detection of Staphylococcal enterotoxins (SEs) N, O, P, Q, R, U, and survey of SE types in Staphylococcus aureus isolates from food-poisoning cases in Taiwan.
Phospholipase A2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin: some implications for its functional role.
Phospholipase A2-induced hypotension in the rat and its pharmacological modulation.
Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes.
Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.
Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock.
Rat liver mitochondrial phospholipase A2 is an endotoxin-stimulated membrane-associated enzyme of Kupffer cells which is released during liver perfusion.
Relevance of serum phospholipase A2 assays to the assessment of septic shock.
SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock.
Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock.
Serum phospholipase A2 values and septic shock.
Subcellular membrane impairment and application of phospholipase A2 inhibitors in endotoxic shock.
Toxic effects of human pancreatic and snake and bee venom phospholipases A2 on MCF-7 cells in culture.
[The effect of Staphylococcus aureus toxic shock exotoxin on whole blood cell chemiluminescence in vitro and in vivo]
[The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock]
Shwartzman Phenomenon
Differentiation of the anti-shock effect of ulinastatin from steroid hormone, by the continuous observation of microcirculation dynamics.
Skin Abnormalities
Expression and Function of Group IIE Phospholipase A2 in Mouse Skin.
Skin Diseases
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
A unique phospholipase A2 in human epidermis: its physiologic function and its level in certain dermatoses.
Secretory and cytosolic phospholipase A(2)regulate the long-term cytokine-induced eicosanoid production in human keratinocytes.
Targeting phospholipase A2 for the treatment of inflammatory skin diseases.
Tetracycline Actions Relevant to Rosacea Treatment.
Skin Neoplasms
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis.
Expression and Function of Group IIE Phospholipase A2 in Mouse Skin.
Small Cell Lung Carcinoma
Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.
Solitary Pulmonary Nodule
Combination diagnosis of multi-slice spiral computed tomography and secretary phospholipase A2-IIa for solitary pulmonary nodules.
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Spasm
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Spastic Paraplegia, Hereditary
Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).
Pla2g6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia.
PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia.
Sphincter of Oddi Dysfunction
Toward routine use of nonsteroidal anti-inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography.
Spinal Cord Injuries
A novel role of phospholipase A2 in mediating spinal cord secondary injury.
Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury.
Characterizing Phospholipase A2-Induced Spinal Cord Injury-A Comparison with Contusive Spinal Cord Injury in Adult Rats.
Computational Exploration of Natural Compounds to Target Cytosolic Phospholipase A 2 Protein: A Novel Therapeutic Target for Spinal Cord Injury.
cPLA2 activation contributes to lysosomal defects leading to impairment of autophagy after spinal cord injury.
Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury.
Differential expression of sPLA(2) following spinal cord injury and a functional role for sPLA(2)-IIA in mediating oligodendrocyte death.
Immunocytochemical localization of cPLA2 in rat and monkey spinal cord.
Inhibition of cPLA2 has neuroprotective effects on motoneuron and muscle atrophy following spinal cord injury.
Lentivirus-mediated Inhibition of Tumour Necrosis Factor-? improves motor function associated with PRDX6 in spinal cord contusion rats.
Neuroprotection and its molecular mechanism following spinal cord injury.
Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats.
Phospholipase A2 superfamily members play divergent roles after spinal cord injury.
RhoA/Rho Kinase Mediates Neuronal Death Through Regulating cPLA2 Activation.
Role of phospholipase A2s and lipid mediators in secondary damage after spinal cord injury.
Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.
The effects of myelin on macrophage activation are phenotypic specific via cPLA2 in the context of spinal cord injury inflammation.
Spinocerebellar Ataxias
Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3?-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1).
Spinocerebellar Degenerations
Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations.
Spondylolisthesis
Human group II phospholipase A2 in normal and diseased intervertebral discs.
Spondylosis
Human group II phospholipase A2 in normal and diseased intervertebral discs.
Spotted Fever Group Rickettsiosis
Rickettsial phospholipase A2 as a pathogenic mechanism in a model of cell injury by typhus and spotted fever group rickettsiae.
Squamous Cell Carcinoma of Head and Neck
A novel read-through transcript JMJD7-PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and survival.
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer.
Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-?B in oral squamous cell carcinoma.
Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
Prognostic value of lipid metabolism-related genes in head and neck squamous cell carcinoma.
Starvation
Gene expression of type I phospholipase A2 in pancreatic beta cells. Regulation of mRNA levels by starvation or glucose excess.
Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells.
Starvation decreases insulin secretion, prostaglandin E2 production and phospholipase A2 activity in rat pancreatic islets.
[Oxidative phosphorylation and the activity of the polyenzyme systems of rat liver mitochondrial membranes in starvation]
Status Epilepticus
Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy.
The accumulation of free arachidonic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy.
Stomach Diseases
Cytosolic phospholipase A2 activation in Helicobacter pylori lipopolysaccharide-induced interference with gastric mucin synthesis.
Stomach Neoplasms
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer.
Flavonoids Identified from Korean Scutellaria baicalensis Induce Apoptosis by ROS Generation and Caspase Activation on Human Fibrosarcoma Cells.
Gastric carcinogenesis: diet as a causative factor.
Group II phospholipase A2 in invasive gastric cancer cell line is induced by interleukin 6.
Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer.
Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with gastric cancer.
The effect of ?-fatty acids on the expression of phospholipase A2 group 2A in human gastric cancer patients.
[Expression of peroxiredoxin 6 in gastric cancer and its clinical significance].
Stomach Ulcer
Antioxidant and gastric cytoprotective prostaglandins properties of Cassia sieberiana roots bark extract as an anti-ulcerogenic agent.
Duodenogastric reflux in patients with gastric ulcer disease.
Impaired gastric ulcer healing in diabetic mice: role of methylglyoxal.
Relative contribution of bile and pancreatic juice duodenogastric reflux in gastric ulcer disease and cholelithiasis.
Stroke
A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke.
CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.
Genetic contribution of the leukotriene pathway to coronary artery disease.
Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis.
Identification of pleiotropic genes between risk factors of stroke by multivariate metaCCA analysis.
Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation.
NADPH Oxidase-2: Linking Glucose, Acidosis, and Excitotoxicity in Stroke.
Phospholipase A2 of Peroxiredoxin 6 Plays a Critical Role in Cerebral Ischemia/Reperfusion Inflammatory Injury.
Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke.
Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death.
Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat.
S1PR2 antagonist alleviates oxidative stress-enhanced brain endothelial permeability by attenuating p38 and Erk1/2-dependent cPLA2 phosphorylation.
Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat.
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation.
The Roles of Peroxiredoxin 6 in Brain Diseases.
Subacute Sclerosing Panencephalitis
On the activity of brain phospholipase A2 towards specifically labelled glycerophospholipids during subacute sclerosing panencephalitis.
Phospholipid metabolism in subacute sclerosing panencephalitis: activity of brain phospholipase A2 towards specifically labelled 1,2-diacyl-,1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-sn-glycero-3-phosphorycholine.
Subarachnoid Hemorrhage
Endothelins activate phospholipase A2 in brain capillary endothelial cells.
Sunburn
Effect of Artocarpus communis Extract on UVB Irradiation-Induced Oxidative Stress and Inflammation in Hairless Mice.
Synovitis
Cytosolic phospholipase A2 regulates TNF-induced production of joint destructive effectors in synoviocytes.
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.
The synovial-like membrane at the bone interface in loose total hip replacements contains high levels of extracellular group II phospholipase A2.
Tachycardia, Ventricular
Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition.
Tangier Disease
Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha-RXR.
Tetanus
Characterization of enhancing factor (EF) prepared from spleen of mice immunized with tetanus toxoid.
Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins.
Nordihydroguaiaretic acid blocks the synaptic component of long-term potentiation and the associated increases in release of glutamate and arachidonate: an in vivo study in the dentate gyrus of the rat.
Selective restimulation of antigen or allergen preactivated T cells using OKT3 F(ab)2 results in the secretion of TH-1 or TH-2-like cytokine patterns.
Some general rules governing fate and action of polypeptide and protein drugs, as derived from investigations with staphylococcal alpha-toxin, tetanus toxin, and so-calledd crotoxin.
Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production.
The effect of enhancing factor on the immunity of mice against tetanus.
Thrombocythemia, Essential
Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide.
Phospholipase A2 activity in platelets of patients with primary thrombocythemia.
Thrombocytopenia
Comparative proteomes, immunoreactivities and neutralization of procoagulant activities of Calloselasma rhodostoma (Malayan pit viper) venoms from four regions in Southeast Asia.
Hemolytic anemia, spherocytosis, and thrombocytopenia associated with honey bee envenomation in a dog.
Peroxiredoxin 6 is a natural radioprotector.
Thromboembolism
[Preventive effect of liquemin depot in thromboembolism; experimental proof with myotoxin thrombokinase test.]
Thrombophilia
Anticoagulant and membrane-degrading effects of secretory (non-pancreatic) phospholipase A2 are inhibited in plasma.
Revealing the mechanisms and the material basis of Rubia cordifolia L. on abnormal uterine bleeding with uniting simultaneous determination of four components and systematic pharmacology approach-experimental validation.
Thrombosis
Characterization of phospholipase A2 secretion from human platelets.
Crotoxin, a neurotoxin from Crotalus durissus terrificus snake venom, as a potential tool against thrombosis development.
Derrone Inhibits Platelet Aggregation, Granule Secretion, Thromboxane A2 Generation, and Clot Retraction: An In Vitro Study.
Fractionation of Bothrops jararacussu snake venom: partial chemical characterization and biological activity of bothropstoxin.
Group V secretory phospholipase A2 impairs endothelial protein C receptor-dependent protein C activation and accelerates thrombosis in vivo.
Group VIB calcium-independent phospholipase A2 (iPLA2?) regulates platelet activation, hemostasis and thrombosis in mice.
Inhibition by Ethanol of Shear Stress-Induced Formation of Platelet Thrombi in Whole Blood.
Phospholipase A2 expression in coronary thrombus is increased in patients with recurrent cardiac events after acute myocardial infarction.
[The secretory phospholipase A2 and transport of lipids by lipoproteins in patients with the risk of cardio-vascular pathology (the system "score") of lower and average degree. The diagnostic significance of the test].
Thyroid Cancer, Papillary
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Thyroid Diseases
A possible link between genetic hemochromatosis and autoimmune thyroiditis.
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Thyroiditis
Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy.
PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Toxemia
In vivo protective role of human group IIa phospholipase A2 against experimental anthrax.
Toxoplasmosis
Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis.
Tremor
Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration.
Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy.
Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats.
triacylglycerol lipase deficiency
Alpha-lecithin:cholesterol acyltransferase deficiency. Lack of both phospholipase A2 and acyltransferase activities characteristic of high density lipoprotein lecithin:cholesterol acyltransferase in fish eye disease.
Triple Negative Breast Neoplasms
Antitumor and antimetastatic effects of PLA2-BthTX-II from Bothrops jararacussu venom on human breast cancer cells.
Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.
Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.
Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging.
Trypanosomiasis
The effects of bee (Apis mellifera) venom phospholipase A2 on Trypanosoma brucei brucei and enterobacteria.
Tuberculosis
Activation of apoptosis, but not necrosis, during Mycobacterium tuberculosis infection correlated with decreased bacterial growth: role of TNF-alpha, IL-10, caspases and phospholipase A2.
Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the anti-microbial activity of macrophages against Mycobacterium tuberculosis.
Cytosolic Phospholipase A2 Enzymes Are Not Required by Mouse Bone Marrow-Derived Macrophages for the Control of Mycobacterium tuberculosis In Vitro.
Cytosolic phospholipase A2 participates with TNF-alpha in the induction of apoptosis of human macrophages infected with Mycobacterium tuberculosis H37Ra.
Detection and characterization of extracellular phospholipase A2 in pleural effusion of patients with tuberculosis.
Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis.
Redox chemistry of Mycobacterium tuberculosis alkylhydroperoxide reductase E (AhpE): Structural and mechanistic insight into a mycoredoxin-1 independent reductive pathway of AhpE via mycothiol.
RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection.
Rv0807, a putative phospholipase A2 of Mycobacterium tuberculosis; Elucidation through sequence analysis, homology modeling, molecular docking and molecular dynamics studies of potential substrates and inhibitors.
Secretory phospholipase A(2) plays an essential role in microglial inflammatory responses to Mycobacterium tuberculosis.
[Profiles of the expression of phospholipase A2 family mRNAs by macrophages infected with Mycobacterium tuberculosis]
[Role of phospholipase A2 in regulating lipid peroxidation and the respiratory chain in experimental tuberculosis]
Tuberous Sclerosis
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Typhoid Fever
Phospholipase A2 is a circulating mediator in typhoid fever.
Typhus, Epidemic Louse-Borne
Rickettsial phospholipase A2 as a pathogenic mechanism in a model of cell injury by typhus and spotted fever group rickettsiae.
Tyrosinemias
[Epidemiology and risk factors of hepatocellular carcinoma].
unspecific monooxygenase deficiency
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.
Uremia
Activity of phospholipase A2 in plasma increases in uremia.
Phospholipase A2 activity in platelets of patients with uremia.
Plasma phospholipids and platelet function in uremic patients.
Urinary Bladder Neoplasms
Suppressive Effect of Matrine on Tumor Invasion in N-Butyl-N-(4-Hydroxybutyl)Nitrosamine-Induced Urinary Bladder Carcinogenesis.
Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy.
Urinary Tract Infections
Premature labor. II. Bacterial sources of phospholipase.
Urticaria
Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients.
Uterine Cervical Neoplasms
Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing ?-catenin signaling.
Overexpression and biological function of PRDX6 in human cervical cancer.
Uterine Diseases
Defining Postpartum Uterine Disease and the Mechanisms of Infection and Immunity in the Female Reproductive Tract in Cattle.
Uterine Inertia
[The influence of nitric oxide generation on the production of interleukins and processes of prostaglandin synthesis in fetal membranes in spontaneous parturition and uterine inertia]
Uveitis
Effects of antiflammins on endotoxin-induced uveitis in rats.
Fluctuation of lysosomal phospholipase A2 in experimental autoimmune uveitis in rats.
Increase of lysosomal phospholipase A2 in aqueous humor by uveitis.
Phospholipase A2, leukotriene C4 and prostaglandin E2 levels in aqueous humour of guinea pigs with experimental S-antigen induced autoimmune uveitis.
Suppression of experimental autoimmune uveitis in guinea-pigs by inhibition of phospholipase A2.
[A study on RBC immunofunction in experimental traumatic uveitis]
Uveitis, Anterior
Effects of antiflammins on endotoxin-induced uveitis in rats.
Vaginosis, Bacterial
Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity.
The determination of phospholipase A2 enzyme activity in the vaginal secretions of pregnant and non-pregnant women with bacterial vaginosis-and in culture exudates of its causative organisms.
Varicocele
Cytosolic phospholipase A2 and F2 isoprostanes are involved in semen quality and human infertility-A study on leucocytospermia, varicocele and idiopathic infertility.
Fatty Acid Profile and Metabolism Are Related to Human Sperm Parameters and Are Relevant in Idiopathic Infertility and Varicocele.
Vascular Calcification
Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.
Vascular Diseases
Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-kappaB.
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Plasma levels of the lyso-derivative of platelet-activating factor are related to age.
Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation.
Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: A systematic review of the literature.
Vascular System Injuries
Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium.
Vasculitis
Shedding new light on vasculitis: how the LAMP story unfolded.
Vasospasm, Intracranial
Endothelins activate phospholipase A2 in brain capillary endothelial cells.
Ventilator-Induced Lung Injury
A Peptide Inhibitor of Peroxiredoxin 6 Phospholipase A2 Activity Significantly Protects against Lung Injury in a Mouse Model of Ventilator Induced Lung Injury (VILI).
Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice.
Cytosolic phospholipase A2 and arachidonic acid metabolites modulate ventilator-induced permeability increases in isolated mouse lungs.
Virus Diseases
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
Genetic and pharmacologic evidence that calcium-independent phospholipase A2beta regulates virus-induced inducible nitric-oxide synthase expression by macrophages.
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2.
Methyltransferase and phospholipase A2 activity in membranes of neutrophils and lymphocytes from patients with bacterial and viral infections.
Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope.
Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.
Rapid phospholipase A2 stimulation and diacylglycerol cholinephosphotransferase inhibition in baby hamster kidney cells during initiation of dengue virus infection.
Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED.
Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study.
Serum phospholipase A2 in dengue.
The role and regulation of COX-2 during viral infection.
Vitamin E Deficiency
Phospholipase A2 of rat liver mitochondria in vitamin E deficiency.
Vitamin E differentially regulates the expression of peroxiredoxin-1 and -6 in alveolar type II cells.
[Non-antioxidative mechanism of cytochrome P-450 stabilization by alpha-tocopherol: the effectiveness in avitaminosis E]
Vitiligo
Down-regulation of Prdx6 contributes to DNA vaccine induced vitiligo in mice.
Wasting Syndrome
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
West Nile Fever
High-mobility group box-1, promising serological biomarker for the distinction of human WNV disease severity.
Whooping Cough
A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release.
Activation of a keratinocyte phospholipase A2 by bradykinin and 4 beta-phorbol 12-myristate 13-acetate. Evidence for a receptor-GTP-binding protein versus a protein-kinase-C mediated mechanism.
Activation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.
Agonist-mediated activation of PLA2 initiates Ca2+ mobilization in intestinal longitudinal smooth muscle.
Agonist-specific alterations in receptor-phospholipase coupling following inactivation of Gi2alpha gene.
Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms.
Alpha adrenergic receptor subtypes involved in prostaglandin synthesis are coupled to Ca++ channels through a pertussis toxin-sensitive guanine nucleotide-binding protein.
Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2.
Angiotensin II and proximal tubule sodium transport.
Angiotensin II directly increases rabbit renal brush-border membrane sodium transport: presence of local signal transduction system.
Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line.
ATP produces potassium currents via P3 purinoceptor in the follicle cell layer of Xenopus oocytes.
Basic fibroblast growth factor stimulates cytosolic phospholipase A2, phospholipase C-gamma1 and phospholipase D through distinguishable signaling mechanisms.
Basic fibroblast growth factor-stimulated endothelial cell movement is mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity.
beta2-Adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathway.
Bradykinin activates protein kinase C in cultured cortical collecting tubular cells.
Cholera toxin and pertussis toxin stimulate prostaglandin E2 synthesis in a murine macrophage cell line.
Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent.
Effects of ATP on phosphoinositide hydrolysis and prostaglandin E2 generation in rabbit astrocytes.
Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment.
Enhancement of HIV-1 replication in human macrophages is induced by CD8+ T cell soluble factors.
Enhancement of stress-induced synthesis of stress proteins by mastoparan in C6 rat glioma cells.
Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway.
Evidence for coupling of bradykinin receptors to a guanine-nucleotide binding protein to stimulate arachidonate liberation in the osteoblast-like cell line, MC3T3-E1.
Evidence that the ATP-induced increase in vasomotion of guinea-pig mesenteric lymphatics involves an endothelium-dependent release of thromboxane A2.
Further evidence that the CCK2 receptor is coupled to two transduction pathways using site-directed mutagenesis.
G protein regulation of phospholipase A2.
Glucose transport stimulation by bradykinin in Swiss 3T3 fibroblasts: a pertussis toxin-sensitive mechanism operates without involvement of arachidonic acid and cyclic AMP.
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
GVI phospholipase A2 role in the stimulatory effect of sphingosine-1-phosphate on TRPC5 cationic channels.
Heterotrimeric G proteins containing G alpha i3 regulate multiple effector enzymes in the same cell. Activation of phospholipases C and A2 and inhibition of adenylyl cyclase.
High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor.
Histamine activates a background, arachidonic acid-sensitive K channel in embryonic chick dorsal root ganglion neurons.
Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets.
Increase in cytosolic free Ca2+ in corticotropin-stimulated white adipocytes.
Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
Induction of microvascular leakage and histamine release by promutoxin, an Arg49 phospholipase A2.
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.
Intracellular calcium mobilization and phospholipid degradation in sphingosylphosphorylcholine-stimulated human airway epithelial cells.
Involvement of a pertussis toxin-sensitive G protein-coupled phospholipase A2 in agonist-stimulated arachidonic acid release in membranes isolated from bovine iris sphincter smooth muscle.
Involvement of a pertussis toxin-sensitive G-protein-coupled phospholipase A2 in lipopolysaccharide-stimulated prostaglandin E2 synthesis in cultured rat mesangial cells.
Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation.
LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression.
LysoPC and PAF Trigger Arachidonic Acid Release by Divergent Signaling Mechanisms in Monocytes.
Mastoparan elicits prostaglandin E2 generation and inhibits inositol phosphate accumulation via different mechanisms in rabbit astrocytes.
Mechanism of arachidonic acid liberation in platelet-activating factor-stimulated human polymorphonuclear neutrophils.
Mechanism of induction of prostaglandin E2 production by endothelin 1 in cultured rat mesangial cells.
Mechanism of N-formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-induced arachidonic acid release in guinea pig alveolar macrophages: involvement of a GTP-binding protein and role of protein kinase A and protein kinase C.
Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation.
Muscarinic regulation of phospholipase A2 and iodide fluxes in FRTL-5 thyroid cells.
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
NMDA receptor-mediated arachidonic acid release in neurons: role in signal transduction and pathological aspects.
No direct correlation between Ca2+ mobilization and dissociation of Gi during platelet phospholipase A2 activation.
Permissive stimulation of Ca(2+)-induced phospholipase A2 by an adenosine receptor agonist in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells: a new 'cross-talk' mechanism in Ca2+ signalling.
Pertussis toxin-sensitive activation of phospholipase A2 can be resolved from phosphoinositidase C in primary cultures of mouse osteoblasts using indomethacin.
Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets.
Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes.
Pharmacological comparison of UTP- and thapsigargin-induced arachidonic acid release in mouse RAW 264.7 macrophages.
Phospholipase A2 and phospholipase C are activated by distinct GTP-binding proteins in response to alpha 1-adrenergic stimulation in FRTL5 thyroid cells.
Platelet-activating factor stimulates multiple signaling pathways in cultured rat mesangial cells.
Potential role for local luminal angiotensin II in proximal tubule sodium transport.
Prostaglandin E2-induced arachidonic acid release and catecholamine secretion from cultured bovine adrenal chromaffin cells.
Proteolytic activation of protein kinase Calpha by peroxynitrite in stimulating cytosolic phospholipase A2 in pulmonary endothelium: involvement of a pertussis toxin sensitive protein.
Purinergic P2Y receptors on astrocytes are directly coupled to phospholipase A2.
Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes.
Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages.
Role of an aprotinin-sensitive protease in protein kinase Calpha-mediated activation of cytosolic phospholipase A2 by calcium ionophore (A23187) in pulmonary endothelium.
Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells.
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.
Secretory phospholipase A2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity.
Signal transduction by tumor necrosis factor alpha is mediated through a guanine nucleotide-binding protein in osteoblast-like cell line, MC3T3-E1.
Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2.
Stimulation of phospholipase A2 activity in bovine rod outer segments by the beta gamma subunits of transducin and its inhibition by the alpha subunit.
Stimulation of reactive oxidant production in neutrophils by soluble and insoluble immune complexes occurs via different receptors/signal transduction systems.
Studies on opsonized zymozan, FMLP, carbachol, PMA and A23187 stimulated respiratory burst of human PMNLs.
The coupling of pertussis toxin-sensitive G proteins to phospholipase A2 and adenylyl cyclase in CHO cells expressing bovine rhodopsin.
The guanine-nucleotide-binding protein subunit G alpha i2 is involved in calcium activation of phospholipase A2. Effects of the dominant negative G alpha i2 mutant, [G203T]G alpha i2, on activation of phospholipase A2 in Chinese hamster ovary cells.
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells.
Wound Infection
Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns.
Yellow Fever
Crotoxin and phospholipases A(2) from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses.
Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope.